Ghid ERHA Privitor NOAK 2018 PDF

European Heart Journal (2018) 39, 1330–1393 SPECIAL ARTICLE
doi:10.1093/eurheartj/ehy136
The 2018 European Heart Rhythm Association

Practical Guide on the use of non-vitamin K
antagonist oral anticoagulants in patients
with atrial fibrillation
Jan Steffel1*, Peter Verhamme2, Tatjana S. Potpara3, Pierre Albaladejo4,
Matthias Antz5, Lien Desteghe6, Karl Georg Haeusler7, Jonas Oldgren8,
Holger Reinecke9, Vanessa Roldan-Schilling10, Nigel Rowell11, Peter Sinnaeve2,
Ronan Collins12, A. John Camm13, and Hein Heidbüchel6,14
Advisors: Martin van Eickels, M.D. (Bayer Healthcare), Jutta Heinrich-Nols, M.D.
(Boehringer Ingelheim), Markus Müller, M.D., Ph.D. (Pfizer), Wolfgang Zierhut M.D.
(Daiichi-Sankyo) and Poushali Mukherjea, Ph.D. (Bristol-Myers Squibb)
Document reviewers (ESC scientific document group): Gregory YH Lip (EHRA

Review Coordintaor; UK, Denmark), Jeffrey Weitz (Canada), Laurent Fauchier
(France), Deirdre Lane (UK), Giuseppe Boriani (Italy), Andreas Goette (Germany),
Roberto Keegan (Argentina), Robert MacFadyen (Australia), Chern-En Chiang
(Taiwan), Boyoung Joung (Korea), and Wataru Shimizu (Japan)
1
Department of Cardiology, University Heart Center Zurich, R€amistrasse 100, CH-8091 Zurich, Switzerland; 2Department of Cardiovascular Sciences, University of Leuven,
Leuven, Belgium; 3School of Medicine, Belgrade University, Belgrade, Serbia; 4Grenoble-Alps University Hospital, Grenoble, France; 5City Hospital Braunschweig, Braunschweig,
Germany; 6Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; 7Center for Stroke Research Berlin and Department of Neurology, Charité—
Universit€atsmedizin Berlin, Berlin, Germany; 8Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 9Department of
Cardiovascular Medicine, University Hospital Münster, Münster, Germany; 10University of Murcia, Murcia, Spain; 11Middlesbrough, UK; 12Age-Related Health Care & Stroke-
Service, Tallaght Hospital, Dublin Ireland; 13Cardiology Clinical Academic Group, Molecular & Clinical Sciences Institute, St George’s University, London, UK, and Imperial
College; and 14Antwerp University and University Hospital, Antwerp, Belgium
Online publish-ahead-of-print 19 March 2018
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm
Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625–651;
Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in pa-
tients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alter-
native for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice,
particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these
drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The
European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs.
A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence.
The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring
adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug–drug inter-
actions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of
* Corresponding author. Tel: þ41 44 255 15 15, Fax: +41 44 255 8701, Email: [email protected]
Published on behalf of the European Society of Cardiology. All rights reserved. V
C The Author(s) 2018. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

by University of Medicine and Pharmacy of Timisoara user
on 23 April 2018
2018 EHRA Practical Guide on NOACs in AF 1331
NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors;
(10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding;
(11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients
requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across
indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in
special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information
and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).
..
Abbreviations ..
..
ELDERCARE-AF Edoxaban low-dose for elder care AF
patients,
..
ACS Acute Coronary Syndrome, .. ELIMINATE-AF Evaluation of Edoxaban compared with
ACT Activated Clotting Time, .. VKA in subjects undergoing catheter abla-
..
AF Atrial Fibrillation, .. tion of non-valvular atrial fibrillation,
AMPLIFY Apixaban for the Initial Management of .. EMANATE Eliquis evaluated in acute cardioversion
..
Pulmonary Embolism and Deep-Vein .. compared to usual treatments for anticoa-
Thrombosis as First-Line Therapy, .. gulation in subjects with NVAF,
..
ANNEXA Andexanet Alfa, a Novel Antidote to the .. ENGAGE AF-TIMI 48 Effective Anticoagulation with Factor Xa
Anticoagulation Effects of FXA Inhibitors .. Next Generation in Atrial Fibrillation -
..
study, .. Thrombolysis in Myocardial Infarction 48,
aPCC Activated Prothrombin Complex .. ENSURE-AF Edoxaban versus warfarin in subjects
..
Concentrates, .. undergoing cardioversion of Atrial
aPTT Activated Prothrombin Time, .. Fibrillation,
..
ARISTOTLE Apixaban for Reduction in Stroke and .. ENTRUST AF-PCI Evaluation of the Safety and Efficacy of an
Other Thromboembolic Events in Atrial .. Edoxaban-Based Compared to a Vitamin
..
Fibrillation, .. K Antagonist-Based Antithrombotic
ATLAS ACS–TIMI Anti-Xa Therapy to Lower Cardiovascular
.. Regimen in Subjects With Atrial
..
Events in Addition to Standard Therapy in .. Fibrillation Following Successful
Subjects with Acute Coronary Syndrome
.. Percutaneous Coronary Intervention
..
– Thrombolysis in Myocardial Infarction, .. With Stent Placement,
AUGUSTUS Apixaban Versus Vitamin K Antagonist in
.. ESC European Society of Cardiology,
..
Patients With Atrial Fibrillation and Acute .. GFR Glomerular filtration rate,
Coronary Syndrome and/or Percutaneous
.. ICB Intracranial bleeding,
..
Coronary Intervention, .. INR International Normalized Ratio,
..
AXAFA-AFNET Anticoagulation using the direct factor Xa .. ISTH International Society of Thrombosis and
inhibitor apixaban during Atrial Fibrillation .. Hemostasis,
..
catheter Ablation: Comparison to vitamin .. LMWH Low molecular weight heparin,
K antagonist therapy – Atrial Fibrillation .. MI Myocardial infarction,
..
Network, .. NOAC Non-Vitamin K Antagonist Oral
BMI Body Mass Index, .. Anticoagulant,
..
BMS Bare metal stent, .. Non-STEMI Non- ST-elevation myocardial infarction,
BRIDGE Bridging Anticoagulation in Patients who .. NSAID Non-steroidal anti-inflammatory drug,
..
Require Temporary Interruption of .. PAUSE Perioperative Anticoagulant Use for
Warfarin Therapy for an Elective Invasive .. Surgery Evaluation,
..
Procedure or Surgery, .. PCC Prothrombin Complex Concentrates,
CAD Coronary artery disease, .. PCI Percutaneous Coronary Intervention,
..
CKD Chronic kidney disease, .. P-gp P-glycoprotein,
COMPASS Cardiovascular Outcomes for People .. PIONEER AF-PCI Open-Label, Randomized, Controlled,
..
Using Anticoagulation Strategies, .. Multicenter Study Exploring Two
CrCl Creatinine clearance,
.. Treatment Strategies of Rivaroxaban and
..
DAPT Dual antiplatelet therapy, .. a Dose-Adjusted Oral Vitamin K
DES Drug-eluting stent,
.. Antagonist Treatment Strategy in Subjects
..
dTT Diluted thrombin time, .. with Atrial Fibrillation who Undergo
ECA Ecarin chromogenic assay,
.. Percutaneous Coronary Intervention,
..
EHRA European Heart Rhythm Association, .. PPI Proton pump inhibitor,

on 23 April 2018
1332 J. Steffel et al.
..
PT Prothrombin time, .. drugs as ‘direct oral anticoagulants’,4 we prefer to continue to use
RCT Randomized clinical trial,
.. NOAC. Ultimately, both terms are interchangeable when referring
..
RE-CIRCUIT Randomized Evaluation of Dabigatran .. to the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxa-
Etexilate Compared to Warfarin in
.. ban as well as the direct thrombin inhibitor dabigatran.
..
Pulmonary Vein Ablation: Assessment of .. Non-vitamin K antagonist oral anticoagulants have an improved effi-
an Uninterrupted Periprocedural
.. cacy/safety ratio, a predictable anticoagulant effect without need for rou-
..
Anticoagulation Strategy, .. tine coagulation monitoring, and fewer food and drug interactions
.. compared with VKAs. However, the proper use of NOACs requires a
RE-DUAL PCI Randomized Evaluation of Dual ..
Antithrombotic Therapy with Dabigatran .. carefully considered approach to many practical aspects. Whereas the
.. ESC Guidelines3 mainly discuss the indications for anticoagulation in gen-
versus Triple Therapy with Warfarin in ..
Patients with Nonvalvular Atrial .. eral and of NOACs in particular, they offer less guidance on how to deal
.. with NOACs in specific clinical situations. Moreover, there are still sev-
Fibrillation Undergoing Percutaneous ..
Coronary Intervention, .. eral less well researched aspects of NOAC use, which are nonetheless
.. relevant when these drugs are used by cardiologists, neurologists, geria-
RE-LY Randomized Evaluation of Long-Term ..
Anticoagulation Therapy, .. tricians, general practitioners, and other healthcare providers in daily
.. clinical practice. Each of the NOACs available on the market is accom-
RE-VERSE AD Reversal Effects of Idarucizumab in ..
Patients on Active Dabigatran, .. panied by the instructions for its proper use in many clinical situations
.. [summary of product characteristics (SmPCs); patient card; information
ROCKET AF Rivaroxaban Once Daily Oral Direct ..
Factor Xa Inhibition Compared with .. leaflets for patients; and physicians], but multiple, and often slightly differ-
..
Vitamin K Antagonism for Prevention of .. ent, physician education tools sometimes create confusion rather than
Stroke and Embolism Trial in Atrial .. clarity. Based on these premises, the European Heart Rhythm
..
Fibrillation, .. Association (EHRA) set out to coordinate a unified way of informing
SEE Systemic embolic event,
.. physicians on the use of NOACs. The first edition of the Practical Guide
..
SmPC Summary of product characteristics, .. was published in 2013 to supplement the AF guidelines as guidance for
STEMI ST-elevation myocardial infarction,
.. safe and effective use of NOACs when prescribed; a first update was
..
TIA Transient ischaemic attack, .. published in 2015.1,2 This text is the 2018 update to the original Guide.
TT Thrombin time,
.. A writing group formulated practical answers to 20 clinical scen-
..
TTR Time in therapeutic range, .. arios, based on available and updated knowledge. The writing group
UFH Unfractionated heparin,
.. was assisted by medical experts from the manufacturers of the
..
VENTURE-AF Active-controlled multi-center study with .. NOACs, who provided assurance that the latest information on the
.. different NOACs was evaluated, and provided feedback on the align-
blind-adjudication designed to evaluate ..
the safety of uninterrupted Rivaroxaban .. ment of the text with the approved SmPCs. However, the final re-
.. sponsibility of this document resided entirely with the EHRA writing
and uninterrupted vitamin K antagonists in ..
subjects undergoing catheter ablation for .. group. In some instances, the authors opted to make recommenda-
.. tions that do not fully align with all SmPCs, with the goal to provide
non-valvular Atrial Fibrillation, ..
VHD Valvular heart disease, .. more uniform and simple practical advice (e.g. on the start of NOAC
.. after cessation of VKA, on advice after a missed or forgotten dose, on
VKA Vitamin K Antagonist, ..
VTE Venous thromboembolic event, .. perioperative management, and others).
.. An EHRA website, www.NOACforAF.eu, accompanies the
WOEST What is the Optimal antiplatelet and anti- ..
coagulant therapy in patients with oral .. Practical Guide. The Practical Guide is summarized in a Key Message
.. booklet which can be obtained through EHRA and ESC; the website
anticoagulation and coronary stenting, ..
X-VeRT Explore the efficacy and safety of once- .. also provides EHRA members with a downloadable slide kit on the
..
daily oral rivaroxaban for the prevention .. Practical Guide.
of cardiovascular events in patients with
.. We hope that with the current revision the practical tool that
..
non- valvular atrial fibrillation scheduled .. EHRA envisioned has further improved. The authors realize that
for cardioversion
.. there will be gaps, unaddressed questions, and areas of uncertainty
..
.. and debate. Therefore, readers can address their suggestions for
.. change or improvement on the website. This whole endeavour
..
Introduction .. should be one for and by the medical community with the ultimate
.. goal of improving patient care and outcome.
..
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alter- ..
native for vitamin K antagonists (VKAs) to prevent stroke in patients ..
..
with atrial fibrillation (AF) and have emerged as the preferred choice, .. 1. Eligibility for non-vitamin K
particularly in patients newly started on anticoagulation.1–3 The term ..
.. antagonist oral anticoagulants
NOAC has been used for many years, is used by the current ..
European Society of Cardiology (ESC) AF guidelines3 and is widely
.. Non-vitamin K antagonist oral anticoagulants are approved for stroke
..
recognized. Therefore, even though some authors refer to these . prevention in non-valvular atrial fibrillation. Strictly, the term ‘non-

on 23 April 2018
Table 1 Selected indications and contraindications for non-vitamin K antagonist oral anticoagulant therapy in atrial
fibrillation patients
Condion Eligibility for NOAC therapy

Mechanical prosthec valve Contraindicated
Moderate to severe mitral stenosis
Contraindicated
(usually of rheumac origin)
Mild to moderate other nave valvular
disease (e.g., mild-moderate aorc
Included in NOAC trials
stenosis or regurgitaon, degenerave
mitral regurgitaon etc.)
Limited data (excluded in RE-LY)
Severe aorc stenosis
Most will undergo intervenon
Not advised if for rheumac mitral stenosis
Bioprosthec valve (aer > 3 months
post operavely) Acceptable if for degenerave mitral
regurgitaon or in the aorc posion
Mitral valve repair (aer > 3 months

Some paents included in some NOAC trials
post operavely)
No prospecve data yet
PTAV and TAVI May require combinaon with single or dual
anplatelet therapy
Hypertrophic cardiomyopathy Few data, but paents may be eligible for NOACs
Hatched—limited data.
PTAV, percutaneous transluminal aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.
..
valvular AF’ refers to AF in the absence of a mechanical prosthetic .. Atrial fibrillation in patients with biological valves or after valve re-
heart valve or moderate to severe mitral stenosis (usually of rheum- .. pair constitute a grey area, even though these patients were included
..
atic origin) (Table 1),3,5,6 which were exclusion criteria for all Phase III .. in some of the landmark NOAC trials.6,7,9,10 Since most of these pa-
NOAC vs. warfarin trials in AF. In order to avoid confusion, the term .. tients do not require long-term oral anticoagulation following their
..
‘non-valvular’ has been eliminated in the 2016 ESC guidelines on the .. valve procedure, the use of a NOAC for the management of con-
management of patients with AF, and reference is made to the spe- .. comitant AF is considered to be a valid option. One exception may
..
cific underlying valvular heart disease (VHD).3,6 However, the term is .. be AF in the presence of a biological mitral prosthesis implanted for
still found in the individual SmPCs of each of the NOACs due to the .. rheumatic mitral stenosis. Although mitral valve flow is normalized
..
original wording used in the exclusion criteria of the clinical trials on .. post-mitral valve replacement in these patients, their atria usually re-
which their regulatory approval was based. .. main large and severely diseased. As such, VKA may be the preferred
..
Based on these new developments, a novel classification has recently .. option over NOACs in these patients, but more data are needed.
been suggested where a functional EHRA (Evaluated Heartvalves, .. There are no prospective data available yet on NOACs in patients
..
Rheumatic or Artificial) categorization is proposed, depending on the .. after percutaneous aortic valve interventions [percutaneous translu-
type of OAC use in patients with AF.6 In this scheme, EHRA Type 1 .. minal aortic valvuloplasty or transcatheter aortic valve implantation
..
refers to AF patients with VHD needing therapy with a vitamin K antag- .. (TAVI)] in the presence of AF. Percutaneous transluminal aortic val-
onist (VKA), including in particular moderate–severe mitral stenosis of
.. vuloplasty or TAVI usually requires single or even transient dual anti-
..
rheumatic origin and mechanical prosthetic valve replacement. In con- .. platelet therapy (DAPT).5 The addition of an anticoagulant increases
trast, EHRA Type 2 valvular heart disease refers to VHD patients need-
.. the bleeding risk, and the optimal combination and duration is the
..
ing thromboembolic prevention therapy for AF with a VKA or a .. subject of ongoing studies, in analogy to the situation in acute coron-
NOAC, including essentially all other native valvular stenoses and insuffi-
.. ary syndrome (ACS) patients (see chapter 14).
..
ciencies as well as mitral valve repair, bioprosthetic valve replacements .. In hypertrophic (obstructive) cardiomyopathy (HCM), AF is associ-
and transaortic valve intervention (TAVI).6 Patients with EHRA Type 2
.. ated with a high rate of thromboembolism. There is limited experience
..
valvular heart disease were variously included in these trials and NOACs .. with NOACs in this condition.14,15 In contrast to patients with AF in
..
demonstrated a comparable relative efficacy and safety vs. warfarin in pa- .. the setting of mechanical valves or rheumatic mitral stenosis, however,
tients with vs. without valvular disease, except for a higher risk of bleed- .. there does not seem to be a mechanistic rationale why NOACs should
..
ing with rivaroxaban vs. warfarin in patients with valvular heart disease in .. be inferior to warfarin in HCM. On the contrary, AF in HCM shares
a post hoc analysis of the ROCKET-AF trial.6–12 Non-vitamin K antagonist .. many similarities of HFpEF related AF, for which there has been no indi-
..
oral anticoagulants may therefore be used in such patients (Table 1).3,6,13 .. cation that NOAC would be inferior to VKA.16–18 Moreover, NOACs

on 23 April 2018
..
demonstrate a sustained efficacy over VKA also in other high risk sub- .. rivaroxaban), patients received one dose which was reduced in the
groups (e.g. patients with a high CHA2DS2-VASC score). As such, pa- .. presence of predefined patient characteristics.29,30 In contrast, in RE-
..
tients with HCM may be eligible for NOAC therapy. .. LY (with dabigatran) and ENGAGE-AF (with edoxaban) both a lower
.. and a higher dose were tested in fully powered patient cohorts (with
..
.. further dose reduction for edoxaban in certain patients, see chapter
2. Practical start-up and follow-up .. 15).28,31 Dose reduction of NOACs is primarily recommended only
..
scheme for patients on .. according to the dose reduction criteria investigated in the large
.. phase III trials (see chapter 15). Whenever possible, the tested
non-vitamin K antagonist oral ..
.. standard dose of NOACs should be used. In addition, it is also im-
anticoagulants .. portant to consider co-medications, some of which may be contrain-
..
.. dicated or result in unfavourable drug–drug interactions (see
Choice of anticoagulant therapy and .. chapter 5). Also, patient age, weight, renal function (see chapters
..
initiation .. 6 and 18), and other comorbidities influence the choice. In some pa-
Indication for anticoagulation and choice between .. tients, proton pump inhibitors (PPIs) may be considered to reduce
..
vitamin K antagonist and non-vitamin k antagonist oral .. the risk for gastrointestinal (GI) bleeding, especially in those with a
anticoagulant .. history of GI bleeding or ulcer and patients requiring concomitant
..
Before prescribing a NOAC to a patient with AF, it needs to be .. use of (dual) antiplatelet therapy.32,33 This gastroprotective effect
decided that anticoagulation is indicated based on a risk/benefit
.. was especially demonstrated in patients receiving antiplatelet or VKA
..
analysis.3 The choice of anticoagulant (VKA or NOAC; choice of .. therapy,34–36 while data on the preventive effects in NOAC treated
NOAC) should be made on the basis of indications approved by regu-
.. patients are limited.37 Decision aids are available to guide clinicians
..
latory authorities and specified within guidelines from professional soci- .. about which NOAC may be best suited for a specific target group.38–
eties. Knowledge of kidney function is required, since all NOACs have
.. 41
..
precautions and contraindications based on creatinine clearance (CrCl) ..
(see chapter 6). Also product characteristics (as explained in the
..
.. An anticoagulation card for non-vitamin K antagonist
SmPCs), patient-related clinical factors, and patient preference need to ..
.. oral anticoagulants and the importance of education
be taken into account.3,19,20 .. Patients on VKAs have routinely been advised to carry information
European guidelines have expressed a preference for NOACs ..
.. about their anticoagulant therapy to alert any healthcare provider
over VKA in stroke prevention for AF patients, especially if newly ini- .. about their treatment. It is equally important that those treated with
tiated. This recommendation (Class I, level of evidence A) is based on ..
.. NOACs carry details of this therapy. Each manufacturer provides
the overall clinical benefit of NOACs.3 ..
In some countries, NOAC therapy can only be prescribed (and/or .. proprietary information cards to be completed by physicians and car-
.. ried by patients; however, we recommend that a uniform card should
are reimbursed) if international normalized ratio (INR) control with ..
VKA has been shown to be suboptimal (i.e. after a failed ‘trial of .. be used instead. The proposed NOAC card presented in this version
.. of the Practical Guide has been updated and will be available for
VKA’). There is evidence that clinical scores such as SAMe-TT2R2 ..
may be able to predict poor INR control.21–27 However, further pro- .. download in various languages at www.NOACforAF.eu.
.. It is critically important to educate patients at each visit about the
spective studies would be required to validate and implement such ..
strategies (which are not generally needed from a medical perspec- .. modalities of intake [once daily (OD) or twice a day (BID); intake
.. with food in case of 15 mg/20 mg of rivaroxaban], the importance of
tive, but may be a reasonable cost containment strategy). For the ma- ..
jority of patients, and in accordance with current ESC guidelines, .. strict adherence to the prescribed dosing regimen, how to deal with
.. any lapse in dosing, and to be careful not to leave their medication be-
NOACs need to be considered as the first choice anticoagulation ..
based on the positive results of the large outcome trials.3,28–31
.. hind when travelling. Key educational aspects are also listed on the
.. NOAC anticoagulation card. Education sessions can be further facili-
..
.. tated using specific checklists.3,20,42,43
Choosing the type and dose of non-vitamin K antagonist ..
oral anticoagulant ..
..
With four NOACs available in different dosages for different indica- .. How to organize follow-up?
tions and with different dose reduction criteria, identification of the .. The follow-up of AF patients who are taking anticoagulant therapy
..
correct dose has become more complicated and is one of the key .. needs to be carefully specified and communicated among the differ-
challenges in the daily use and individualization of treatment .. ent caregivers of the patient. The use of any anticoagulant is associ-
..
(see chapter 15). Non-vitamin K antagonist oral anticoagulants do .. ated with some drug–drug interactions which may increase the risk
not have precisely the same rules for prescription and availability in .. of serious bleeding or diminish stroke protection. Treatment re-
..
every country. Local factors, such as regulatory approval, formulary .. quires vigilance due to potentially severe complications, particularly
committees and the cost of therapy, may influence NOAC .. as the target patient population tends to be of older age and frail.
..
availability. .. Patients’ treatment should be reviewed on a regular basis (preferably
All NOACs have been tested in large randomized prospective tri- .. after 1 month initially and at least every 3 months thereafter). As clin-
..
als and resulted in documented efficacy and safety of the respective .. ical experience with NOACs grows,44,45 follow-up intervals may be-
agent. Testing of different doses, however, was carried out differently.
.. come longer, based on individual (patient-specific) or local (centre-
..
In ARISTOTLE (using apixaban) and ROCKET-AF (using . specific) factors. Patient follow-up may be undertaken by general

on 23 April 2018
Figure 1 Structured follow-up. Initiation and structured follow-up of patients on non-vitamin K antagonist oral anticoagulants. It is mandatory to
ensure safe and effective drug intake. The anticoagulation card is intended to document each planned visit, each relevant observation or examination,
and any medication change, so that every person following up the patient is well-informed. Moreover, written communication between different
healthcare providers is required to inform them about the follow-up plan and execution. FU, follow-up.
practitioners with experience in this field and/or by appropriate sec- .. risk factors is of critical importance in order to minimize the risk of
..
ondary care physicians (Figure 1). Growing evidence shows that .. bleeding while on treatment with a NOAC. This approach is also the
nurse-coordinated AF clinics may be very helpful in this regard.46–50
.. one recommended by current AF guidelines.3 Similarly, frailty and risk
..
Each caregiver, including specially trained nurses and pharmacists, .. of falling should not generally be a reason not to anticoagulate patients,
should indicate with a short input on the patient NOAC card
.. but rather to ensure careful education on the best choice of (N)OAC
..
whether any relevant findings were present, and when and where the .. and dose selection, and follow-up of the patient (see chapter 18).
next follow-up is due.
..
..
Table 2 and Figure 1 list the appropriate timing of the relevant aspects ..
which need to be systematically assessed during follow-up.
..
.. 3. Ensuring adherence to
Importantly, the individual patient profile needs to be taken into con- ..
.. prescribed oral anticoagulant
sideration; for example, renal function needs to be assessed more fre- ..
quently (Table 2) in compromised individuals including older patients ..
.. intake
(>_75 years), frail patients,52,53 or in those where an intercurrent condi- ..
tion (such as infection or cancer), which may affect hepatic or renal .. Strict adherence to NOAC intake is crucial as its anticoagulant effect
..
function. Also stroke risk factors alter over time and need to be re- .. wanes within 12–24 h after the last intake.62 Non-vitamin K antagon-
assessed at every patient visit.54 Bleeding risk schould be systematically .. ist oral anticoagulant plasma level as well as general coagulation tests
..
assessed, e.g. by the HAS-BLED score, which has also been validated in .. cannot be considered as tools to monitor adherence since they only
patients on NOACs55 and has shown a better prediction than an ap- .. reflect intake over the last 24(–48) h and the measured level is heavily
..
proach based only on modifiable bleeding risk factors.56–60 Also other .. dependent on the time between last intake and sampling (see chap-
bleeding risk scores have been proposed.59,60 Importantly, however, a .. ter 7). The absence of a need for routine plasma level monitoring
..
high bleeding risk in itself should not automatically result in the decision .. means that NOAC patients are likely to be less frequently seen for
not to anticoagulate as stroke risk tracks along with bleeding risk.3,61 .. follow-up compared with VKA patients. However, there are argu-
..
For the practical management, correcting and minimizing modifiable . ments in favour of regular follow-up assessment for patients on

on 23 April 2018
Table 2 Checklist during follow-up contacts of atrial fibrillation patients on anticoagulation
Interval Comments
1. Adherence Each visit • Instruct patient to bring NOAC card and complete list of medication: make note and assess
average adherence
• Re-educate on importance of strict intake schedule
• Inform about adherence aids (special boxes; smartphone applications; . . .). Consider specific
adherence measuring interventions (review of pharmacy refill data; electronic monitoring51;
special education session; . . .)
2. Thromboembolism Each visit • Systemic circulation (TIA, stroke, peripheral)

• Pulmonary circulation
3. Bleeding Each visit • ‘Nuisance’ bleeding: preventive measures possible? Motivate patient to diligently continue
anticoagulation
• Bleeding with impact on quality-of-life or with risk: prevention possible? Need for revision of
anticoagulation indication, dose or timing?
4. Other side effects Each visit Carefully assess relation with NOAC: decide for continuation (and motivate), temporary cessa-
tion, or change of anticoagulant drug
5. Co-medications Each visit • Prescription drugs; over-the-counter drugs (Pharmacokinetics and drug–drug interactions of
non-vitamin K antagonist oral anticoagulants section).
• Careful interval history: also temporary use can be risky
6. Blood sampling Yearly Patients other than those specified below

(incl. hemoglobin,
6-monthly >_75 years (especially if on dabigatran) or frail (see chapter 2)
renal and liver function)
x-monthly If renal function CrCl <_60 mL/min: recheck interval = CrCl/10
If needed If intercurrent condition that may impact renal or hepatic function
7. Assessing and Each visit • As recommended by current guidelines3

minimizing modifiable • Particularly: uncontrolled hypertension (systolic >160 mmHg), medication predisposing for
risk factors for bleeding bleeding (e.g. aspirin, NSAIDs), labile INR (if on VKA), excessive alcohol intake)
8. Assess for optimal Each visit Especially based on the above, re-assess whether
NOAC and correct a. The chosen NOAC is the best for the patient
dosing b. The chosen dose is correct
For frequency of visits: see Figure 1.

CrCl, creatinine clearance (preferably measured by the Cockcroft–Gault method); NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; TIA, transient is-
chaemic attack.
..
NOACs, particularly in case of relevant co-morbidities such as renal .. discontinuation is still a relevant issue.67,76,77,84,95,99–107 Despite lim-
failure, older age, multiple comorbidities, or frailty. .. ited data on how NOAC adherence can best be optimized, all means
..
Available ‘real world’ data suggest variable adherence to NOAC .. possible should be considered.
intake from 38% to 99% depending on the setting and definition.63–78 ..
..
Although caution is needed when interpreting these results, low ad- ..
herence rates severely diminish the benefit of treatment. Some of .. Practical considerations (Figure 1)
..
these concerns have been alleviated by recent ‘real world’ implemen- .. (1) Patient education on the need for oral anticoagulation therapy and
tation data which mostly confirm the improved risk/benefit profile in .. the importance of strict adherence is important.19,20,42,63,108–111
..
patients treated with NOACs vs. VKAs as observed in the random- .. Many simultaneous approaches can be employed to provide educa-
ized controlled trials suggesting adequate adherence also in daily clin- .. tion including leaflets and instructions at initiation of therapy, a
..
ical practice.66,72,79–98 Although there is evidence for significantly .. patient anticoagulation card, group sessions, and re-education at
lower discontinuation rates with NOACs than with VKAs, .. every prescription renewal. Several organizations also offer online

on 23 April 2018
patient support websites, including EHRA (http://www.afibmatters.

.. (8) Some patients may explicitly prefer INR monitoring to no monitor-
..
org/), the AF Association in the UK (http://www.atrialfibrillation.org. .. ing, or VKA over NOAC therapy. Patient education needs to dis-
..
uk/), Anticoagulation UK (www.anticoagulationuk.org), and AFNET .. cuss these preferences in the context of available clinical trial data
(http://www.kompetenznetz-vorhofflimmern.de/de/vorhofflim .. (including reduction in ICH with NOACs even in the setting of high
..
mern/patienteninformation-vorhofflimmern). Education may be .. TTR).19,42
more effective if directed to specific knowledge gaps of the patient, .. (9) In NOAC patients in whom low adherence is suspected despite
..
measured by validated questionnaires which can be administered .. proper education and additional tools, conversion to VKAs may be
to the patient at the time of a visit, or even via online platforms.64,109,112 .. considered. It needs to be kept in mind, however, that poor adher-
..
(2) Family members should be involved in the care of the patient, so .. ence in VKA treated patients is equally associated with INR fluctua-
that they understand the importance of adherence and help the .. tions and less preferable outcomes.
..
patient in this regard. ..
(3) There should be a pre-specified follow-up schedule for the NOAC ..
..
patient (as suggested in Figure 1) known to and shared by general ..
..
4. Switching between
practitioners, cardiologists, pharmacists, anticoagulation clinics, ..
and other professionals providing care. Each of those involved .. anticoagulant regimens
has a responsibility to reinforce adherence. Everyone’s efforts
..
.. When switching between different anticoagulant therapies, it is
should be communicated to the others, e.g. by filling out a line .. important to ensure the continuation of anticoagulant therapy while
on the NOAC anticoagulation card (see chapter 2). Nurse-coor-
..
.. minimizing the risk for bleeding. This requires insights into the
dinated AF centres may be helpful in coordinating patient follow-up .. pharmaco-kinetics and -dynamics of different anticoagulation regi-
and checking on adherence.46–50
..
.. mens, interpreted in the context of the individual patient.
(4) Some countries have a highly networked pharmacy database, which ..
can help track the number of NOAC prescriptions that individual
..
.. Vitamin K antagonist to non-vitamin K
patients claim. In such countries, pharmacists could be involved in ..
.. antagonist oral anticoagulant
adherence monitoring, and this information should be used to .. The NOAC can immediately be initiated once the INR is <_2.0. If the
cross-check appropriate prescription and dosing. It has been shown ..
.. INR is 2.0–2.5, NOACs can be started immediately or (better) the
that an increased follow-up and adherence monitoring by pharma- .. next day. For INR >2.5, the actual INR value and the half-life of
cists may improve NOAC adherence.113 ..
.. the VKA need to be taken into account to estimate the time when
(5) Many technological aids are being explored to enhance adherence: .. the INR value will likely drop to below this threshold value [half-lives
the day-marked blister pack format; medication boxes (conven- ..
.. for acenocoumarol 8–24 h, warfarin 36–48 h, phenprocoumon
tional or with electronic verification of intake); smartphone applica- ..
.. 120–200 h (6 days)]. The proposed scheme (also shown in Figure 2,
tions114 with reminders and/or SMS messages to alert the patient
.. top panel) tries to unify different specifications from the SmPCs,
about the next intake some even requiring confirmation that the ..
dose has been taken. Popular apps for both Android and iOS devi- .. which state that NOAC can be started when INR is <_3 for rivaroxa-
.. ban, <_2.5 for edoxaban, and <_2 for apixaban and dabigatran.
ces are Medisafe Pill Reminder (also available for watchOS), ..
Dosecast, MyMeds, CareZone, and many others.115 Again, the ..
.. Non-vitamin K antagonist oral
long-term effects of such tools are unknown and one tool may not ..
suit all patients. .. anticoagulant (NOAC) and Vitamin K
..
(6) Once daily dosing regimens generally results in greater adherence .. antagonist (VKA)
vs. BID regimens in cardiovascular patients.116–118 Most, but not all
.. Because of the slow onset of action of VKAs, it may take 5–10 days
..
studies evaluating adherence for NOACs indicate that an OD .. before the INR is in the therapeutic range, with large individual varia-
dosing regimen is superior from a total tablet count perspec-
..
.. tions (see also chapter 20). Therefore, the NOAC and VKA should
tive.66,67,70–74,95,112,119,120 However, it is still uncertain whether any .. be administered concomitantly until the INR is in a range that is consid-
regimen is superior in guaranteeing the clinical thromboembolic
..
.. ered appropriate (Figure 2, lower panel)—similar to the situation when
preventive effects and safety profile as seen in the clinical trials.73,83– .. low molecular weight heparins (LMWHs) are administered during VKA
86,90–95,121,122
Although there are modelling data suggesting that
..
.. initiation. A loading dose is not recommended for acenocoumarol and
there is potentially a larger fluctuation in the anticoagulant activity .. warfarin, but is appropriate with phenprocoumon (see chapter 20).
..
when a single dose is omitted from an OD dosing regimen com- .. As NOACs may have an impact on INR measurements, it is impor-
pared with when a single or even two doses are omitted from a BID .. tant that the INR (i) is measured just before the next intake of the
..
regimen,123 the clinical relevance of these fluctuations is .. NOAC during concomitant administration and (ii) is re-measured
unknown.124 Therefore, it is essential to ensure that drugs are taken .. early after stopping the NOAC (i.e. reflecting solely VKA therapy) to
..
according to the prescribed regimen. .. assure adequate anticoagulation. It is also recommended to closely
(7) In cases where suboptimal adherence is suspected, electronic moni- .. monitor INRs within the first month until stable values have been
..
toring may help to educate the patient by exposing patterns of .. attained (i.e. three consecutive measurements yielded values between
missed doses. Electronic medication intake monitoring can even be .. 2.0 and 3.0). At the end of the ENGAGE-AF trial, patients on edoxa-
..
set up as a telemonitoring service, with the possibility of faster feed- .. ban transitioning to VKA received up to 14 days of a half dose of the
back to the patient.51 The health-economic validity of such an .. NOAC until the INR was within range, in combination with the above
..
approach needs further study. . intensive INR testing strategy.125 Switching according to this scheme

on 23 April 2018
Figure 2 Switching between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants and vice versa. TE, thromboembolic.
..
has proven to minimize the risks of stroke and bleeding125 while, con-
.. Non-vitamin K antagonist oral
..
versely, inadequate transitioning was associated with increased stroke
.. anticoagulant to non-vitamin K
rates.126,127 Whether the half-dose bridging regimen also applies to ..
transitioning of NOACs other than edoxaban is unknown. .. antagonist oral anticoagulant
.. The alternative NOAC can be initiated when the next dose of the ini-
When concomitant administration of a NOAC during the initiation ..
of the VKA is not deemed appropriate, initiation of the VKA can be per- .. tial NOAC is due, except in situations where higher than therapeutic
.. plasma concentrations are expected (e.g. in a patient with impaired
formed after switching the NOAC to LMWH (see below), which may ..
be considered especially in patients with a high thromboembolic risk. .. renal function). In such situations, a longer interval in between
.. NOACs is recommended.
..
..
Non-vitamin K antagonist oral ..
. Aspirin or clopidogrel to non-vitamin K
anticoagulant to parenteral anticoagulants ...
The parenteral anticoagulant [unfractionated heparin (UFH) and ... antagonist oral anticoagulant
LMWH] can be initiated when the next dose of the NOAC would ... The NOAC can be started immediately and aspirin or clopidogrel
be due. .. stopped, unless combination therapy is deemed necessary (see
.. chapter 14).
..
.
Parenteral anticoagulant to non-vitamin ...
..
K antagonist oral anticoagulant ..
Intravenous UFH: NOACs can usually be started 2 (to 4) h after ...
5. Pharmacokinetics and drug–
intravenous UFH (half-life 2 h) is discontinued. .. drug interactions of non-vitamin K
.
Low molecular weight heparin: NOACs can be initiated when the ... antagonist oral anticoagulants
next dose of LMWH would be due. Care should be taken in patients ..
.
with renal impairment where the elimination of LMWH may be ..
. Treatment with VKAs requires careful consideration of multiple food
prolonged.
.. and drug–drug interactions. Despite fewer interactions with the

on 23 April 2018
..
NOAC drugs, physicians should consider the pharmacokinetic inter- .. ARISTOTLE (for apixaban) and as such, no clinical outcome data are
actions of accompanying drugs and comorbidities when prescribing .. available for the use of these doses outside the tested dose reduction
..
NOACs. This section aims to provide a simple guide to deal with .. algorithms. (Of note, a small study in Japanese patients investigated
such situations. However, every patient may require more specific .. the use of 15 mg rivaroxaban as standard dose for stroke prevention
..
consideration, especially when a combination of interfering factors is .. in Japanese patients with apparently preserved efficacy, but the impli-
present. Knowledge regarding interactions (with effect on plasma lev- .. cations of these results outside this setting are unclear.)156
..
els and/or on clinical effects of NOAC drugs) is expanding, so that .. The use of plasma level monitoring for NOAC dose-adjustment
new information may modify existing recommendations. .. or in the setting of ‘off label’ lower dose prescription (see chap-
..
The absorption, distribution, metabolism, and excretion of the dif- .. ters 7 and 8) is discouraged for the vast majority of patients due
ferent NOACs are summarized in the previous version of the guide.2 .. to the lack of outcome data to support such an approach. Indeed,
..
An important interaction mechanism for all NOACs consists of sig- .. an increased risk of bleeding frequently goes along with an
nificant gastrointestinal re-secretion over a P-glycoprotein (P-gp) .. increased risk of stroke due to the overlapping risk factors (includ-
..
transporter after absorption in the gut. Competitive inhibition of this .. ing advanced age, frailty etc.), and inappropriate use of a reduced
pathway will result in increased plasma levels. The P-gp transporter is .. dose may result in lack of stroke prevention.157 However, in rare
..
also involved in renal clearance.128 Many drugs used in AF patients .. cases of potentially substantial drug–drug interactions or special
are P-gp inhibitors (e.g. verapamil, dronedarone, amiodarone, and
.. situations in which a certain NOAC is preferred for certain
..
quinidine). CYP3A4-type cytochrome P450-dependent elimination is .. reasons (e.g. patients after transplantation, patients on HIV medi-
relevantly involved in the hepatic clearance of rivaroxaban and apixa-
.. cation etc.) this may be considered (Figure 3). Importantly,
..
ban.129 Strong CYP3A4 inhibition or induction may affect plasma .. this approach should be limited to centres with extensive
concentrations, and should be evaluated in context (see Tables 3–5
.. experience in the performance and interpretation of such assays
..
and colour coding, discussed below). Non-metabolic clearance of .. as well as in the care of NOAC-treated patients.
..
apixaban is diverse (including excretion of the unchanged compound .. In summary, possible drug–drug interactions, especially when com-
by >50%), which reduces the potential for drug–drug interaction.130 .. bined with other clinical risk factors affecting NOAC plasma levels
..
In general, NOAC use is not recommended in combination with .. are important aspects for choosing a specific NOAC for a specific
drugs that are strong inhibitors of both CYP3A4 and P-gp. .. patient. Table 3 gives an overview of the effect of various frequently
..
Conversely, strong inducers of P-gp and/or CYP3A4 (such as rifampi- .. used agents on NOAC plasma levels; Table 4 focusses on common
cin, carbamazepine, etc.) will markedly reduce NOAC plasma levels; .. cancer drugs (see also chapter 19), Table 5 on antiepileptic drugs
..
such combinations should be avoided or used with great caution and .. (see also chapter 18.4). Taking into consideration these factors as
surveillance. .. well as the setup and results from the large randomized NOAC out-
..
Specific dosing algorithms for the different NOACs have been .. come trials the algorithm shown in Figure 3 may assist in a rational
evaluated in large Phase III clinical trials and resulted in documented .. selection of a specific NOAC and/or a ‘reduced dose’ based on
..
efficacy and safety of the respective agent. Of note, only one Phase III .. drug–drug interactions and other clinical risk factors. Unfortunately,
study prospectively used concomitant therapy with certain drugs as a .. for many potential interactions with drugs that are often used in AF
..
dose reduction criterion (dose reduction of edoxaban in ENGAGE- .. patients no detailed information is available yet (hatched in the
AF in patients treated with potent P-gp inhibitors verapamil, quini- .. tables).
..
dine, or dronedarone). Dose reduction of all NOACs is primarily ..
recommended along the published dose reduction criteria (see
..
..
chapter 15). Whenever possible, the tested standard doses of ..
NOACs should be used.
.. Food intake, antacids, and nasogastric
..
However, there is some rationale for reducing the dose of .. tube administration
NOACs in patients with a high bleeding risk and/or when a higher
..
.. Rivaroxaban 15 mg/20 mg for stroke prevention in AF needs to be
plasma level of the drug can be anticipated based on a combination of .. taken with food [the area under the curve (AUC) plasma concentra-
factors.3,151–154 Prospective clinical trial data only exist for ‘lower
..
.. tions increases by 39% to a very high bioavailability of almost 100%],
doses’ of dabigatran (110 mg BID) and edoxaban (30/15 mg OD; but .. while there is no food interaction with the other NOACs. The con-
..
not approved). For dabigatran 110 mg BID, a similar stroke risk and .. comitant use of PPIs and H2-blockers leads to a small reduction in
reduced major bleeding vs. warfarin was observed28; however, this .. bioavailability of dabigatran, but without effect on clinical effi-
..
was in an unselected AF population and not in selected high-risk .. cacy.158,159 There is also no relevant antacid interaction for the other
patients in whom plasma levels may be increased and the benefit of a .. NOACs.140,160,161 There are no pharmacokinetic data on fish oil sup-
..
reduction in major bleeding may be lost.152,155 For edoxaban 30/ .. plements for any of the NOACs, but interaction is unlikely.
15 mg OD a 41% higher ischaemic stroke risk compared with a well- .. Data have shown that administration in crushed form, e.g. via a
..
controlled warfarin arm (median TTR >68%) was observed leading .. nasogastric tube, does not alter the bioavailability for apixaban, rivar-
to non-approval of this dosing regimen; at the same time, a reduction .. oxaban, and edoxaban.162–164 Also an oral solution of apixaban 5 mg
..
in major bleeding, cardiovascular- and all-cause mortality was .. (12.5 mL of 0.4 mg/mL oral solution administered via oral syringe
observed compared with warfarin.31,153 These data represent the .. together with 240 mL of water) has been developed, which has
..
only available RCT evidence of a ‘lower dose’ of a NOAC for stroke .. shown comparable exposure as the tablet formulation.165 In contrast,
prevention in AF on hard clinical endpoints.28,31 In contrast, no ‘lower .. dabigatran capsules must not be opened as it results in a substantial
..
dose’ arm was included in ROCKET-AF (for rivaroxaban) or . increase in drug bioavailability (þ75% per SmPC).

on 23 April 2018
Table 3 Effect of drug–drug interactions and clinical factors on NOAC plasma levels (‘area under the curve’)

on 23 April 2018
The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC (where available) or expert opinion.
White: No relevant drug–drug interaction anticipated.
Yellow: Consider dose adjustment or different NOAC if 2 or more ‘yellow’ factors are present (see Figure 3).
Orange: Consider dose adjustment or different NOAC (see Figure 3).
Red: contraindicated/not recommended.
Brown: Contraindicated due to reduced NOAC plasma levels.
Blue: The label for edoxaban mentions that co-administration is possible in these cases, despite a decreased plasma level, which are deemed not clinically relevant. Since not
tested prospectively, however, such concomitant use should be used with caution, and avoided when possible.
BCRP, breast cancer resistance protein; NSAID, non-steroidal anti-inflammatory drugs; H2B, H2-blockers; PPI, proton pump inhibitors; P-gp, P-glycoprotein; GI,
gastrointestinal.
a
Based on in vitro investigations, comparing the IC50 for P-gp inhibition to maximal plasma levels at therapeutic dose, and/or on interaction analysis of efficacy and safety end-
points in the Phase-3 clinical trials.29,30 No direct PK interaction data available.
b
Dose reduction based on published criteria (see Table 13, Figure 3).
c
Age had no significant effect after adjusting for weight and renal function.
d
Data from Phase I study. Evidence from Re-DUAL PCI indicate safety in the (small) subgroup on dabigatran and ticagrelor.141

on 23 April 2018
Table 4 Anticipated effects of common anticancer drugs on non-vitamin K antagonist oral anticoagulants plasma
levels

on 23 April 2018

on 23 April 2018

on 23 April 2018
Purine analogs: Mercaptopurine, Thioguanine, Pentostatin, Cladribine, Clofarabine, Fludarabine.

Pyrimidine analogs: Fluorouracil, Capeticabine, Cytarabine, Gemcitabine, Azacitadine, Decitabine.
Anticipated effects of common anticancer drugs on NOACs plasma levels.144
The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC (where available) or expert opinion.
Some of the colour codes will likely require adaptation as more data become available over time.
Yellow (light): Caution is needed in case of polypharmacy or in the presence of >_2 bleeding risk factors.
Yellow: Consider dose adjustment or different NOAC if 2 or more ‘yellow’ factors are present (see Figure 3).
Orange: Consider dose adjustment or different NOAC (see Figure 3).
Red: contraindicated/not recommended.
Brown (dark): Contraindicated due to reduced NOAC plasma levels.
Brown (light): Use with caution or avoid. Either expert opinion or the NOAC label mentions that co-administration is possible despite a decreased plasma level, which is
deemed not clinically relevant (nevertheless, since not tested prospectively, such concomitant use should be used with caution, and avoided when possible).
Where no data or SmPC instructions were available, expert opinion was based on the following principles:
• Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).

• Moderate CYP3A4 or P-gp inducer—use with caution or avoid (light brown).
• Strong CYP3A4 and/or inhibitor—should not be used (red).
• Moderate CYP3A4 or P-gp inhibitor—use with caution, consider dose reduction or different NOAC (orange).
• Mild CYP3A4 and/or P-gp inducers or inhibitors—caution is needed with polypharmacy or in the presence of >_2 bleeding risk factors (yellow).
Rate and rhythm control drugs .. interaction pharmacokinetic data available for apixaban or rivaroxaban
..
Possible interactions are listed in Table 3. The P-gp inhibiting effects .. with verapamil. Diltiazem has a lower inhibitory potency of P-gp, result-
of verapamil on dabigatran levels are dependent on the verapamil for-
.. ing in non-relevant interactions,166 although there is a 40% increase in
..
mulation: when an immediate release preparation is taken within 1 h .. plasma concentrations of apixaban (‘yellow’; Table 3).136
prior to dabigatran intake, plasma levels of dabigatran may increase
.. For edoxaban a 40% increase in AUC was observed in patients on
..
up to 180%. Separating both drugs’ intake >_2 h removes the interac- .. amiodarone with normal renal function.132 Of note, there was a sig-
..
tion (but is hard to guarantee in clinical practice). With a slow-release .. nificant interaction for amiodarone on the efficacy of the low-dose
verapamil preparation, there may be a 60% increase in dabigatran .. edoxaban regimen in the Phase III trial, exemplifying the potential
..
concentration. Pharmacokinetic data from the RE-LY trial showed an .. impact of changed plasma levels.133 Nevertheless, dose reduction is
average 23% increase in dabigatran levels in patients taking verapa- .. not recommended in case of concomitant administration.
..
mil.166 It is advised to use the lower dose dabigatran (110 mg BID) .. There is a strong effect of dronedarone on dabigatran plasma lev-
when combining it with verapamil (‘orange’, Table 3). .. els, which constitutes a contraindication for concomitant use. The
..
A similar interaction had initially been noted for edoxaban.167 .. interaction potential is considered moderate for edoxaban (‘orange’),
However, after analysis of Phase III data, this interaction was considered .. and dronedarone intake was a dose reduction criterion in the
..
not to be clinically relevant and no dose reduction is recommended in .. ENGAGE-AF protocol.31 There are no interaction pharmacokinetic
the European label. However, caution might be warranted in combina- .. data available for rivaroxaban and apixaban but effects on their
..
tion with other factors (‘yellow’, Table 3). On a more general level, .. plasma levels can be anticipated based on P-gp and CYP3A4 interac-
these findings underline the difference between changes in plasma lev- .. tions, calling for caution (i.e. ‘yellow’) or avoidance (for rivaroxaban).
..
els and influence on hard clinical endpoints. There are no specific . Interestingly, a recent analysis of NOAC plasma levels before surgical

on 23 April 2018
Table 5 Anticipated effects of common antiepileptic drugs on non-vitamin K antagonist oral anticoagulants plasma
levels
– –
Anticipated effects of common antiepileptic drugs on NOACs plasma levels.147,150

The hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC, where available, or expert opinion.
Some of the colour codes will likely require adaptation as more data become available over time.
Brown (dark): Contraindicated due to reduced NOAC plasma levels.
Brown (light): Use with caution or avoid—either the label for the respective NOAC mentions that co-administration is possible despite a decreased plasma level, which are
deemed not clinically relevant (nevertheless, since not tested prospectively, such concomitant use should be used with caution, and avoided when possible) or expert opinion.
Where no data or SmPC instructions were available, expert opinion was based on the following principles:
• Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).

• Moderate CYP3A4 or P-gp inducer—use with caution or avoid (light brown).
• Strong CYP3A4 and/or inhibitor—should not be used (red).
• Moderate CYP3A4 or P-gp inhibitor—use with caution, consider dose reduction or different NOAC (orange).
• Mild CYP3A4 and/or P-gp inducers or inhibitors—caution is needed with polypharmacy or in the presence of >_2 bleeding risk factors (yellow).
..
intervention demonstrated that concomitant intake of verapamil, .. enzymes or P-gp/breast cancer resistance protein (BCRP), they do
dronedarone, or amiodarone was significantly associated with higher .. not inhibit or induce any of them.
..
pre-operative plasma levels.168 .. Co-administration of NOACs with other substrates of CYP3A4
.. (e.g. midazolam), P-gp (e.g. digoxin), or both (e.g. atorvastatin) does
..
Other drugs .. not significantly alter plasma levels of these drugs.
Table 3 also lists the potential interaction mechanisms for other drugs .. The platelet inhibitor ticagrelor is a P-gp inhibitor. Concomitant
..
and their possible clinical relevance. Since some drugs are inhibitors .. administration of ticagrelor 180 mg loading dose with dabigatran
of both CYP3A4 and P-gp, they may have an effect on NOAC plasma
.. 110 mg increased dabigatran Cmax by 65% (AUC þ49%), compared
..
levels although the P-gp and/or CYP3A4 effect in itself is less pro- .. with dabigatran given alone. When a loading dose of 180 mg ticagrelor
nounced. In general, although NOACs are substrates of CYP
.. was given 2 h after 110 mg dabigatran etexilate, the increase of

on 23 April 2018
Figure 3 NOAC selection based on drug–drug interactions and/or risk of bleeding. Use of plasma level measurements to guide dosing is generally
discouraged and should only be used in rare cases of potentially substantial interactions or special situations, and only in centres with great experi-
ence in the performance and interpretation of such assays as well as the care of NOAC-treated patients.
dabigatran Cmax and AUC was reduced to þ23% and þ27%, respec- ..
.. Polypharmacy
tively, compared with dabigatran given alone. As per the dabigatran .. Polypharmacy is a well-established risk factor for adverse events
SmPC, this staggered intake is the recommended administration strat- ..
.. resulting from drug–drug interactions.173–175 In ROCKET-AF and
egy for starting with the loading dose of ticagrelor. Concomitant .. ARISTOTLE, patients concomitantly taking several (>_5 or >_9) medi-
administration of 90 mg ticagrelor BID (maintenance dose) with ..
.. cations experienced similar outcomes and consistent treatment
110 mg dabigatran increased the adjusted dabigatran AUC and Cmax by .. effects of either NOAC relative to warfarin.174,175 Although reassur-
26% and 29%, respectively, compared with dabigatran given alone.
..
.. ing, these findings are derived from post hoc analyses with many limita-
These data are based on a Phase I study; the use of ticagrelor and dabi- .. tions. In addition, concomitant use of strong CYP3A4 inhibitors (e.g.
gatran post-percutaneous coronary intervention (PCI) as studied in the
..
.. ketoconazole, ritonavir) or inducers (e.g. phenytoin, rifampicin) was
RE-DUAL PCI study is discussed in detail later (see chapter 14).141 .. not allowed. Conversely, event rates with warfarin also increase in
Of note, ‘herbal’ medicines are frequently underestimated regard-
..
.. patients with polypharmacy, likely not only due to interactions but
ing their potential for interaction, including the potent CYP3A4 and .. also due to the higher baseline risk of these patients. While polyphar-
P-gp inducer St. John’s wort, although relevant interactions have
..
.. macy in itself is not a contraindication for the use of NOACs, special
been published (also outside the anticoagulation field).169 Due to the .. care needs to be taken when treating these vulnerable patients
..
relevant decrease in NOAC levels, the concomitant use of St. John’s .. (Tables 3–5; Figure 3).
wort is not recommended. ..
..
..
Pharmacodynamic interactions ..
..
Apart from the pharmacokinetic interactions, co-administration .. 6. Non-vitamin K antagonist oral
of NOACs with other anticoagulants, platelet inhibitors (e.g. ..
.. anticoagulants in patients with
aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, others), and ..
non-steroidal anti-inflammatory drugs increases the risk of bleed- .. chronic kidney disease or
..
ing.170–172 Therefore, such combinations should be carefully balanced .. advanced liver disease
against the potential benefit in each clinical situation. Co-
..
..
administration of NOACs with dual antiplatelet drugs requires active .. Kidney and liver function both play an important role in the metabo-
measures to reduce time on triple therapy (see chapter 14).
.. lism and elimination of NOACs.

on 23 April 2018
.. OD in the upper range of CrCl in an exploratory (not pre-defined)

Oral anticoagulation in chronic kidney ..
.. subgroup analysis, the safety and net clinical benefit of edoxaban
disease ..
.. compared with warfarin were consistent across the spectrum of
There is a bidirectional interaction between AF and chronic kidney
disease (CKD): AF facilitates the development or progression of ... renal function.190
..
CKD, and the prevalence and incidence of AF increases with decreas- ..
ing renal function.176–179 Patients with AF and CKD have an increased .. Oral anticoagulant therapy in patients with mild or
.. moderate CKD (CrCl 30 mL/min)
morbidity and mortality due to their excessive risk for both throm- ..
boembolic and severe bleeding events, making risk stratification and .. The benefit of VKAs in terms of reduced stroke and mortality is well
.. established in AF patients with mild to moderate CKD.191–194
treatment challenging.180,181 In addition, all four NOACs are at least ..
partly eliminated by the kidneys. Dabigatran has the greatest extent
.. Compared with warfarin, all four NOACs showed consistent efficacy
..
of renal elimination (80%), whereas 50%, 35%, and 27% of edoxaban, .. and safety in patients with mild to moderate CKD compared with non-
rivaroxaban, and apixaban, respectively, are cleared via the kidneys as
.. CKD patients in the respective Subgroup analyses of pivotal NOAC
..
unchanged drug (Table 6). .. trials.190,195–199 In addition, the ARISTOTLE trial data analysis sug-
Clinical decisions on how to treat an AF patient with CKD who
.. gests that the bleeding benefit with apixaban compared with warfarin
..
needs OAC requires the assessment of renal function. Basic informa- .. becomes significantly more prominent at lower CrCl values, while
tion on the diagnosis/staging of CKD and assessment of renal function
.. the stroke reduction benefit is maintained.181,197 In contrast, the
..
is provided in Table 7. Several equations are available to gauge a .. bleeding benefit of 110 mg dabigatran over warfarin is lost in patients
.. with CrCl <50 mL/min while maintaining a similar stroke risk reduc-
patient’s renal function, all with inherent strengths and limitations. ..
The CKD-EPI equation estimating the glomerular filtration rate is rec- .. tion compared with VKA.195
.. A post hoc analysis of the RE-LY trial data showed a significantly
ommended by the National Kidney Foundation because it has been ..
shown to be reliable across the range of CKD stages.187 However, in .. faster rate of decline in renal function during the trial in patients on
.. warfarin (especially at lower TTRs) compared with those on dabiga-
the context of NOAC treatment, renal function should preferably be ..
estimated by calculating the CrCl using the Cockcroft–Gault method, .. tran200 suggesting that it may delay the decline in renal function com-
.. pared with warfarin. Moreover, it has been suggested that warfarin
which was used in most NOAC trials and therefore also in this ..
Practical Guide. Importantly, CKD can only be diagnosed and assessed .. use may be associated with increased vascular calcification and/or the
.. development of acute warfarin-related nephropathy with or without
in stable situations and must not be confused with acute renal failure. ..
In the latter case, serum creatinine levels and calculated CrCl may .. clinically overt haematuria.201
.. Appropriate dosing is an essential issue to be addressed when
indicate mildly reduced (or even normal) renal function when in real- ..
ity it is severely impaired. In situations with acute renal failure, any .. using NOACs in patients with CKD (Figure 4). While rivaroxaban,
.. apixaban, and edoxaban doses were reduced according to renal func-
NOAC therapy needs to be discontinued and parenteral anticoagula- ..
tion initiated (after careful risk-benefit analysis). .. tion in their respective randomized clinical trials (RCTs), patients in
.. the RE-LY trial were randomized to dabigatran 150 mg BID or
In patients on NOACs, renal function needs to be monitored dili- ..
gently, at least yearly, to detect changes in renal function and adapt
.. 110 mg BID without dose reduction for renal insufficiency. Per SmPc,
..
the dose accordingly. If renal function is impaired (i.e. CrCl <_60 mL/ .. a recommendation for the use of dabigatran 110 mg BID is made in
min), a more frequent evaluation is recommended (e.g. by dividing
.. patients with CrCl< 50 mL/min at high risk of bleeding. With the
..
CrCl by 10 to obtain the minimum frequency of renal function testing .. availability of three FXa inhibitors with less pronounced renal clear-
in months; Table 2). In patients with additional risk factors (e.g. older
.. ance, the use of the latter may be preferred in this patient population.
..
age, frail, multiple co-morbidities etc.), it may be evaluated even more .. The use of NOAC doses inconsistent with drug labelling has been
frequently, especially if on dabigatran. Intercurrent acute illness (like
.. associated with worse outcome; for example, underdosing of apixa-
..
infections, acute heart failure, etc.) may transiently affect renal func- .. ban in patients with normal or only mildly reduced renal function has
.. been associated with less effectiveness (i.e. higher stroke rates) and
tion and should also trigger re-evaluation; importantly, patients need ..
to be alerted that in such situations they should seek contact with .. no additional safety benefit in a large ‘real-world’ AF cohort.202
..
their healthcare provider. This guidance is also presented in the ..
updated NOAC Card. .. Oral anticoagulant therapy in patients with a CrCl
..
On the other side of the spectrum, a possibly decreased efficacy .. of 15–29 mL/min
of edoxaban 60 mg OD compared with warfarin was observed in .. There are no RCT data on the use of NOACs for stroke prevention
..
patients with a CrCl of >95 mL/min.31 Interestingly, as a result of .. in AF patients with severe CKD or on renal replacement therapy
these findings, further post hoc analyses revealed a similar effect .. (RRT) since all landmark NOACs trials essentially excluded patients
..
also for Rivaroxaban188 and Apixaban.189 In 2015 the FDA issued a .. with a CrCl of <30 mL/min (except for a few patients on apixaban
warning about the use of edoxaban in individuals with such a high- .. with CrCl 25–30 mL/min). However, VKA have also never been pro-
..
normal CrCl, and recommended the use of other oral anticoagu- .. spectively assessed in a RCT in this patient population.
lants in these patients. Also the EMA advised that ‘edoxaban .. Rivaroxaban, apixaban, and edoxaban (but not dabigatran) are
..
should only be used in patients with high CrCl after a careful evalu- .. approved in Europe for the use in patients with severe CKD (Stage 4,
ation of the individual thromboembolic and bleeding risk’. A post
.. i.e. a CrCl of 15–29 mL/min), with the reduced dose regimen (see
..
hoc analysis of the ENGAGE AF data showed that despite the .. chapter 15 and Figure 4). In view of the individual NOACs’ pharma-
trend towards a decrease in relative efficacy of edoxaban 60 mg
.. cokinetics, dose-reduction criteria and available evidence from RCTs,

on 23 April 2018
Table 6 Absorption and metabolism of the different NOACs
Dabigatran158,182 Apixaban183 Edoxaban184 Rivaroxaban185,186
Bioavailability 3–7% 50% 62% 15 mg/20 mg: 66% without food,

80–100% with food
Prodrug Yes No No No
Clearance non-renal/renal 20%/80% 73%/27% 50%/50% 65%/35%

of absorbed dose
Plasma protein binding 35% 87% 55% 95%
Dialysability 50–60% 14% n.a. n.a.

(in part dialysable) (in part dialysable) (in part dialysable) (in part dialysable)
Liver metabolism: No Yes [elimination, Minimal (<4% of Yes (hepatic elimination 18%)131
CYP3A4 involved moderate contribution elimination)
(25%)a]
Absorption with food No effect No effect 6-22% more; minimal þ39% more (see above)
effect on exposure
Absorption with H2B/PPI -12% to 30% (not No effect No effect No effect

clinically relevant)
Asian ethnicity þ25%166 No effect No effect No effect
Elimination half-life 12–17 h 12 h 10–14 h 5–9 h (young)
11–13 h (elderly)
Other Dyspepsia (5–10%) Intake of 15 mg/20 mg with

food mandatory
a
Hepatic metabolism in total of 25%, mostly via CYP3A4, with minor contributions of CYP1A2, 2J2, 2C8, 2C9, and 2C19.
..
the use of either apixaban or edoxaban may be preferable in these .. assessed the net benefit found no changes in overall-mortality for war-
patients. Apixaban is least renally cleared (27%), and the dose is .. farin in dialysis-dependent patients.193 Of note, the use of warfarin in
..
reduced by 50% in rather stringent conditions according to its dose .. patients with end-stage renal failure may in some cases result in calci-
reduction algorithm; furthermore the relative safety of apixaban vs.
.. phylaxis, a painful and often lethal condition caused by calcification and
..
warfarin has been demonstrated to increase with decreasing renal .. occlusion of cutaneous arteries and arterioles.204–208
function.197 Edoxaban is 50% renally cleared, but its dose reduction
.. The efficacy and safety of NOACs in patients with end-stage renal
..
to 50% is applied more rapidly and was tested in a large subgroup. .. dysfunction and on dialysis is unclear and subject to ongoing studies.
Rivaroxaban has an intermediate renal clearance (33%), and its dose
.. Registry data have shown a higher incidence of hospitalization or death
..
is reduced less (by 25%) under similar conditions as edoxaban. In the .. from bleeding in dialysis-dependent patients started on off-label dabiga-
US (but not in Europe), a low dose dabigatran 75 mg BID regimen has
.. tran or rivaroxaban compared with VKA.209 In the US (but not in
..
been approved for patients with severe CKD (a CrCl of 15–29 mL/ .. Europe) apixaban 5 mg BID is currently approved in chronic, stable
..
min), based on pharmacokinetic simulations. Further randomized trial .. dialysis-dependent patients. However, plasma levels with apixaban
data are urgently required for these difficult to treat patients. .. 5 mg BID were recently shown to be supra-therapeutic.210 Levels simi-
..
.. lar to those in patients with normal renal function on the respective
Oral anticoagulant therapy in patients with a CrCl of .. NOACs were found for apixaban 2.5 mg BID in a small number
..
15 mL/min and on dialysis .. of patients on dialysis,210 for edoxaban 15 mg OD (in Japanese patients
Numerous observational studies yielded conflicting results for VKA .. with severe renal insufficiency)211 and rivaroxaban 10 mg OD in end-
..
regarding efficacy without a clear consistent benefit of VKA in patients .. stage renal disease patients.212 It needs to be kept in mind, however,
with severe renal dysfunction,192–194,203 Most studies confirmed a sig-
.. that plasma levels are a surrogate endpoint. In the absence of hard end-
..
nificantly lower incidence of stroke and embolism under warfarin, but .. point studies (which are currently ongoing, e.g. NCT02942407,
also a markedly increased bleeding risk.192–194 The only registry that
.. NCT02933697), the routine use of NOACs in patient with severe

on 23 April 2018
Table 7 Criteria for diagnosing chronic kidney disease; estimation of renal function and categories of renal
dysfunction
Decreased GFRa GFR <60 mL/min/1.73 m2
Markers of kidney damage (>_1) • Excessive albuminuria (AER >_30 mg/24 h; ACR >_30 mg/g or >_3 mg/mmol)
• Urine sediment abnormalities
• Electrolyte or other abnormality caused by tubular disorders
• Abnormal histology
• Structural abnormalities detected by kidney imaging
• History of kidney transplantation
GFR category CKD stage GFRa Descriptions
G1 1 >_90 Normal or high
G2 2 60–89 Mildly decreased
G3a 45–59 Mildly to moderately decreased

3
G3b 30–44 Moderately to severely decreased
G4 4 15–29 Severely decreased
G5 5 <15 Kidney failure (requires renal replacement therapy – dialysis or kidney transplantation)
Estimation of renal function in NOAC patients best by Creatinine Clearance (Cockroft–Gault):
ð140 – ageÞweight ðin kgÞ½0:85 if female

CrCl ½mg=dl=
72serum creatinine ðin mg=dLÞ
Online calculators available at (e.g.): www.kidney.org/professionals/kdoqi/gfr_calculator; www.nephron.com/cgi-bin/CGSI.cgi; www.mdcalc.com/creatinine-clearance-cockcroft-

gault-equation; https://reference.medscape.com/calculator/creatinine-clearance-cockcroft-gault.
Popular Apps are NephroCalc, MedMath, MedCalc, Calculate by QxMD, and Archimedes.
CKD, chronic kidney disease; GFR, glomerular filtration rate; AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CrCl, creatinine clearance.
a
mL/min/1.73 m2.
renal dysfunction (CrCl <15 mL/min) as well as in patients on dialysis is .. values and difficulties in selecting appropriate VKA dosing.216 Patients
..
best avoided. In fact, given the lack of strong evidence also for VKA in .. with significant active liver disease including cirrhosis, or those
this patient population, the decision to anticoagulate remains a very
.. with persistent (as confirmed by repeated assessment >_1 week
..
individualized one requiring a multidisciplinary approach considering .. apart) elevation of the liver enzymes or bilirubin [e.g. alanine transa-
and respecting patients’ preferences.180,208,213
.. minase or aspartate transaminase >_2(–3) times the upper limit of
..
There are no data on the use of NOACs in AF patients after kid- .. normal (ULN) or total bilirubin >_1.5 times the ULN] were excluded
ney transplantation. If NOACs are used in such patients, the dosing
.. from the landmark NOAC trials in AF.28–31 Consequently, all four
..
regimen should be selected according to the estimated renal func- .. NOACs are contraindicated in patients with hepatic disease associ-
tion, and caution is needed with respect to possible drug–drug inter-
.. ated with coagulopathy and clinically relevant bleeding risk including
..
actions between the NOAC and concomitant immunosuppressive .. Child-Turcotte-Pugh C cirrhosis (Table 8). Rivaroxaban should also
..
therapies (see chapter 5). .. not be used in AF patients with Child B liver cirrhosis due to a >two-
.. fold increase in drug exposure in these patients.217 Dabigatran, apixa-
..
.. ban and edoxaban may be used with caution in patients with Child B
Non-vitamin K antagonist oral .. cirrhosis (Table 8).218,219 Initiation and follow-up at a specialised
..
anticoagulants in liver disease .. centre in a multidisciplinary team (including a hepatologist and a hae-
Advanced liver disease is associated with increased bleeding risk, .. matologist) is recommended.
..
but is also a prothrombotic disorder.214 In addition, significant .. Due to the withdrawal/non-approval of the direct thrombin inhibi-
liver disease can profoundly affect hepatic clearance and drug .. tor ximelagatran from the market in 2006 as a result of its hepato-
..
metabolism, and altered functionality of the liver enzymes and .. toxic side effects,220 there had been some concern about the
transporters may alter drug response and facilitate drug-induced .. potential of NOACs to cause drug-induced liver injury. However, no
..
liver injury.215 .. signal for increased hepatotoxicity has been observed in any of the
The use of VKAs in patients with advanced liver disease and coa-
.. NOAC trials.221 In fact, the risk of liver injury may even be lower
..
gulopathy (Table 8) is challenging due to intrinsically elevated INR . than with VKA.222–224

on 23 April 2018
CrCl Dabigatran Rivaroxaban Edoxaban Apixaban
60 mg
95 ml/min
2x 150 mg 20 mg
60 mg #
2x5 mg /
2x2.5 mg $
50 ml/min
2x150 mg or
40 ml/min 2x110 mg * 15 mg 30 mg
30 ml/min
15 mg 30 mg 2x2.5 mg
15 ml/min
Dialysis
Figure 4 Use of non-vitamin K antagonist oral anticoagulants according to renal function. *2 110 mg in patients at high risk of bleeding (per
SmPc). #Other dose reduction criteria may apply (weight <_60 kg, concomitant potent P-Gp inhibitor therapy). $2 2.5 mg only if at least two out of
three fulfilled: age >_80 years, body weight <_60 kg, creatinine >_1.5 mg/dL (133 mmol/L). Orange arrows indicate cautionary use (dabigatran in moder-
ate renal insufficiency, FXa inhibitors in severe renal insufficiency, edoxaban in ‘supranormal’ renal function); see text for details.
Table 8 Calculation of the Child-Turcotte-Pugh score and use of NOACs in hepatic insufficiency
Parameters 1 point 2 points 3 points
Encephalopathy No Grade 1–2 (suppressed with medication) Grade 3–4 (refractory/chronic)
Ascites No Mild (diuretic-responsive) Moderate–severe (diuretic-refractory)
Bilirubin <2 mg/dL 2–3 mg/dL >3 mg/dL
<34 lmol/L 34–50 lmol/L >50 lmol/L
Albumin >3.5 g/dL 2.8–3.5 g/dL <2.8 g/dL
>35 g/L 28–35 g/L <28 g/dL
INR <1.7 1.71–2.30 >2.30
Child–Pugh category Dabigatran Apixaban Edoxaban Rivaroxaban
A (5–6 points) No dose reduction No dose reduction No dose reduction No dose reduction
B (7–9 points) Use with caution Use cautiously Use cautiously Do not use
C (10–15 points) Do not use Do not use Do not use Do not use

on 23 April 2018
..
7. How to measure the ... coagulation assay in a patient treated with a NOAC, it is important to
.. know when the NOAC was administered relative to the time of
anticoagulant effect of non-vitamin .. blood sampling. The maximum effect of the NOAC on the clotting
..
K antagonist oral anticoagulants? .. test will occur at its maximal plasma concentration, which is approxi-
.. mately (1-)2–3 h after intake for each of these drugs (Table 9).
Routine coagulation tests [prothrombin time (PT) and activated ..
.. Of note, NOACs affect routine coagulation test (PT and aPTT),
partial thromboplastin time (aPTT)] generally do not provide an .. and also more specialized assays (such as lupus anticoagulant assays
accurate assessment of NOAC anticoagulant effects. In contrast, the ..
.. and coagulation factors) can be altered.
latter can be measured via specific coagulation assays developed for ..
the quantification of NOAC plasma levels.225–227 Most routine coa-
..
.. Specific considerations
gulometers are capable of measuring NOAC plasma levels within ..
<_30 min. Institutions are recommended to consider 24/7 availability
.. Dabigatran
.. For dabigatran, the aPTT may provide a qualitative assessment of dabi-
of these tests for emergency situations. In contrast, point-of-care ..
tests are not yet available for patients on NOACs.228
.. gatran level and anticoagulant activity. The relationship between dabiga-
.. tran and the aPTT is curvilinear.229 An aPTT in the normal range does
Anti-FXa chromogenic assays are available to measure plasma con- ..
centrations of the FXa inhibitors using validated calibrators. Low and
.. not exclude dabigatran levels in the ‘on therapy’ range, but excludes
.. drug levels above the ‘on therapy’ range when a sensitive assay is used.
high plasma levels can be measured with acceptable inter-laboratory ..
.. Dabigatran has little effect on the PT and INR at clinically relevant
precision. The absence of anti-Xa activity with these assays excludes .. plasma concentrations, which are therefore unsuitable for the assess-
clinically relevant drug levels. Conversely, the diluted thrombin time ..
.. ment of the anticoagulant activity of dabigatran.228
(dTT) test as well as the ecarin chromogenic assay (ECA) display a ..
.. The thrombin time (TT) is very sensitive to the presence of dabiga-
direct linear relationship with dabigatran concentration and are suit-
.. tran and a normal TT excludes even very low levels of dabigatran.
able for the quantitative assessment of dabigatran concentrations. ..
The use of appropriate calibrators allows for the determination of .. The TT is not suited for the quantitative assessment of dabigatran
.. plasma concentrations in the range expected with clinical use. In con-
plasma concentrations of all NOACs. Even though levels in clinical ..
trials were measured using HPLC/MS, drug measurement and moni- .. trast, dTT tests and the ECA allow for the measurement of dabiga-
.. tran levels in the range that is clinically relevant.
toring can be closely approximated using a calibrated dTT/ECA assay ..
for dabigatran or chromogenic anti-FXa assay for FXa-inhibitors. It is ..
..
recommended to primarily use plasma concentrations rather than .. Factor Xa inhibitors (rivaroxaban, apixaban, and
anti-FXa activity or dTT to quantitatively assess the concentration of .. edoxaban)
..
a NOAC. An overview of the expected peak and trough levels in .. The different factor Xa-inhibitors affect the PT and the aPTT to a
patients on NOACs can be found in Table 9. When interpreting a .. varying extent. The aPTT cannot be used for any meaningful
Table 9 Plasma levels and coagulation assays in patients treated with non-vitamin K antagonist oral anticoagulants
Dabigatran229,230 Apixaban231, SmPc Edoxaban184,232 Rivaroxaban131,186
Expected plasma levels of NOACs in patients treated for AF (based on dTT/ECA for dabigatran and anti-FXa activity for Xa inhibitors)
Expected range of plasma levels at peak 64–443 69–321 91–321 184–343

for standard dose (ng/mL)a
Expected range of plasma levels at trough 31–225 34–230 31–230 12–137

for standard dose (ng/mL)a
Expected impact of NOACs on routine coagulation tests
PT " (") "(") "" (")
aPTT ""(") (") " "
ACT "(") " " "
TT """" — — —
Ranges indicate the P5/95 percentiles for dabigatran, rivaroxaban, and apixaban, and the interquartile ranges for edoxaban.
The reagents influence the sensitivity of the PT for FXa inhibitors and of the aPTT for dabigatran. When a sensitive assay is used, normal aPTT excludes above on-therapy levels
in dabigatran-treated patients, and normal PT excludes above on-therapy levels in rivaroxaban and edoxaban, but not apixaban treated patients. Point-of-care INR devices
developed to monitor vitamin K antagonists do not accurately reflect the anticoagulant status of NOAC treated patients.
ACT, activated clotting time; aPTT, activated partial thromboplastin time; dTT, diluted thrombin time; ECA, ecarin clotting assay; INR, international normalized ratio; PT, pro-
thrombin time.

on 23 April 2018
..
evaluation of FXa inhibitory effect because of the limited prolonga- .. emergencies as well as in special situations. Laboratory monitoring to
tion, variability of assays, and paradoxical response at low concentra- .. guide long-term use can also be considered in exceptional patients
..
tions.233 Although Factor Xa-inhibitors demonstrate a .. with special characteristics. This, however, should only be done
concentration-dependent prolongation of the PT, the effect depends .. under the guidance of a coagulation expert and in the knowledge that
..
both on the assay and on the FXa inhibitor. Furthermore, PT is not .. hard clinical outcome data do not exist for such a strategy.
specific and can be influenced by many other factors (e.g. hepatic ..
..
impairment, vitamin K deficiency).233 For apixaban, the PT cannot be .. Measurement in emergencies
used for assessing the anticoagulant effect. For rivaroxaban and to a .. In emergencies such as bleeding (chapter 11), urgent procedures
..
lesser extent edoxaban, the PT may provide some quantitative infor- .. (chapter 13), or an acute stroke (chapter 17), routine coagulation
mation, even though the sensitivity of the different PT reagents varies .. tests are rapidly available and may quickly inform the clinician on
..
importantly and may be insensitive for the anti-FXa effect.226 .. recent exposure; specific assays may provide accurate assessment of
Assessment of the sensitivity of the employed PT reagent for the Xa- .. plasma levels (chapter 7).
..
inhibitors is strongly recommended. .. In case of serious bleeding, coagulation tests may help the clinician
Importantly, conversion of PT to INR does not correct for the .. to support haemostasis (chapter 11). Coagulation tests may also
..
variation and even increases the variability. The INR (especially a .. uncover associated bleeding disorders. In case of urgent surgery as
point-of-care determined INR) is unreliable for the evaluation of FXa
.. well as in exceptional cases of planned surgery with high-bleeding
..
inhibitory activity. Furthermore, the prolongation of the PT/INR by .. risk, coagulation tests may help the clinician define the timing of sur-
NOACs can be misleading during the transition of a NOAC to a
.. gery (see chapters 12 and 13).
..
VKA. Therefore, switching needs to be executed diligently, as dis- .. Information on drug exposure may also guide treatment in patients
cussed in chapter 4.
.. who present with acute thrombotic events, particularly in patients
..
.. with acute ischaemic stroke for whom thrombolysis is considered
..
Impact of non-vitamin K antagonist oral .. (chapter 17). Other emergency situations where assessment of
.. anticoagulant activity may be valuable include suspected overdosing
anticoagulants on other coagulation ..
.. or intoxication.
assays ..
NOACs also interfere with thrombophilia tests and the measure- ..
.. Measurement before elective procedures
ment of coagulation factors. Therefore, a time window of at least .. In general, routine measurement of the anticoagulant activity is
24 h is recommended between the last intake of a NOAC and blood ..
.. not recommended prior to elective procedures (chapter 12).
sampling to confidently assess coagulation parameters. This time win- .. When the timing since last intake is unknown or uncertain, or
dow may be even longer for lupus anticoagulant measurements
..
.. when there are concerns on the clearance of the drug because of
(>_48 h). .. special patient characteristics (potential drug–drug interactions,
The activated clotting time (ACT) test is used as a point-of-care
..
.. change in renal or hepatic function), it is reasonable to check the
test in settings where high heparin doses are administered and where .. absence of clinically relevant plasma concentrations when specific
the aPTT is too sensitive (e.g. bypass surgery, coronary interventions,
..
.. assays are available.168 Importantly, however, there are currently
ablation procedures, etc.). It is a test on whole blood, based on con- .. no prospectively validated data with hard clinical endpoints on
tact activation. Dabigatran increases the ACT in a curvilinear fashion,
..
.. cut-off values of any coagulation test to guide the timing of elective
consistent with the effects on aPTT.229 The ACT has not been inves- .. or urgent surgery.236
..
tigated to gauge dabigatran anticoagulant activity in clinical practice. ..
There is a small dose-dependent effect of apixaban, edoxaban, and .. Monitoring during long-term exposure
..
rivaroxaban on the ACT.234,235 It seems reasonable to use the same .. The expected drug levels while on therapy, as observed in clinical tri-
target ACT levels for heparin titration in NOAC-treated patients ..
.. als, are shown in Table 9. Importantly, no studies have investigated if
undergoing interventions. However, since ACT is a non-standardized .. measurement of drug levels and dose adjustment based on labora-
test, ACT target levels require centre validation. The ACT cannot be ..
.. tory coagulation parameters reduces the risk for bleeding or throm-
used to gauge FXa anticoagulant activity. .. boembolic complications, e.g. by dose reduction in case of higher
..
.. than expected levels or by dose increase in case of lower than
.. expected levels, during chronic treatment. As such, routine monitor-
..
8. Non-vitamin K antagonist oral .. ing of plasma levels and subsequent dose adaptation is generally dis-
.. couraged. For the (rare) patients with multiple factors that interfere
anticoagulant plasma level ..
.. with the pharmacokinetics of a given NOAC (e.g. the very obese;
measurement: rare indications, .. uncontrolled cancer patients receiving therapy for malignancies;
..
precautions and potential pitfalls .. treatment with anti-cancer drugs with unclear/unknown pharmacoki-
.. netic interactions), a reasonable strategy could be to verify that
..
Non-vitamin K antagonist oral anticoagulants do not require moni- .. plasma levels are within the ‘on treatment’ range, taken into account
toring of coagulation: neither the dose nor the dosing intervals need .. the different ‘on therapy’ range for samples taken at peak or at trough
..
to be altered in response to changes in coagulation parameters for .. levels (Table 9). However, this should only be performed in the hands
the currently registered indications. However, laboratory assessment
.. of a coagulation expert with sufficient experience in the performance
..
of drug exposure and anticoagulant effect may help clinicians in . and interpretation of these assays as well as the care of these patients.

on 23 April 2018
..
Alternatively, reverting to VKA therapy in these very special situa- ..
..
10. What to do if there is a
tions may be an option.
..
.. (suspected) overdose without
.. bleeding, or a clotting test is
Over- and underweight patients ..
.. indicating a potential risk of
Patients at the extremes of the weight spectrum (i.e. <50 kg and ..
>120 kg) have been underrepresented in the clinical trials, and .. bleeding?
..
NOAC use may be a challenge in these individuals (chapter 18). If ..
NOAC treatment is decided on in such a patient, assessment of .. Excessive NOAC plasma concentrations potentially expose the
..
plasma trough levels may be considered. .. patient to an increased risk of bleeding. This may occur when the
.. patient has (intentionally) taken an overdose. Also intercurrent
..
.. events such as acute renal failure (especially with dabigatran) or
.. administration of drugs with known drug–drug interactions (see
9. How to deal with dosing errors? ..
.. chapter 5) may increase NOAC plasma concentrations to supra-
.. therapeutic levels. In terms of management, it is important to dis-
Questions relating to dosing errors are very common in daily prac- ..
tice, and patients need to be informed on what to do in such cases. .. tinguish between an overdose with bleeding complications
.. (chapter 11) and without.
To avoid dosing errors as described below, patients on NOACs ..
should be encouraged to make use of well-labelled weekly contain-
.. In case of a suspected overdose, coagulation tests can help to
.. determine its degree and possible bleeding risk (see chapter 7). A
ers, with separate spaces for each dose timing. Importantly, however, ..
dabigatran must not be taken out of its original bottle until immedi-
.. normal aPTT excludes high levels of dabigatran; similarly a normal PT
.. excludes very high levels of rivaroxaban and edoxaban. However,
ately before intake. In order to provide a more uniform and simple ..
practical advice some of the below recommendations do not fully
.. these routine coagulation tests are not appropriate for a quantitative
.. assessment of high levels of these drugs.
align with all SmPCs. Also, patients’ individual risk of stroke and ..
bleeding need to be taken into consideration.
.. Given the relatively short plasma half-life of the NOACs, a ‘wait-
.. and-see’ strategy can be used in most cases without active bleeding.
..
.. The elimination half-life can be estimated taking into account age and
..
Missed dose .. renal function. As a result of limited absorption, a ceiling effect with
A forgotten dose may be taken until 50% of the dosing interval has .. little to no further increase in plasma exposure is seen at supra-
..
passed. Hence, for NOACs with a BID dosing regimen (i.e. every .. therapeutic doses of >_50 mg rivaroxaban.237 There are no data in
12 h), a forgotten dose can be taken up until 6 h after the scheduled .. this respect concerning the other FXa inhibitors or dabigatran.
..
intake. For patients with a high stroke risk and low bleeding risk, this .. In the case of recent acute ingestion of an overdose (especially
may be extended up until the next scheduled dose. .. when <_2 h ago), the use of activated charcoal to reduce absorption
..
For NOACs with an OD dosing regimen, a forgotten dose can be .. may be considered for any NOAC (with a standard dosing scheme
taken up until 12 h after the scheduled intake. After this time point, .. for adults of 30–50 g) although clinical data on its effectiveness are
..
the dose should be skipped and the next scheduled dose should be .. lacking.238–240
taken. The 12 h interval may be extended in patients with a high .. If a more aggressive normalization of plasma levels is deemed nec-
..
stroke risk. .. essary, or rapid normalization is not expected (e.g. major renal insuffi-
.. ciency) the steps outlined below (chapter 11) may need to be
..
.. considered, including the use of a specific reversal agent.241 Only in
Double dose .. exceptional cases, strategies to non-specifically support haemostasis
For NOACs with a BID dosing regimen, the next planned dose (i.e.
..
.. awaiting clearance of the drugs may be considered, although clearly
after 12 h) may be left out, with BID intake restarted 24 h after the .. in these situations balancing the benefit of normalizing coagulation in
double dose intake.
..
.. a non-bleeding patient needs to be carefully weighed against a possi-
For NOACs with an OD dosing regimen, the patient should con- .. bly strong prothrombotic effect.
..
tinue the normal dosing regimen, i.e. without skipping the next daily ..
dose. ..
..
..
..
11. Management of bleeding
Uncertainty about dose intake ..
.. under non-vitamin K antagonist
For NOACs with a BID dosing regimen, it is generally advisable .. oral anticoagulant therapy
to not take another tablet/capsule, but to simply continue with the ..
..
regular dose regimen, i.e. starting with the next dose at the 12 h .. The Phase III NOAC studies have consistently shown that NOACs
interval. .. cause less intracranial and less life-threatening bleedings than war-
..
For NOACs with an OD dosing regimen, when thrombotic risk is .. farin, despite the absence of reversal strategies in these trials.
high (CHA2DS2-VASc >_3), it may generally be advisable to take .. Not only was there similar or even a reduced bleeding incidence, but
..
another tablet and then continue the planned dose regimen. In case .. patients experiencing a major (particularly extracranial) bleeding
the thrombotic risk is low (CHA2DS2-VASc <_2), it is recommended
.. under NOACs were also shown to have a more favourable outcome
..
to wait until the next scheduled dose. . than for bleeding under VKA treatment.240,242–245,378,379 Overall, a

on 23 April 2018
.. plasma is not considered a useful reversal strategy, primarily due to

reduction in all-cause mortality was observed with NOACs vs. war- ..
farin for stroke prevention in AF.246 .. the plasma abundance of NOACs which will inhibit newly adminis-
..
Nevertheless, as more patients are being treated with NOACs, the .. tered coagulation factors upon activation and the resulting large vol-
absolute number of NOAC-related bleeding events will increase. .. ume that would need to be administered.247 Vitamin K and
..
Importantly, any bleeding is an opportunity to review the correct .. protamine administration have no role in the management of a
choice and dosing of the NOAC (see chapters 2, 5, 6, 15 and .. bleeding under NOACs, but are useful in the management of bleed-
..
others) and to evaluate modifiable bleeding risk factors including sub- .. ing under NOACs when vitamin K deficiency is suspected or in case
optimally treated hypertension, labile INR (if on VKA) or erratic dos- .. of concomitant treatment with heparin, respectively.
..
ing, excessive alcohol intake and concomitant antiplatelet therapy, ..
NSAIDs, glucocorticoids etc. (see also chapter 14).3 .. Nuisance and minor bleeding
..
We recommend a hospital-wide policy concerning bleeding man- .. The clinical relevance of both nuisance and minor bleedings under
agement under NOAC, developed in an interdisciplinary manner
.. NOAC therapy should not be underestimated as they are a frequent
..
among cardiologists, haemostasis experts, emergency physicians/ .. cause of treatment interruptions. Patients need to be made aware of
intensivists and others. This protocol should describe the availability
.. the signs and symptoms of such bleedings and instructed to alert their
..
and indications of specific coagulation tests as well as of specific and .. healthcare provider in case of such an event (see chapter 2).
.. Cessation or temporary interruption without consultation needs to
nonspecific reversal agents. Such a policy needs to be communicated ..
well and be easily accessible (e.g. on an Intranet site, in the emergency .. be discouraged due to the subsequently increased thromboembolic
.. risk.
room, in pocket-sized leaflets etc.). ..
Strategies to manage bleeding complications in patients treated .. Nuisance bleeds can usually be managed by delaying intake or
.. withholding the NOAC for a maximum of one dose. Minor bleedings
with NOACs rely on a precise analysis of the clinical situation. ..
.. may require more aggressive therapy with a focus aimed at treating
(1) The type of bleeding: nuisance/minor, major non-life threatening, or ..
.. the cause of the bleeding (e.g. PPI for gastric ulcers, antibiotics for uri-
life-threatening. .. nary tract infection, etc.). Epistaxis and gum bleeds can be treated
(2) The patient and his/her treatment: The exact time of last NOAC ..
.. with local anti-fibrinolytics.
intake, prescribed dosing regimen, renal function, other factors .. In case of recurrent minor bleeding events without causal thera-
influencing plasma concentrations (incl. co-medication, see also ..
.. peutic options, an alternative NOAC with a potentially different
Table 3), and other factors influencing haemostasis (such as con- .. bleeding profile should be considered while maintaining effective
comitant use of antiplatelet drugs). ..
.. stroke prevention (see chapter 5).
.. A suspected or documented occult bleeding should trigger a
Both routine coagulation tests and assays that specifically measure ..
plasma levels of NOACs are important pillars in the assessment of .. work-up to uncover the underlying cause and the treatment thereof
.. whenever possible.
NOAC related bleeding. Normal results of dTT/ecarin clotting time ..
(for dabigatran) and anti-Xa activity (for anti-FXa treated patients) ..
.. Non-life-threatening major bleeding
likely exclude relevant levels of the anticoagulant. Specific assays ..
allow for the quantification of plasma levels of the anticoagulant .. Causal therapy to stop the bleeding and standard supportive meas-
.. ures (such as mechanical compression, endoscopic or surgical hae-
(chapter 7).247 However, it needs to be kept in mind that restora- ..
tion of coagulation does not necessarily result in improved clinical
.. mostasis, fluid replacement, transfusion, and other haemodynamic
.. support) are the main pillars in the management of non-life-
outcome. Conversely, conventional coagulation tests may be abnor- ..
mal not only due to the effect of the NOAC itself, but for a variety of
.. threatening major bleeding. With increasing time a waning of the anti-
.. coagulant activity can be anticipated in view the relatively short elimi-
other reasons, particularly in the setting of severe bleeding. ..
.. nation half-lives of all NOACs (see Tables 6, 10 and Figure 5).252
Depending on the clinical scenario, the anticoagulant effects in a ..
NOAC-treated patient who presents with bleeding can be addressed .. Adequate diuresis is recommended for all NOACs, but particu-
.. larly in case of dabigatran (given the large degree of renal elimination
with the following strategies: ..
.. of the drug). In addition, dialysis may be an option for non-life-threat-
(1) Waiting until the anticoagulant activity of the NOAC effect wanes as .. ening, severe bleeding with dabigatran in cases of severe renal failure
..
a result of spontaneous clearance of the drug (Table 6), facilitated by .. if idarucizumab is not available.253,254 In contrast, dialysis has no signif-
maintaining (and potentially by stimulating) diuresis. .. icant impact in patients treated with any of the FXa inhibitors due to
..
(2) Specific reversal: A specific reversal agent is available for dabigatran .. their high degree of protein plasma binding.255,256
(idarucizumab, a humanized antibody fragment that specifically .. The use of antifibrinolytics (e.g. tranexamic acid, 1 g i.v., repeated
..
binds dabigatran).248 Specific agents for FXa inhibitors are under- .. every 6 h if needed) or desmopressin 0.3 mg/kg i.v. infusion (with a
going clinical testing, including andexanet alfa (a recombinant human .. maximal dosing of 20 mg) – especially in special situations with associ-
..
FXa analogue that competes with FXa to bind FXa inhibitors)249 .. ated coagulopathy or thrombopathy – may be considered.
and ciraparantag (PER 977), a small synthetic molecule that seems .. Tranexamic acid has proven efficacy to support haemostasis, particu-
..
to have more generalized antagonistic effects.250 .. larly in trauma-induced bleeding, with a favourable safety pro-
(3) Non-specific support of haemostasis using coagulation factors concen- .. file.257,258 Even when not yet supported by clinical data its use can
..
trates. There is increasing information about the effects of (acti- .. therefore be considered for bleeding under NOACs, especially in sit-
vated) prothrombin complex concentrates in cohorts of NOAC- .. uations of severe bleeding where frequently many factors of the
..
treated patients with bleeding.251 In contrast, the use of fresh frozen . coagulation cascade are deficient.

on 23 April 2018
Table 10 Possible measures to take in case of bleeding
Direct thrombin inhibitors FXa inhibitors

(dabigatran) (apixaban, edoxaban, rivaroxaban)
Non life-threatening major bleeding • Inquire about last intake þ dosing regimen
• Local haemostatic measures
• Fluid replacement
• RBC substitution, if necessary
• Platelet substitution (in case of thrombocytopenia <_60 109/L or thrombopathy)
• Fresh frozen plasma not as reversal agent (may be considered as plasma expander)
• Tranexamic acid can be considered as adjuvant (1 g i.v., repeat every 6 h, if necessary)
• Desmopressin can be considered in special cases such as coagulopathy or thrombopathy;
0.3 mg/kg i.v. infusion (max dose 20 mg)
• Estimate normalization of plasma levels: • Normalization of plasma levels: 12–24 h

• Normal renal function: 12–24 h
• CrCl 50–80 mL/min: 24–36 h
• CrCl 30–50 mL/min: 36–48 h
• CrCl <30 mL/min: >_48 h
• Maintain diuresis
• Consider idarucizumab (see below)
Life-threatening bleeding • All of the above • All of the above

• Direct reversal: Idarucizumab 5 g i.v. in two • Direct reversal: Andexanet alpha
doses a 2.5 g i.v. no more than 15 min apart (if available and approved)a
• Bolus over 15–30 min, followed by 2-h infusion
• Rivaroxaban (last intake >7 h before) or apixaban:
400 mg bolus, 480 mg infusion @ 4 mg/min
• Rivaroxaban (last intake <7 h before or unknown)
or enoxaparin or edoxaban: 800 mg bolus,
960 mg infusion @ 8 mg/min
• Prothrombin complex concentrate (PCC) 50 U/kg (with additional 25 U/kg if clinically needed)
• Activated PCC 50 U/kg; max 200 U/kg/day): no strong data about additional benefit over PCC.
Can be considered before PCC, if available
RBC, red blood cells; CrCl, creatinine clearance; PCC, prothrombin complex concentrate.
a
Andexanet alpha is currently neither approved nor available and final results of the ANNEXA-4 study are pending.
..
Life-threatening bleeding .. minutes in almost all patients.248 It is hence recommended as first-
.. line therapy in such situations. A total of 5 g idarucizumab is adminis-
Patients with life-threatening bleeding while treated with NOACs ..
may benefit from its reversal in addition to the standard measures .. tered intravenously in two bolus doses of 2.5 g no more than 15 min
outlined above. ... apart (Figure 6). Continued clinical and laboratory monitoring is rec-
.. ommended, since a 5 g dose of idarucizumab may not completely
Importantly, even after direct reversal, significant NOAC concen- ..
trations may reappear in some patients and contribute to recurrent .. neutralize an exceptional high level of dabigatran (e.g. in case of over-
.. dose or renal insufficiency). Also, low levels of dabigatran may reap-
or continued bleeding (particularly after andexanet alpha, less after ..
idarucizumab administration),249,259 underlining the necessity for .. pear after 12–24 h.
.. After 24 h, dabigatran can be re-started if clinically indicated and
continued clinical and laboratory monitoring. ..
.. feasible, with normal kinetics.
..
Idarucizumab ..
..
In the REVERSE-AD study, idarucizumab was successfully used in .. Direct reversal of apixaban, edoxaban, or rivaroxaban
patients on dabigatran presenting with major or life-threatening
.. (FXa-inhibitors)
..
bleeding, or with the necessity of emergency surgery. Idarucizumab .. Based on the ongoing ANNEXA-4 study (which, in contrast to
completely reversed the anticoagulant activity of dabigatran within
.. REVERSE-AD only includes patients with major/life-threatening

on 23 April 2018
Figure 5 Management of bleeding in patients taking non-vitamin K antagonist oral anticoagulants.
bleeding),249 andexanet alpha may become the first choice of therapy .. (including PCC/aPCC).240,242–243 The efficacy on clinical outcomes of
..
in life-threatening bleeding under FXa-inhibitor therapy (pending its .. PCCs or aPCCs in patients taking NOACs who are actively bleeding
regulatory approval and availability). In the ANNEXA-4 study, the .. has not been firmly established in a RCT. However, several observa-
..
drug is administered as a bolus over 15–30 min, followed by a 2-h .. tional studies in patients with major bleeding have been published
infusion. The dosing depends on the NOAC and on the timing since
.. (with some inherent limitations including the retrospective, non-
..
last intake: For rivaroxaban (with the last intake >7 h before reversal) .. controlled setting as well as absence of a control group)
or apixaban, a 400 mg bolus is administered followed by a 480 mg
.. indicating that (a)PCCs appeared to be efficacious in supporting
..
infusion (4 mg/min). For rivaroxaban (with the last intake <7 h before .. haemostasis.268,269
reversal or unknown recent intake), edoxaban or enoxaparin, a
.. The administration of PCCs or aPCCs can be considered in a
..
800 mg bolus followed by a 960 mg infusion (8 mg/min) is given .. patient with life-threatening bleeding if immediate haemostatic sup-
(Figure 6). Importantly, reappearance of anticoagulant activity may
.. port is required, especially in situations where a specific reversal
..
occur after stopping the infusion. Therefore, it is currently less clear .. agent is not available (Table 10). The choice between PCC and aPCC
..
at what point in time and with which anticoagulant effect FXa inhibi- .. may depend on their availability and the experience of the treatment
tors or heparin can be re-administered following andexanet alpha .. centre. Particularly aPCC induces a strong pro-coagulant effect and
..
administration. .. should only be used by physicians experienced in their use. PCC and
.. aPCC are preferred over recombinant activated factor VIIa
..
Coagulation factors .. (NovoSeven, 90 mg/kg) given the absence of any outcome data and
.. the latter’s pronounced pro-coagulant effect.247,270
Clinical trials and registry data with NOACs have shown that admin- ..
istration of coagulation factors is rarely needed.251,260 Indeed, any ..
.. Anticoagulation post-extracranial
NOAC-antagonizing effect has to be balanced carefully against the ..
potential prothrombotic effect. Animal experiments as well as studies .. bleeding
..
in healthy volunteers have indicated the potential usefulness of PCCs .. In most cases of nuisance or minor bleeding anticoagulation can be
and activated PCCs (aPCC) for the normalization of coagulation .. re-started, sometimes simply by delaying or skipping a single dose. All
..
parameters under NOAC treatment as a surrogate for haemostatic .. other bleedings, particularly life-threatening bleeding episodes,
support.261–267 As indicated above, data from the large Phase III trials
.. require a careful re-assessment of the risks and benefits of re-
..
demonstrated that outcomes of bleedings under NOACs were simi- .. initiating anticoagulation. In most cases of bleedings due to secondary
lar (if not better) than in the VKA arm with similar treatment used
.. (e.g. bleeding post-trauma) or reversible causes (e.g. genito-urinary

on 23 April 2018
Figure 6 Application and effect of idarucizumab and andexanet

alpha. *Per protocol of ANNEXA-4.249 Andexanet alpha: The out-
come study (ANNEXA-4) is still pending, the drug is not yet
approved and not yet available.
Figure 7 (Re-) initiation of anticoagulation post-gastrointestinal
bleeding. #Without evidence; ideally include patient in ongoing trial.
bleed due to cancer) anticoagulation can be resumed once the cause

of the bleed has been eliminated. As exemplified for GI bleedings, i.e. .. interruption prior to surgery or interventions. It is impossible to
..
one of the most frequently encountered bleeds, many additional fac- .. summarize all recommendations, and healthcare providers are
tors need to be taken into consideration (Figure 7). Particularly for .. recommended to check this guide’s recommendations against the
..
severe and life-threatening bleedings without a clear secondary or .. relevant recommendations of their country/healthcare setting and
reversible/treatable cause the risks of re-initiating anticoagulation ..
.. professional society. The EHRA practical guide intends to provide
may outweigh the benefits. In such cases, implantation of a left atrial .. a unified approach, which is as simplified as possible to allow its
appendage (LAA) occluder or surgical LAA occlusion may be consid- ..
.. broad implementation.
ered as a potential substitute for long-term anticoagulation.3 .. Patient characteristics (including age, history of bleeding complica-
However, RCT evidence for LAA occlusion after bleeding under ..
.. tions, concomitant medication, and kidney function) as well as surgi-
OAC is missing, which is why, ideally, treatment should occur wher- .. cal factors (Table 11) need to be taken into account to determine
ever possible in the framework of a randomized trial to contribute to
..
.. when to discontinue and restart a NOAC. While invasive surgical
evidence for this difficult to treat population. .. interventions require temporary discontinuation of a NOAC, many
The approach post-intracerebral, intracranial, subdural, and epi-
..
.. less invasive procedures carry a relatively low bleeding risk and do
dural bleeding is outlined below (chapter 17). .. not necessarily require discontinuation (Table 12; Figure 8). All
..
.. patients undergoing a planned intervention as well as caregivers (pri-
.. mary care physician etc.) should receive a written note indicating the
..
.. anticipated date and time of their intervention as well as the date and
12. Patients undergoing a planned .. time of the last intake of their NOAC (and any other medication).
..
invasive procedure, surgery or ..
..
..
ablation .. Minor bleeding risk
.. It is recommended not to interrupt oral anticoagulation for most
When to stop non-vitamin K antagonist ..
.. minor surgical procedures and those procedures where bleeding is
oral anticoagulants? .. easily controllable (Figure 8). In general, these procedures can be per-
..
About one quarter of anticoagulated patients require temporary .. formed 12–24 h after the last NOAC intake. It may be practical to
cessation for a planned intervention within 2 years.260 Awaiting .. have the intervention scheduled 18–24 h after the last NOAC intake,
..
the results of the ongoing Perioperative Anticoagulant Use for .. and then restart 6 h later (skipping one dose of dabigatran or apixaban
Surgery Evaluation (PAUSE; NCT02228798) study, few prospec-
.. or no dose of edoxaban or rivaroxaban). The patient may only leave
..
tive data on the management of NOACs are available.271 Various .. the ambulatory practice/outpatient clinic/hospital, if any peri-
societies have issued separate guidelines on the timing of NOAC
.. interventional bleeding has completely stopped. Moreover, the

on 23 April 2018
Table 11 Timing of last non-vitamin K antagonist oral anticoagulant intake before start of an elective intervention
Dabigatran Apixaban – Edoxaban – Rivaroxaban
No important bleeding risk and/or adequate local haemostasis possible: perform at trough level
(i.e. 12 h or 24 h after last intake)
Low risk High risk Low risk High risk
CrCl >_80 mL/min >_24 h >_48 h >_24 h >_48 h
CrCl 50–79 mL/min >_36 h >_72 h >_24 h >_48 h
CrCl 30–49 mL/min >_48 h >_96 h >_24 h >_48 h
CrCl 15–29 mL/min Not indicated Not indicated >_36 h >_48 h
CrCl <15 mL/min No official indication for use
No bridging with LMWH/UFH
Resume full dose of NOAC >_24 h post-low bleeding risk interventions and 48 (–72) h post-high-bleeding risk interventions (see also Figure 8)
Patients undergoing a planned intervention should receive a written note indicating the anticipated date and time of their intervention,
and the date and time of the last intake of their NOAC (and any other medication)
Low risk: with a low frequency of bleeding and/or minor impact of a bleeding; high risk: with a high frequency of bleeding and/or important clinical impact. See also Table 12.
CrCl, creatinine clearance; LMWH, low molecular weight heparin; UFH, unfractionated heparin.
..
patient has to be instructed about the normal post-procedural course .. longer interruption of the NOAC intake is required, especially for
and the measures to be taken in case of bleeding. The physician/dentist .. dabigatran (Table 11, Figure 8). In cases with combined factors that
..
(or an informed colleague) has to be accessible in such a case. .. make prediction of NOAC clearance unclear, measurement of
.. NOAC plasma levels may be considered, and only go ahead with the
..
Low bleeding risk .. planned surgical intervention when the level is considered low
For invasive procedures with a low bleeding risk (i.e. low frequency of
.. enough (chapter 7, Table 9). However, it needs to be clearly stated
..
bleeding and/or minor impact of bleeding; Table 11), it is recom- .. that such an approach is without evidence base, including the deter-
.. mination of ‘safe’ NOAC levels in this setting as well as waiting for
mended to take the last dose of a NOAC 24 h before the elective ..
procedure in patients with normal kidney function (Table 12, Figure 8). .. levels to drop into that range whilst accepting the inherent risk of
.. thromboembolism during that time.
For patients on dabigatran and a CrCl <80 mL/min a graded interrup- ..
tion should be considered. For patients taking a FXa inhibitor and ..
.. Bridging
with a CrCl of 15–29 mL/min the last NOAC should be taken 36 h or ..
more before surgery (Table 12). In patients taking concomitant drone- .. Preoperative bridging with LMWH or heparin is not recommended in
.. NOAC-treated patients since the predictable waning of the anticoa-
darone, amiodarone or verapamil, it may be advisable to add an extra ..
24 h of interruption, especially if the thromboembolic risk is not very .. gulation effect allows properly timed short-term cessation of NOAC
..
high (CHA2DS2-VASc <_3).168 Conversely, for some procedures (e.g. .. therapy before surgery. On the contrary, the mixing of two anticoagu-
cardiac device implantations, see below) a shorter interruption may .. lants (although with similar pharmaco-dynamics and -kinetics) has
..
been associated with an increased bleeding risk.272 As demonstrated
be warranted, including intake of the last dose the morning of the day ...
before the procedure. The PAUSE trial will provide more information .. in the BRIDGE trial for VKA, bridging with heparin/LMWH was associ-
on the relation between last intake, preprocedural plasma level and, .. ated with a significantly higher risk of major bleeding during cessation
..
most importantly, clinical outcome.271 .. of oral anticoagulation but did not reduce cardiovascular events.273
..
..
High bleeding risk .. Dental surgery
In case of invasive procedures that carry a high risk for major bleeding .. Dental surgery is generally considered a procedure with minor bleed-
..
(i.e. with a high frequency of bleeding and/or important clinical .. ing risk and with the possibility for adequate local haemostasis. Most
impact), it is recommended to take the last NOAC dose 48 h or lon- .. professional statements on dental surgery advise not to suspend
..
ger before surgery. Again, the decision to halt therapy for longer .. NOAC treatment and avoid the use of NSAIDs.274 However, recom-
should take into account the patient‘s thromboembolic vs. bleeding
.. mendations are often based on a low quality of evidence and mainly
..
risk as well as concomitant therapy with antiarrhythmic drugs as .. rely on available pharmacological information.275 Dental extractions
described above. Moreover, in patients with impaired renal function
.. can generally be performed safely in an outpatient facility by applying

on 23 April 2018
..
Table 12 Classification of elective surgical interven-
.. local haemostatic measures, without interrupting anticoagulation or
.. by just skipping the morning dose of the NOAC.276–279
tions according to bleeding risk ..
.. Periprocedural management includes specific haemostatic techniques
.. including the use of oxidized cellulose or absorbable gelatin sponge,
Interventions with minor bleeding risk ..
.. sutures, tranexamic acid mouthwashes, or compressive gauze soaked
Dental interventions
.. in tranexamic acid.
..
..
Extraction of 1–3 teeth .. Device implantation procedures
..
Paradontal surgery .. Device implantations are generally considered procedures with a low
.. bleeding risk. For patients undergoing device implantation, prospec-
Incision of abscess
..
.. tive, and randomized data in VKA-treated patients have indicated
.. lower thromboembolic and bleeding rates if the VKA is continued in
Implant positioning ..
.. an uninterrupted fashion.280 For NOAC-treated patients, the
Cataract or glaucoma intervention .. recently presented BRUISE-CONTROL 2 trial demonstrated similar
..
.. bleeding and embolic rates in patients with a last intake 48 h before
Endoscopy without biopsy or resection .. the implantation for rivaroxaban/apixaban (and based on glomerular
..
Superficial surgery (e.g. abscess incision; small dermatologic .. filtration rate for dabigatran) vs. continued NOAC until the morning
excisions; . . .)
.. of the procedure (Birnie et al., presented at AHA 2017). Therefore, a
..
.. standard strategy as for ‘low bleeding risk’ procedures with intake of
Interventions with low bleeding risk (i.e. infrequent or with low .. the last dose in the morning of the day before the procedure can be
clinical impact) ..
.. recommended in most cases, followed by restarting one day after-
..
Endoscopy with biopsy .. wards (Table 12 and Figure 8). An overview of data and recommenda-
.. tions can be found in the recent EHRA/HRS/APHRS consensus
Prostate or bladder biopsy ..
.. document.281
Electrophysiological study or catheter ablation (except complex ..
..
procedures, see below) .. Regional anaesthesia and pain medicine
.. Invasive procedures such as spinal anaesthesia, epidural anaesthe-
Non-coronary angiography (for coronary angiography and ACS: ..
.. sia, and lumbar puncture require complete haemostatic function,
see Patients undergoing a planned invasive procedure, surgery .. and fall under the ‘high bleeding risk’ category. European as well as
or ablation section) ..
.. North American guidelines do not recommend neuraxial anaes-
.. thesia or deep blocks in the presence of uninterrupted NOAC
Pacemaker or ICD implantation (unless complex anatomical set- ..
ting, e.g. congenital heart disease) .. use and recommend interruption of NOACs for up to five half-
.. lives (corresponding to an interruption of 3 days in FXa-inhibitors
Interventions with high bleeding risk (i.e. frequent and/or with
..
.. and 4–5 days for dabigatran).282,283 NOAC therapy can usually
high impact) .. be resumed 24 h after the intervention. On the other hand, ‘low
..
Complex endoscopy (e.g. polypectomy, ERCP with sphincterot- .. risk’ procedures (such as peripheral nerve blocks or peripheral
.. joint and musculoskeletal injections) do not necessarily require
omy etc.) ..
.. NOAC interruption and if so for only a short period (e.g. two
Spinal or epidural anaesthesia; lumbar diagnostic puncture .. half-lives).284
..
..
Thoracic surgery .. Lab testing before surgery or invasive procedures
..
Abdominal surgery .. Specific coagulation measurements (see chapter 7) prior to surgery
.. or invasive procedures provide a direct assessment of the (residual)
Major orthopaedic surgery ..
.. drug concentration285 and may be useful in high-risk interventions
..
Liver biopsy .. and/or patients at risk for relevant residual drug concentrations such
.. as older age, renal impairment, or certain concomitant medication
Transurethral prostate resection ..
.. (see chapter 5).168 However, as indicated, such an approach is with-
Kidney biopsy .. out evidence base, including the determination of ‘safe’ NOAC levels.
..
.. For the majority of patients and procedures, a ‘time-based’ interrup-
Extracorporeal shockwave lithotripsy (ESWL) .. tion as outlined above appears safe.
..
Interventions with high bleeding risk AND increased throm- ..
boembolic risk
..
.. When to restart a non-vitamin K
..
Complex left-sided ablation (pulmonary vein isolation; some VT .. antagonist oral anticoagulant after an
ablations)
..
.. invasive procedure?
.. After a procedure with immediate and complete haemostasis,
..
For each patient, individual factors relating to bleeding and thromboembolic risk . NOACs can generally be resumed 6–8 h after the end of the
need to be taken into account, and be discussed with the operating physician.

on 23 April 2018
Figure 8 Stopping and re-initiation of non-vitamin K antagonist oral anticoagulant therapy in elective surgery. Yellow star, time point of the inter-
vention/operation. Consider þ24 h of interruption in situations likely resulting in increased plasma levels [e.g. patients taking verapamil, body weight
<50 kg, significant interactions (see chapter 5)]. *Consider measurement of plasma levels (see chapter 7) in very special situations, e.g. highest risk
neurosurgery/cardiac surgery, severe renal insufficiency, and combination of factors predisposing to higher non-vitamin K antagonist oral anticoagu-
lant levels (see chapter 5). Rivaroxaban needs to be taken with food for stroke prevention in atrial fibrillation, which needs to be looked after (also)
in the post-operative setting. Apix, apixaban; CrCl, creatinine clearance; Dabi, dabigatran; Edo, edoxaban; LMWH, low molecular weight heparin;
Riva, rivaroxaban.
..
intervention. However, there are some surgical interventions in .. Special considerations for atrial
.. fibrillation ablation procedures
which resuming full dose anticoagulation within the first 48–72 h after
...
the procedure carries a bleeding risk that may outweigh the risk of .. Left atrial catheter ablation constitutes an intervention with a risk of
AF-related embolism. In such cases, initiation of post-operative .. serious bleeding secondary to trans-septal puncture or extensive
..
thromboprophylaxis 6–8 h after surgery and restarting the NOAC .. manipulation and ablation in the left atrium, although the incidence
48–72 hours postoperatively (but as soon as possible) can be consid- .. has been decreasing.286 Major bleeds in the groin are not uncommon.
..
ered. There are, however, no data on the safety and efficacy of the .. On the other hand, left atrial catheter ablation implies a pro-
post-operative use of a reduced dose of the NOACs (such as used .. thrombotic setting, increasing the risk of thromboembolic complica-
..
for the prevention of venous thromboembolism (VTE) after hip/knee .. tions.286,287 Recent international consensus statements and guidelines
replacement) in patients with AF undergoing a surgical procedure. .. recommend performing left atrial catheter ablation under uninter-
..
It is strongly recommended to develop and implement institutional .. rupted anticoagulant treatment (target INR 2–2.5),3,286 since such a
guidelines and a hospital-wide policies concerning perioperative anti- .. strategy was associated with less thromboembolic events and less
..
coagulation management in different surgical settings, which are .. bleeding.288 The randomized RE-CIRCUIT (comparing dabigatran to
widely communicated and readily available. .. warfarin in addition to peri-interventional heparin)289 as well as the

on 23 April 2018
VENTURE AF trial (comparing rivaroxaban to warfarin in addition to ... (1) Immediate procedures (Immediate life-, limb- or organ-saving
..
peri-interventional heparin)290 showed a similar risk of embolism in .. intervention, typically cardiac, vascular, and neurosurgical emer-
the uninterrupted NOAC vs. VKA arms, although both studies by .. gency procedures) need to be performed within minutes of the
..
themselves were underpowered to detect statistically significant dif- .. decision to operate and cannot be delayed. In these cases, rever-
ferences in endpoints. While in VENTURE-AF, patients preferentially .. sal with idarucizumab (for dabigatran)248 should be considered,
..
received their last dose rivaroxaban in the evening before the proce- .. especially in moderate- to high-haemorrhagic risk proce-
dure, dabigatran was routinely administered even in the morning .. dures.299 While the REVERSE-AD trial with idarucizumab
..
before ablation in RE-CIRCUIT. As a result, approximately 80% of .. enrolled both bleeding patients as well as those requiring urgent
patients received their last dose <8 h before the procedure and 41% .. surgery, the prospective open-label Phase III trial with andexanet
..
underwent ablation within 4 h of the last dabigatran dose. While a sim- .. alfa, a reversal agent for FXa inhibitors, only enrols patients
ilar risk of major bleedings between rivaroxaban and warfarin was .. experiencing an acute major bleed under therapy but not
..
observed in VENTURE-AF, a large reduction in major bleeding was .. patients requiring urgent surgical interventions (Clinicaltrials.gov
seen in RE-CIRCUIT with dabigatran compared with warfarin. Similar .. NCT02329327).249 After publication of the full dataset and
..
trials for apixaban (AXAFA-AFNET 5)291 as well as edoxaban .. approval of the drug (expected by the end of 2018) its usefulness
(ELIMINATE-AF) are ongoing. Registry data as well as a subanalysis of
.. in this setting needs to be re-evaluated. If specific reversal agents
..
the ENGAGE-AF trial (with varying protocols and timings of NOAC .. are not available, PCCs or aPCCs should be considered despite
interruption) did not indicate an increased risk of stroke or bleeding
.. the lack of evidence for efficacy and safety (see also chapter 11
..
for apixaban or edoxaban in the setting of AF ablation.292–294 .. section).269,272,283 Especially, if no specific reversal agent is avail-
An institutional protocol for NOAC patients undergoing AF abla-
.. able it may be advisable to perform immediate (and urgent) pro-
..
tion should be developed to ensure a uniform approach. Whether .. cedures under general rather than spinal anaesthesia in order to
opting to administer the last NOAC dose shortly before the proce-
.. reduce the risk of epidural haematoma.
..
dure (i.e. ‘truly uninterrupted’) or to go for a short cessation period .. (2) Urgent procedures (e.g. intervention for acute onset or clinical
..
(last NOAC dose on the day before the procedure), depends on a .. deterioration of potentially life-threatening conditions, condi-
number of factors including renal function, CHA2DS2-VASc score, .. tions that may threaten the survival of limb or organ, fixation of
..
experience of the operator, and routine practice of heparin adminis- .. fractures, relief of pain, or other distressing symptoms) need to
tration prior to (first) trans-septal puncture.2,281,286 It is reasonable .. be performed within hours of the decision to operate. In these
..
to administer a last dose of NOAC 12 h before the start of the inter- .. situations, surgery or intervention should be deferred, if possi-
vention, especially if trans-septal puncture is performed without peri- .. ble, until at least 12 h and ideally 24 h after the last dose. Also,
..
procedural imaging (as is mostly the case in Europe). Especially, when .. coagulation test results (see below) can be awaited in this situa-
adherence is uncertain over the weeks prior to the intervention, left .. tion to gauge the necessity for reversal or application of
..
atrial thrombus should be ruled out prior to ablation. A similar .. (a)PCCs.
approach may be advisable if the last NOAC dose is taken >_36 h .. (3) Expedite procedures (patients requiring early treatment where the
..
before the intervention as the patient would be without adequate .. condition is not an immediate threat to life, limb, or organ survival)
anticoagulation for a prolonged period of time as well as in patients at .. should be performed within days of decision to operate. In these sit-
..
high risk for thromboembolism. During the ablation, intravenous .. uations, interruption of NOACs should follow the proposed rules
heparin should be administered to achieve an ACT of 300–350 s.295 .. for elective surgery (see chapter 12).
..
It seems reasonable to use the same target ACT levels for heparin ..
titration in NOAC-treated patients as in patients on (uninterrupted)
.. In all such situations, particularly prior to the application of any hae-
.. mostatic agents, a full panel of coagulation assays (including PT, aPTT,
VKA. It has been noted that the total need for heparin and the time ..
to target ACT was higher in some NOAC treated patients.290,296,297
.. anti-FXa, or dTT/ECA etc.) should be obtained in order to assess the
..
This likely reflects a difference in whole blood coagulability when .. coagulation status of the patient. Even if in the emergency situation
NOACs are stopped some time before the procedure, rather than a
.. application of pro-haemostatic agents will not be postponed, results of
..
direct interaction between NOACs and the ACT test. .. these initial tests may have implications for further treatment during
NOAC intake can be resumed 3–5 h after sheath removal if
.. the ensuing hours. Importantly, a normal aPTT in case of dabigatran
..
adequate haemostasis is established and pericardial effusion has been ... intake and a normal PT in case of rivaroxaban intake (and to a lesser
ruled out.281 .. extent edoxaban) may rule out high plasma levels of the respective
.. drugs; conversely, however, normal routine coagulation tests do not
..
.. exclude drug levels as expected while on therapy for all of the
..
13. Patients requiring an urgent .. NOACs (see chapter 7). Specific coagulation tests (dTT or ECA for
.. dabigatran; anti-FXa chromogenic assays for FXa inhibitors) and assess-
surgical intervention .. ment of plasma levels may help in interpreting the current anticoagu-
..
If an emergency intervention is required, the NOAC should .. lant status as well as the waning of any anticoagulant effect, particularly
..
be discontinued immediately. Specific management will then .. in situations with potentially increased anticoagulant levels [e.g. in older
depend on the level or urgency (immediate, urgent, or expedite;
.. age (see chapter 18.1), renal insufficiency (see chapter 6), and/or
..
Figure 9).298 . certain co-medications (see chapter 5)].

on 23 April 2018
Figure 9 Non-vitamin K antagonist oral anticoagulant management in the setting of unplanned surgery.
..
14. Patient with atrial fibrillation .. agents.141,308 In essence, these trials focus on bleeding as the primary
.. endpoint, and are underpowered to address relatively rare ischae-
and coronary artery disease ..
.. mic/thromboembolic events including stroke, re-infarction and stent
.. thrombosis. A meta-analysis combining WOEST, PIONEER AF-PCI,
Scope of the problem and randomized ..
.. and RE-DUAL PCI suggests that the likelihood of an excess of throm-
clinical trial evidence .. boembolic events during dual therapy vs. triple therapy is low.309 The
The combination of AF and coronary artery disease (CAD) is not ..
.. two ongoing NOAC in AF trials, AUGUSTUS (NCT02415400) and
only a common and complex clinical setting to deal with regarding .. ENTRUST-AF PCI (NCT02866175)310 will add further information
anticoagulation and antiplatelet therapy, it is also associated with sig- ..
.. on how and how long (if at all) triple anticoagulation should be
nificantly higher morbidity and mortality.300,301 The practice of adding .. administered.
aspirin or a P2Y12 inhibitor to a (N)OAC is referred to as ‘dual ther-
..
..
apy’, while adding both aspirin and a P2Y12 inhibitor to a (N)OAC is ..
called ‘triple therapy’. Dual antiplatelet therapy is referred to as
..
.. Randomized clinical trial evidence for non-vitamin K
‘DAPT’. Stacking antithrombotic agents, i.e. by adding one or two .. antagonist oral anticoagulants post-percutaneous
antiplatelet(s) to NOACs, inevitably increases the risk of bleeding sig-
..
.. coronary intervention
nificantly,170,171,302,303 leading to a clear need to avoid long-term tri- .. In PIONEER AF-PCI, two different rivaroxaban regimens were com-
..
ple therapy in daily clinical practice.304–306
... pared with ‘standard’ triple therapy with VKA and DAPT in 2124 AF
The current understanding is that DAPT is necessary to prevent .. patients undergoing PCI: a low-dose of rivaroxaban 15 mg (10 mg in
stent thrombosis but not sufficient for stroke prevention,307 and vice .. patients with CrCl 30–50 mL/min) with a P2Y12 inhibitor and a very
..
versa, that (N)OAC are essential for stroke prevention but on their .. low dose of rivaroxaban 2.5 mg twice daily combined with aspirin
own not suitable for preventing new coronary events, especially in .. and a P2Y12 inhibitor.311 The trial design was complex: One year
..
the acute/subacute setting.3 A combination of at least one antiplatelet .. fixed treatment of 15 mg rivaroxaban plus P2Y12 inhibitor was com-
agent in addition to (N)OAC is recommended for up to 12 months .. pared to triple anticoagulation with very-low dose rivaroxaban
..
after an ACS event and/or stenting procedure according to the most .. (2 2.5 mg) or VKA. The P2Y12 inhibitor was clopidogrel in the vast
recent ESC guidelines on AF,3 ST-elevation myocardial infarction .. majority of patients, and DAPT durations of 1, 6, and 12 months
..
(STEMI),33 and the use of antiplatelet agents.32 .. were pre-specified for the latter two arms. PIONEER AF-PCI showed
To date, there are a handful of prospective trials addressing the .. that both rivaroxaban arms reduced the risk of clinically significant
..
issue of oral anticoagulation after PCI, including two RCTs comparing .. bleeding complications at 1 year when compared with standard triple
NOACs to VKA, in a variety of combinations with antiplatelet .. therapy with a VKA targeted to an INR between 2 and 3 and with

on 23 April 2018
..
varying DAPT durations.308 While there were numerically similar .. months in case of ACS) are safe and efficacious in patients perceived
rates of cardiovascular death, myocardial infarction, or stroke in all .. to have a high bleeding risk and/or the elderly.314,315 Patients receiv-
..
three arms, the trial was underpowered for efficacy. However, nei- .. ing (N)OAC in combination with dual antiplatelet agents are con-
ther of the rivaroxaban doses in PIONEER AF-PCI (15 mg/10 mg OD
.. sidered to be at high bleeding risk.
..
or 2.5 mg BID) have been investigated for stroke prevention in AF .. (4) Rivaroxaban 15 mg or dabigatran 110/150 mg BID in dual therapy
[with the exception of the 15 mg dose in a relatively underpowered
.. with P2Y12 inhibitor, mainly clopidogrel (but without aspirin) is safer
..
trial conducted in an exclusively Japanese population with normal .. in terms of bleeding risk than triple therapy with VKA, clopidogrel,
renal function (J-ROCKET)].156
.. and low-dose aspirin (PIONEER AF-PCI / RE-DUAL PCI).141,308
..
In RE-DUAL PCI, the safety of two doses of dabigatran (110 or .. (5) Rivaroxaban 2.5 mg BID in triple therapy with aspirin and clopidog-
.. rel is safer in terms of bleeding risk than triple therapy with dose-
150 mg BID) in combination with clopidogrel or ticagrelor (i.e. dual ..
therapy, without aspirin) were compared with standard triple ther- .. adjusted VKA, clopidogrel, and low-dose aspirin.
..
apy (for 1 or 3 months depending on the type of stent) with VKA, .. (6) Measures to reduce the bleeding risk in patients with ACS should
aspirin, and either clopidogrel or ticagrelor in 2725 patients with AF .. be retained: low doses of aspirin (75–100 mg), especially when
..
undergoing PCI.141 The composite of major or clinical relevant non- .. combined with a P2Y12 inhibitor; new-generation drug-eluting
major bleeding events and major bleeding events alone were signifi- .. stents (DES) to minimize the duration of dual/triple therapy; and a
..
cantly reduced in the 110- and 150-mg dabigatran dual therapy arms .. radial approach for interventional procedures (reducing at least the
compared to the standard VKA triple therapy arm. This trial was also .. risk of access site bleeding).33,316
..
underpowered for individual efficacy endpoints; however, it was .. (7) Prolonged antiplatelet therapy beyond 1 year after ACS or DES
powered to show non-inferiority of the combined dual-therapy arms .. implantation has been suggested in non-(N)OAC treated patients
..
vs. the triple therapy in a composite efficacy endpoint of death, .. based on large-scale RCTs.317–319 In the DAPT trial, patients were
thromboembolic events and unplanned revascularization. Stent .. randomized 12 months after a PCI with DES to aspirin plus clopi-
..
thrombosis was observed in 15 (1.5%) patients in the 110-mg dual .. dogrel or aspirin alone, up to 30 months after the PCI. In the
therapy group vs. 8 (0.8%) patients in the triple-therapy group .. PEGASUS TIMI 54 trial, patients were randomized 1–3 years after
..
(P = 0.15) and in 7 (0.9%) patients in the 150-mg dual-therapy .. an myocardial infarction to aspirin plus ticagrelor or aspirin alone,
group.141 Both dabigatran doses in RE-DUAL PCI have been shown
.. and followed for a median of 33 months. Since patients in need of
..
non-inferior (110 mg) or superior (150 mg) to VKA for stroke pre- .. long-term OAC therapy were excluded from these studies, the
vention in AF.28
.. results are of less relevance for treatment of AF patients.
..
..
.. What is unknown
..
Key ‘scientific’ data on the use of non- .. (1) It is unknown whether the doses of rivaroxaban used in PIONEER
vitamin K antagonist oral anticoagulants ..
.. AF-PCI (i.e. 2.5 mg BID or 15 mg OD) are sufficient for stroke pre-
in patients with atrial fibrillation and .. vention, at least compared with standard dose-adjusted VKA or
..
acute coronary syndrome, percutaneous .. compared with the 20 mg OD rivaroxaban dose in patients with a
.. normal renal clearance.29
coronary intervention, or stable ..
coronary artery disease .. (2) It remains unknown whether dual therapy strategies combining a
.. NOAC with clopidogrel are safer in terms of bleeding risk than a
..
.. dual therapy with a VKA and clopidogrel. This is currently being
What is known: .. addressed in the AUGUSTUS study with apixaban.
..
(1) Adding aspirin and/or a P2Y12 inhibitor to oral anticoagulants sub- .. (3) It remains unknown whether dual therapy (i.e. rivaroxaban 15 mg
.. OD or dabigatran 110/150 mg BID in combination with a P2Y12
stantially increases bleeding risk across different clinical scenarios ..
and should thus be avoided in AF patients without clear indication .. inhibitor) sufficiently protects against stent thrombosis or myocar-
.. dial infarction, due to underpowered clinical trials.141,308
for antiplatelet therapy, including CAD patients beyond 12 months ..
after an ACS.170,300,312 However, in general the bleeding risk seems .. (4) It remains unknown whether dual therapy with NOAC and aspirin
.. could be an alternative to NOAC and a P2Y12 inhibitor, as there is
to be lower with a NOAC plus antiplatelet combination than with a ..
VKA plus antiplatelet combination.170,302,313 .. no randomized study evaluating aspirin vs. a P2Y12 inhibitor as part
..
(2) ESC guidelines clearly state that the length of DAPT does not .. of dual therapy with NOAC or VKA.
depend (anymore) on the type of stent (i.e. DES or BMS) but on the .. (5) There were insufficient numbers of patients on ticagrelor or prasu-
..
clinical presentation of the patient.3,32 As contemporary DES are .. grel in both PIONEER AF-PCI and RE-DUAL PCI to conclusively
more efficient and as safe (or safer) as BMS regarding the risk for .. assess the safety of combining these more powerful P2Y12 inhibitors
..
stent thrombosis, it does not make sense to opt for a BMS as a strat- .. in dual or triple therapy regimens.
egy to reduce the duration of P2Y12 inhibitor therapy in patients on .. (6) In VKA-treated patients, a PCI seems safe without bridging and with-
..
a NOAC. The use of a contemporary DES will also minimize the .. out additional periprocedural heparin.320 It is unknown if this applies
risk of avoidable repeat interventions due to restenosis thereby
.. also to NOACs, since most clinical studies have suggested interrup-
..
reducing the need for additional periods of dual or triple therapy. .. tion of NOAC therapy at PCI. A small pilot study in 50 stable patients
(3) Clinical trials with contemporary DES suggest that (very) short dual
.. undergoing planned PCI and on DAPT suggests that pre-procedural
..
antiplatelet regimens (i.e. 1 month after elective stenting or 6 . dabigatran provides insufficient anticoagulation during PCI.321

on 23 April 2018
..
A similar study with rivaroxaban, however, showed suppressed coag- .. in patients in need for chronic anticoagulation due to the reduced
ulation activation after elective PCI, without increased bleeding.322 .. need for long-term dual or triple therapy.
..
The safety of performing a PCI in patients on a NOAC, with or with- .. There is no rationale for switching a NOAC to VKA after (or just
out additional periprocedural intravenous anticoagulation still needs .. prior) to elective PCI, since this may be associated with an increased
..
to be prospectively studied in larger clinical trials. .. bleeding and thromboembolic risk compared with restarting the NOAC.
.. NOAC therapy should be discontinued before patients are taken
..
Scenario 1: coronary interventions in .. to the cath lab and the procedure be performed at least (12–)24 h
.. after last intake (see chapter 12). Periprocedural anticoagulation
patients with known atrial fibrillation ..
.. should be used per local practice. Unfractionated heparin (70 IU/kg)
already on non-vitamin K antagonist oral .. or bivalirudin rather than enoxaparin is preferred.323 Unfractionated
anticoagulant ..
.. heparin should be administered to target ACT or aPTT levels per
Whereas guidelines recommend maintaining VKA patients uninter- .. standard clinical practice. Bivalirudin may be an alternative because of
..
rupted on their treatment, both during elective or urgent PCI, .. its very short therapeutic half-life.
NOACs should preferably be temporarily discontinued for elective ..
..
interventions and upon presentation with non-ST-elevation ACS .. Acute coronary syndrome
where early coronary angiogram is anticipated, as has been done dur- ..
.. In the absence of contraindications, all NOAC patients developing an
ing the pivotal NOAC vs. VKA AF trials. NOACs should be contin- .. ACS should receive low-dose aspirin immediately at admission (150–
ued in non-invasively-managed ACS patients. Performing a PCI ..
.. 300 mg loading dose) as well as a P2Y12 inhibitor. Since clopidogrel as
(scheduled or not) under NOAC is different than under VKA for .. well as the newer P2Y12 inhibitors take considerable time to achieve
many reasons: last dose and adherence needs to be carefully scruti- ..
.. their maximal antiplatelet effect in unstable patients, P2Y12 inhibition
nized; uncertainty about the extent of anticoagulation in the absence .. without aspirin cannot be recommended in the acute setting. In frail
of mainstream/point of care tests, and hence uncertainty about stack- ..
.. patients at high bleeding risk, aspirin only might be a safer initial ther-
ing of additional periprocedural anticoagulants; variability in renal .. apy awaiting invasive management, when indicated.
function (especially when unknown in an acute setting); singular anti- ..
..
factor II or Xa blockade vs. multifactor antagonism with VKA, etc. .. ST-elevation myocardial infarction. In case of a STEMI, primary PCI via a
Temporary discontinuation of the short-acting NOACs allows safe
..
.. radial approach is strongly recommended over fibrinolysis.324 It is
initiation of antiplatelet therapy and standard local anticoagulation .. recommended to use additional parenteral anticoagulation (i.e. UFH,
practices periprocedurally.
..
.. enoxaparin, or bivalirudin, but not fondaparinux), regardless of the
In the 2016 ESC AF guideline and 2017 DAPT focused update, the ..
use of ticagrelor or prasugrel as part of a triple therapy regimen is dis-
.. timing of the last dose of NOAC. Unless used for bail-out situations,
.. routine glycoprotein IIb/IIIa inhibitors should be avoided.
couraged (Class III, level of evidence C), but no comments are made ..
on dual therapy with combination of ticagrelor or prasugrel and a
.. If fibrinolysis is the only available reperfusion therapy, it may be
.. considered if the NOAC-treated patient presents with normal dTT,
NOAC as possible alternative for triple therapy with aspirin, clopi- ..
.. ECT, aPTT (for dabigatran), PT (for FXa inhibitors), and importantly,
dogrel and a NOAC.3,32 It leaves the opportunity to use one of these .. plasma levels below the reference range (Table 9). Also, additional
newer P2Y12 inhibitors with a (N)OAC under certain circumstances ..
.. UFH or enoxaparin in addition to fibrinolysis should be avoided until
such as perceived high thrombotic risk, ACS, or prior stent thrombo- .. the NOAC effect has decreased (12 h or longer after last intake).
sis. In a subset of the RE-DUAL PCI study the use of ticagrelor ..
..
appeared safe and effective in the setting of dual therapy (Oldgren .. Non-ST-elevation myocardial infarction. After discontinuing the NOAC
et al., presented at AHA 2017). Triple anticoagulation with any of the ..
.. and awaiting the waning of its effect (12 h or longer after last intake;
new P2Y12 inhibitors, on the other hand, is clearly discouraged .. chapter 12), fondaparinux or enoxaparin can be initiated. The use
beyond the first day(s) post-PCI. A signal for a relevant role of ‘clopi- ..
.. of upstream glycoprotein IIb/IIIa inhibitors should be avoided in this
dogrel resistance’ has so far not surfaced clinically in the large out- .. setting. Unfractionated heparin or bivalirudin is only recommended
come trials but experience in earlier DAPT studies may provide a ..
.. in bail-out situations, awaiting an intervention (Class IIb C).325 To
rationale for further studies on the use of newer P2Y12 inhibitors in .. reduce the risk of access site bleeding, a radial approach is
the setting of dual anticoagulation. ..
.. preferred.324
.. In more urgent situations, the same approach as in primary PCI
..
In-hospital management .. STEMI patients should be followed, as described above.
..
A general flow diagram indicating possible scenarios is provided in ..
Figure 10. .. Post-procedural resumption of anticoagulation
..
.. In stabilized patients (i.e. no recurrent ischaemia or need for other
Elective coronary intervention (stable coronary artery disease) .. invasive treatments), anticoagulation can be restarted as soon as
..
Contemporary DES are preferred to shorten exposure to dual or tri- .. parenteral anticoagulation has been stopped. There are no data to
ple therapy after the procedure (see below) but also to avoid the .. recommend switching to VKA (which may even be associated with
..
need for repeat interventions. There is no reason anymore to opt for .. higher bleeding and thromboembolic risks, especially in VKA-naive
a BMS as a strategy to reduce DAPT duration.32,314 Sole balloon
.. patients in whom the correct VKA dose is unknown). The same
..
angioplasty or bypass surgery should be considered as an alternative . applies for AF patients after coronary bypass grafting.

on 23 April 2018
Figure 10 Acute management of elective percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation patients treated
with non-vitamin K antagonist oral anticoagulant.
..
The initial combination of antiplatelet agent(s) and NOAC as well .. of the large varieties of possible combinations.141,170,300,302,308,326
as the subsequent duration of aspirin or P2Y12 inhibitor treatment .. Despite two recent studies on dual or triple therapy with
..
need to be individualized, based on a careful assessment of ischaemic .. NOAC (and two more underway), there is no one combination fit-
vs. bleeding risk (Figure 11). Based on PIONEER AF-PCI and RE- .. ting every patient. The type and level of anticoagulation as well as one
..
DUAL PCI, triple treatment should be kept as short as possible .. or two antiplatelet agents and its duration need to be highly individu-
(see chronic phase below). An alternative is to opt for dual therapy
.. alized, based on atherothrombotic risk, cardioembolic risk, and
..
with only a NOAC and a P2Y12 inhibitor within 1–7 days after .. bleeding risk.3,32,33 It is highly recommended to formally assess
the acute phase.
.. stroke and ischaemic event risk using validated tools such as the
..
While awaiting the results of trials with apixaban and edoxaban .. CHA2DS2-VASc and GRACE scores.32 Estimating the bleeding risk
the 150 mg dabigatran dual therapy appears to be the preferred
..
.. should lead to efforts to correct or reduce reversible bleeding risk
choice over triple therapy for the majority of patients based on both .. factors.3 Reducing the time exposed to triple or even dual therapy
..
the results from RE-LY28 and RE-DUAL PCI141; dual therapy using .. needs to drive the physician’s choice between the myriad of possible
110 mg dabigatran or rivaroxaban 15 mg (10 mg in renal insufficiency) .. combinations for long-term therapy. Proton pump inhibitors
..
appears as a viable alternative for patients with estimated high bleed- .. should be encouraged in all patients with a combination of antiplate-
ing risk—provided that dabigatran or rivaroxaban per se appear as a .. lets and anticoagulants, particularly in the setting of triple
..
good choice for this individual patient based on age (see chapter .. anticoagulation.
18.1), comorbidities (e.g. renal insufficiency; see chapter 6), interac- .. In patients at high ischaemic risk (e.g. after an ACS), a default time
..
tions (see chapter 5), and others. .. of triple therapy of 1 month up to 6 months is proposed, thereafter
.. stepping down to dual therapy (with NOAC and either aspirin or clo-
..
Management from discharge to 1 year post-acute .. pidogrel) until 1 year.32 Triple therapy beyond 6 months after PCI is
coronary syndrome/percutaneous coronary intervention
.. not recommended, and (much) shorter regimens will likely suffice for
..
Combining one or two antiplatelet agents with chronic anticoagula- .. most patients. Factors that weigh in to shorten triple therapy with
tion (NOAC or VKA) significantly increases bleeding risk, regardless
.. earlier switch to dual therapy are an estimated low atherothrombotic

on 23 April 2018
Figure 11 Long-term treatment of patients on non-vitamin K antagonist oral anticoagulant therapy after elective percutaneous coronary interven-
tion or acute coronary syndrome. There are innumerable possible variations on this global theme, as discussed in the text. Patient characteristics and
institutional practices should be taken into account to individualize the approach to each and every single patient. This figure wants to create a ‘back-
bone’ as guidance for such tailored approaches. A: aspirin 75–100 mg OD; C: clopidogrel 75 mg OD; Tica: Ticagrelor 90 mg BID. *If triple therapy
needs to be continued after discharge clopidogrel is preferred over ticagrelor (due to lack of data).
risk or a high (uncorrectable) bleeding risk. Conversely, procedural .. Independent of the chosen anticoagulation regimen and timing, the
..
and/or anatomical factors may drive longer triple therapy regimens. .. patient needs to be discharged with a pre-specified planned down-
Beyond those patients at very high ischaemic risk, early dual therapy
.. grade schedule of antithrombotic/antiplatelet agents to reduce the
..
may well become the default strategy for most patients based on .. longer-term risk of bleeding while protecting against coronary events.
PIONEER AF-PCI and RE-DUAL PCI (while awaiting results from
.. Such a schedule should be prominently delineated in the discharge
..
AUGUSTUS and ENTRUST-AF PCI).32,310 .. letter, and reviewed at every following patient visit.
In a small subset of patients with a low stroke risk (CHA2DS2-
..
..
VASc of 0–1 in males or 1–2 in females, i.e. only ACS) and elevated ..
bleeding risk, one could opt to treat with DAPT only, without antico-
.. Scenario 2: management of the patient
..
agulants, from the onset.307 .. with a recent acute coronary syndrome
.. (<1 year) who develops new-onset atrial
..
.. fibrillation
..
Chronic coronary artery disease setting (1 year post- .. Current ACS guidelines recommend DAPT for up to 1 year after the
acute coronary syndrome/percutaneous coronary .. acute event in patients without indication for OAC, while high-risk
..
intervention) .. patients might require an even longer DAPT duration.318,319 They do,
The 2017 ESC DAPT and 2016 AF guidelines recommend discontin- .. however, also allow for shorter DAPT durations (3–6 months) in high
..
uing any antiplatelet agent at 12 months after a PCI or ACS episode .. bleeding risk ACS patients.32,33,327 If AF develops during the first year
(see following paragraphs) and to only consider keeping one antipla- .. after an ACS and there is an indication for thromboembolic preven-
..
telet plus a (N)OAC beyond 12 months in patients at very high risk .. tion with anticoagulation, (N)OAC should be started and the need for
of coronary events.3,32 Switching to NOAC monotherapy at an ear-
.. continuing DAPT carefully weighed against the increased bleeding
..
lier stage (e.g. at 6 months) could represent an alternative for patients .. risk. Following a scheme as outlined above (Management from
at low ischaemic- and high bleeding risk after a PCI for stable angina.
.. discharge to 1 year post-ACS/PCI) appears reasonable in this setting.

on 23 April 2018
..
Scenario 3: a stable coronary artery .. in a patient who is on chronic treatment with a NOAC and now
.. requires cardioversion for a new bout of AF, and cardioversion in a
disease patient (acute coronary ..
syndrome 1 year ago) develops atrial .. patient newly diagnosed with AF and naı̈ve to anticoagulation
.. (Figure 12).
fibrillation ..
..
Stable CAD patients developing AF should receive anticoagulation, .. Cardioverting an atrial fibrillation
depending on their CHA2DS2-VASc score. Based on studies showing ..
.. patient treated for 3 weeks with non-
that VKAs alone are superior to aspirin post-ACS, and VKAs plus ..
aspirin may not be more protective but associated with excess bleed-
.. vitamin K antagonist oral anticoagulant
..
ing, anticoagulation only without additional antiplatelet agents is con- .. Analyses from RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and
sidered sufficient for most AF patients with stable CAD.32,316,328
.. ARISTOTLE (apixaban) suggest that electrical cardioversion in
..
In the four Phase III NOAC AF trials, about one third of the .. patients treated with NOACs has a similar (and very low) throm-
patients had CAD and 15–20% of patients had a prior MI.28–31 No
.. boembolic risk as under warfarin.28–30 Later prospective trials with
..
interaction in terms of efficacy or safety was observed between .. rivaroxaban (X-VeRT),349 edoxaban (ENSURE-AF),350 and apixaban
.. (EMANATE, Ezekowitz et al., presented at ESC 2017) have con-
patients with or without a prior MI, although it is unclear in how ..
many patients antiplatelet therapy was maintained and for how long. .. firmed the low peri-cardioversion stroke risk in patients treated with
.. a NOAC for >_3 weeks compared with warfarin. These trials did not
It is likely that the advantages of NOACs (in monotherapy) over ..
VKAs are preserved in CAD patients with AF. Also for dabigatran, .. include sufficient patient numbers to demonstrate statistically sound
.. non-inferiority. In congregate, however, these data indicated that a
the net clinical benefit was maintained and total myocardial ischaemic ..
events were not increased, which was further supported by the very .. cardioversion without TOE seems reasonably safe under regular and
.. continued NOAC intake, provided that adequate anticoagulation has
large registry follow-up in 134 000 older patients treated with dabiga- ..
tran or VKA, which did not reveal any increased risk for MI.79,329 .. been installed for 3 weeks before cardioversion.3 As there is no coag-
.. ulation assay available for any NOAC that provides information on
Since direct comparative data are lacking, there is no strong argument ..
for choosing one NOAC over another in this setting based purely on .. effective anticoagulation over the past 3 weeks, the patient needs to
.. be inquired about adherence over the last weeks and his/her answer
the existence of stable coronary artery disease. ..
.. documented in their file. If in doubt about adherence, a TOE should
.. be performed prior to cardioversion under a NOAC. Importantly, it
..
15. Avoiding confusion with .. has to be kept in mind that left atrial thrombi can also form in spite of
.. adequate long lasting oral anticoagulation with a VKA or NOAC.
non-vitamin K antagonist oral ..
.. Therefore, it remains an individual decision whether to perform a
anticoagulant dosing across .. cardioversion with or without prior TOE. For this decision, the indi-
..
.. vidual thromboembolic risk of a patient according to the CHADS2 or
indications ..
.. CHA2DS2-VASc score can be considered: in 1.6–2.1% of therapeuti-
In order to replicate the positive findings of the RCTs, using the cor- .. cally anticoagulated patients a TOE prior to AF ablation revealed
..
rect dosing is critical, especially since all NOACs are also studied in .. thrombi or sludge in the left atrium, with the risk of thrombus corre-
other indications. With four NOACs available in different dosages .. lating with the CHADS2 score (thrombus incidence <_0.3% in
..
for different indications and with different dose reduction criteria, .. CHADS2 0–1 patients, thrombus incidence 0.5% in CHADS2 >_2
identification of the correct dose has become more complicated and .. patients).351–353
..
is one of the key challenges in the daily use and individualization of ..
treatment.
.. Cardioverting atrial fibrillation of >48 h
..
Table 13 gives an overview of the currently available NOACs and .. in a patient not on non-vitamin K
their doses in the different populations and indications, including the
..
.. antagonist oral anticoagulant
relevant dose reduction criteria for each NOAC and indication. ..
.. For the scenario of cardioversion in an AF patient who is not on
.. NOAC, the X-VeRT,349 ENSURE-AF,350 and EMANATE (presented
..
.. at ESC 2017)354 studies with rivaroxaban, edoxaban, and apixaban,
16. Cardioversion in a non-vitamin .. respectively, offered important data since they included 57%, 27%,
K antagonist anticoagulant- ..
.. and 100% of OAC-naı̈ve patients, respectively. The cardioversion
..
treated patient .. strategy was either early (with TOE) or without TOE (delayed strat-
.. egy, i.e. with 3–8 weeks anticoagulation before cardioversion). OAC-
Based on current ESC guidelines,3 in patients with AF of >_48 h (or .. naı̈ve patients tended to have slightly higher thromboembolic event
..
unknown) duration undergoing electrical or pharmacological cardio- .. rates (which was not statistically significant). Overall, there was no
version, effective oral anticoagulation needs to be established for at .. difference in ischaemic or bleeding events between NOAC and VKA
..
least 3 weeks prior to cardioversion or transesophageal echocardiog- .. groups (except for lower ischaemic events with apixaban in the
raphy (TOE) performed to rule out left atrial thrombi. After cardio- .. EMANATE trial), nor between early and delayed groups, although
..
version, continuous oral anticoagulation is mandatory for at least .. neither of the trials were powered for non-inferiority. In EMANATE,
another 4 weeks, irrespective of CHA2DS2-VASc score.3,348
.. about half of the patients received an initial loading dose of 10 mg (fol-
..
Different scenarios have to be distinguished: electrical cardioversion . lowed by 5 mg BID); also these patients did not show a higher

on 23 April 2018
Table 13 NOACs and approved/studied doses across indications
Stroke prevention in atrial fibrillation (SPAF)
Standard dose Comments/dose reduction
Apixaban30 2 5 mg 2 2.5 mg if two out of three: weight <_60 kg, age >_80 years,
serum creatinine >_133 mmol/(1.5 mg/dL) [or if CrCl 15–29 mL/min]
Dabigatran28 2 150 mg / 2 110 mg No pre-specified dose-reduction criteriaa
Edoxaban31 1 60 mg 1 30 mg if: weight <_60 kg, CrCl <_50 mL/min, concomitant therapy
with strong P-Gp inhibitor (see chapter 5)
Rivaroxaban29 1 20 mg 1 15 mg if CrCl <_50 mL/min
Treatment of DVT/PE
Initial therapy Remainder of treatment phase

330
Apixaban 2 10 mg, 7 days 2 5 mg, no dose reduction
Dabigatran331 Heparin/LMWH No pre-specified dose-reduction criteriab
Edoxaban332 Heparin/LMWH 1 60 mg, same dose reduction as for SPAF (see above)
333,334
Rivaroxaban 2 15 mg, 21 days 1 20 mg, no dose reductionc
Long-term prevention of recurrent DVT/PE (i.e. after 6 months)

335
Apixaban 2 2.5 mg
Dabigatran336 2 150 mg No pre-specified dose-reduction criteriad
Edoxaban not specifically studied
Rivaroxaban337 1 10 mg e
VTE prevention post-major orthopaedic surgery
Apixaban338 2 2.5 mg
Dabigatran339,340 1 220 mg f
341,342
Edoxaban 1 30 mg Not approved in Europe (only studied in Asia)
Rivaroxaban343–346 1 10 mg
Stroke prevention post-PCI (with concomitant atrial fibrillation)g
Apixaban To be determined (pending results of AUGUSTUS trial)

141
Dabigatran 150 mg BID or 110 mg BID þClopidogrel or Ticagrelor; no dose reduction
Edoxaban To be determined (pending results of ENTRUST-AF PCI trial)310
Rivaroxaban308 15 mg OD (þClopidogrel) Dose reduction to 10 mg OD if CrCl 30–49 mL/min

on 23 April 2018
Secondary prevention of atherothrombotic events post-ACS (without AF)
Rivaroxaban171 2.5 mg BID In addition to Aspirin ± P2Y12 inhibitor
Secondary prevention of atherothrombotic events in stable CAD (without AF)h
Rivaroxaban347 2.5 mg BID In addition to Aspirinh
ACS, acute coronary syndrome; CAD, coronary artery disease.

a
SmPC: 2 110 mg if age >_80 years, concomitant verapamil, increased risk of GI bleeding.
b
SmPC: 2 110 mg if age >_80 years, concomitant verapamil, increased risk of GI bleeding (based on PK/PD analyses; not studied in this setting).
c
SmPc: 15 mg if risk of bleeding outweighs risk for recurrent DVT and PE (based on PK/PD analyses; not studied in this setting).
d
SmPC: 2 110 mg if age >_80 years, concomitant verapamil (both based on PK/PD analyses; not studied in this setting).
e
SmPc: 1 20 mg in patients. At high risk of recurrence.
f
SmPc: 1 150 mg if CrCl 30–50 mL/min; concomitant verapamil, amiodarone, quinidine; age >75 years.
g
As outlined in detail in chapter 14, both PIONEER AF-PCI as well as RE-DUAL PCI were powered for safety and were underpowered to determine non-inferiority for indi-
vidual efficacy endpoints.
h
As studied in COMPASS; approval of this indication and regimen is pending.
Figure 12 Cardioversion work-flow in atrial fibrillation patients treated with NOACs, depending on the duration of the arrhythmia and prior anti-
coagulation. TOE, transoesophageal echocardiography.
..
bleeding tendency. The 10 mg loading dose is not part of the official .. patients with AF of >_ 48 h duration, provided that a TOE is per-
labelling (which may change in the near future). Taken together, a .. formed prior to cardioversion. The alternative is starting anticoagula-
..
strategy with at least a single NOAC dose >_4 h before cardioversion .. tion with a NOAC for at least 3 weeks followed by cardioversion
(>_ 2 h after apixaban loading dose) appears safe and effective in .. (without TOE unless high risk patient or deemed non-adherent).

on 23 April 2018
..
Cardioverting atrial fibrillation .. until resolution of the thrombus (with heparin bridging if necessary).
.. Recently, the prospective X-TRA study indicated a thrombus resolu-
of 48 h in an anticoagulation-naive ..
patient .. tion rate of 41.5% (22/53 patients) with standard dose rivaroxaban
.. (20 mg/d)361 – comparable to the retrospective CLOT-AF registry in
Even in patients with recent onset AF of <_48 h, different observatio- ..
.. which left atrial thrombus resolution was observed in 60/96 patients
nal studies have shown a lower thromboembolic incidence rate with .. (62.5%) in heparin/warfarin treated patients.361 Similarly, in the
vs. without anticoagulation, especially in those with a CHA2DS2- ..
.. EMANATE trial, thrombus resolution rate was similar in patients
VASc >_2 and AF duration >_12 h.355,356 Neither X-VeRT nor .. treated with apixaban (52%, 12/23) as with conventional therapy
ENSURE-AF provided information on whether intake of at least one ..
.. (56%, 10/18; Ezekowitz et al.,8 presented at ESC 2017). Individual
dose of NOAC is a feasible strategy in patients with AF of <_48 h .. case reports are equally available for the other NOACs; the RE-
duration, who are currently often cardioverted after a single dose of ..
.. LATED AF study (with dabigatran; NCT02256683) is still ongoing. In
LMWH (with continuation of anticoagulation for >_4 weeks). Some of .. congregate, these data indicate that using NOACs for left atrial
such patients were included in EMANATE, but publication of the final ..
.. thrombus resolution may be an option (best data available for rivar-
results is still pending and subgroup results are unknown. .. oxaban and apixaban), particularly in patients where a VKA is not
In the absence of data, adherence to current institutional practice ..
.. well tolerated or adequate INR control cannot be obtained.
with heparin/LMWH with or without TOE may be prudent in such ..
patients. Given the consistent efficacy and safety of NOACs in ..
..
patients with AF >_48 h combined with the similar pharmaco-dynamic .. 17. Atrial fibrillation patients
and -kinetic properties of NOACs and LMWH, the use of a single
..
.. presenting with acute stroke while
dose of NOAC (2)–4 h before cardioversion to replace LMWH may ..
..
be justified in patients with AF <48 h, without a TOE. Nevertheless in .. on non-vitamin K antagonist oral
high risk patients (i.e. CHA2DS2-VASc >_4) or those in whom there is ..
any doubt about the onset of AF, a TOE strategy or a strategy with
.. anticoagulants
..
longer term anticoagulation (at least for 3 weeks before cardiover- .. According to controlled clinical trials, the incidence of ischaemic
sion) is recommended. It needs to be kept in mind that the 48 h cut-
..
.. stroke remains 1–2% per year in patients with AF despite anticoagu-
off is not binary and cardioversion in the setting of even shorter dura- .. lant treatment. Adherence to medication needs to be assessed in
..
tions of AF have been associated with an increased risk of stroke, e.g. .. case of stroke in NOAC treated AF patients. The measurement of
cardioversion after 12–48 h vs. <12 h).356,357 .. anticoagulant plasma level at the time of hospital admission may help
..
.. to optimize secondary stroke prevention.362 In addition, alternative
.. causes of stroke should be assessed in any AF patient.
Duration of anticoagulation ..
post-cardioversion ..
.. Management the acute phase of stroke in
The long-term management of patients post-cardioversion depends ..
.. NOAC treated AF patients
on the individual patient’s CHA2DS2-VASc score. Men and women ..
with a CHA2DS2-VASc >_2 and >_3, respectively, require long-term .. Patients with acute ischaemic stroke
.. According to current guidelines and official labelling, thrombolytic
anticoagulation independent of the ‘success’ of cardioversion accord- ..
ing to current guidelines.3 This is also true for AF with a clear ‘trigger’ .. therapy with recombinant tissue plasminogen activator (rt-PA) is
.. approved within 4.5 h of onset of stroke symptoms but should not be
including pulmonary embolism, sepsis, or major surgery, since the ..
trigger does not negate underlying structural or vascular factors asso- .. administered in patients on full anticoagulation (e.g. INR >_1.7 in VKA
.. treated patients) (Figure 13).363 Thrombolytic therapy cannot be
ciated with increased thromboembolic risk. For AF of >48 h duration ..
and a low CHA2DS2-VASc score (0 in men, 1 in women) anticoagula- .. given within 24 h after the last intake of a NOAC due to their plasma
..
tion needs to be continued for 4 weeks post-cardioversion. In con- .. half-lives (Table 6), which may even be prolonged in renal insufficiency
trast, it is currently unknown how long (if at all) the latter patients
.. (see chapter 6), the elderly (see chapter 18) and other situations.
..
should be anticoagulated if AF is of shorter duration (especially when .. The case is different for dabigatran due to the availability of the rapid
<12 h), since AF and/or cardioversion may contribute to atrial
.. acting specific reversal agent, idarucizumab (see chapter 11). After
..
mechanical and/or endothelial dysfunction for hours to days.357 .. reversal and assessment of coagulation status, intravenous thrombol-
.. ysis within 4.5 h of onset of moderate to severe stroke seems feasible
..
.. and safe according to case series.364,365 In the absence of randomized
Management of a patient with .. studies demonstrating the overall efficacy and safety of this approach,
documented left atrial appendage ..
.. balancing the anticipated benefit of this approach vs. its risks is of par-
thrombus .. amount importance. It remains to be demonstrated whether the
..
Patients in whom TOE identifies a left atrial thrombus should not .. same approach will be safe and effective also for Xa-inhibitors once
undergo cardioversion. Observational and prospective data have not .. andexanet alpha becomes available.
..
shown a different thrombus incidence in patients treated with .. Published case series suggest that rt-PA may also be safe in patients
NOAC or VKA.349,358–360 There are no comprehensive hard clinical .. with low plasma concentrations of NOACs.366,367 Despite recent
..
endpoint data on the best strategy how to treat a left atrial thrombus .. advances reliable and sensitive rapid (point-of-care) tests for the indi-
with either form of anticoagulant. Previously, standard therapy con-
.. vidual NOACs are not widely available yet.362,368,369 However, the
..
sisted of VKA therapy with rigorous follow-up and INR monitoring . use of rt-PA may be considered in selected patients on a NOAC in

on 23 April 2018
Figure 13 Acute management of acute ischaemic stroke in a patient on non-vitamin K antagonist oral anticoagulant. *Currently only available for
dabigatran (idarucizumab). #Perform systemic thrombolysis only if there are no (other) contraindications for intravenous application of recombinant
tissue plasminogen activator according to its label. %Perform endovascular thrombectomy only if there is a target vessel occlusion and procedure is
indicated and feasible according to present evidence. **According to expert consensus.370
cases in which a reliable and NOAC specific coagulation assessment .. endovascular thrombectomy may be safe also in these individuals. Of
..
(see chapter 7) is available without long delay and demonstrating a .. note, the potential impact of present anticoagulation on reperfusion-
concentration <30 ng/mL for rivaroxaban, apixaban, or edoxaban (if
.. related bleeding risk has to be taken into account and a comparably
..
measured more than 4 h after drug administration), a reference value .. high rate of asymptomatic haemorrhagic transformation was
which is based on expert consensus only.370 Since the efficacy and
.. observed in a prospective registry including 28 NOAC patients
..
safety of this strategy needs to be further evaluated in clinical studies, .. undergoing mechanical recanalization.375 Further prospective data
we urge for the implementation of easy-to-use point-of-care testing
.. are urgently needed.
..
for the emergency setting. In contrast, the use of thrombolysis in sit- ..
uations with uncertainty about the anticoagulation status (e.g. in AF
.. Patients with acute intracranial bleeding
..
patients with aphasia, unknown time of last NOAC dose, and lack of .. About two thirds of all NOAC-related intracranial bleedings (ICBs)
..
availability of rapid assessment of plasma levels) cannot be .. are intracerebral and about one third of all ICBs are subdural bleed-
recommended. .. ings.376,377 According to a meta-analysis of retro- as well as prospec-
..
There is a proven benefit of endovascular thrombectomy up to .. tive studies, patients with intracerebral bleeds on NOAC (without
7.3 h after stroke onset in selected non-anticoagulated patients with a .. using idarucizumab as a specific reversal agent of dabigatran) had the
..
distal occlusion of the internal carotid artery or the proximal middle .. same poor prognosis as patients on VKA,378 while a more recent and
cerebral artery.371 Interestingly, endovascular thrombectomy also .. much larger retrospective analysis of the Get With the Guidelines-
..
seems to be beneficial in highly selected stroke patients with a distal .. Stroke program found a more favourable outcome with NOACs
occlusion of the internal carotid artery or the proximal middle cere- .. compared with VKA.379 A neurologist/stroke physician should exam-
..
bral artery and favourable perfusion mismatch (according to the .. ine all patients presenting with ICB on a NOAC, and neurosurgical
DEFUSE or DAWN study) within 6 to up to 24 h of last seen nor- .. consult should be solicited.
..
mal.372,373 The European Stroke Organization recommendations .. Recommendations for the treatment of ICB under oral anticoagu-
now mention the use of endovascular thrombectomy as ‘first-line .. lants are published, but the available level of evidence is low for
..
treatment’ in patients with contraindication for intravenous throm- .. NOAC-related ICB. In analogy to patients with acute ICB being
bolysis, while the AHA’s guidelines provide no specific recommenda- .. treated with warfarin, discontinuation of the drug, urgent blood pres-
..
tion in this regard.363,374 Although the trials underlying these .. sure management and rapid correction of the coagulation status (see
recommendations either excluded or contained just a few patients
.. also chapter 11) is needed to limit haematoma enlargement in
..
on VKA or NOAC, the small amount of data available suggests that . patients under NOAC.376,380,381 Whether the use of PCC is helpful

on 23 April 2018
..
in NOAC-related ICB is a matter of debate since a retrospective mul- .. antiplatelet therapy in addition to anticoagulation therapy with a sub-
ticentre analysis did not prove a significant benefit on haematoma .. sequently higher risk of major bleeding. In patients undergoing endar-
..
enlargement.382 For dabigatran related ICB reversal is possible via .. terectomy, aspirin is recommended prior to and for some days after
infusion of idarucizumab (see chapter 11). According to a reported .. surgery. Aspirin should be stopped after (re-) starting oral
..
case series,365 haematoma growth was observed in two out of twelve .. anticoagulation.
ICB patients treated with dabigatran receiving idarucizumab on hospi- ..
..
tal admission. Despite present recommendations, the efficacy of this .. Patients post intracranial bleeding
reversal strategy is unclear and needs to be further evaluated in clini- ..
.. Apart from its immediate prognosis, an ICB in the setting of AF is also
cal studies. .. associated with later ischaemic stroke and mortality, partly due to the
..
.. cessation of anticoagulation after ICB (Figure 15).388–390 Evidence-
Management in the post-acute phase .. based guidelines regarding the use of NOACs in AF patients after ICB
..
Atrial fibrillation patients post-ischaemic stroke .. are not available. A history of a spontaneous ICB constitutes a contra-
.. indication against anticoagulation according to labelling of VKAs and
There is no evidence from RCTs to prefer one NOAC over the ..
other or to switch from one NOAC to another in patients with a his- .. NOACs, unless the cause of the bleeding (like uncontrolled hyperten-
.. sion, aneurysm or arteriovenous malformation, or medical ‘triple’
tory of ischaemic stroke under NOAC therapy (Figure 14). ..
Appropriate dosing as well as patient specific issues need to be .. therapy) has been reversed.3 A recent meta-analysis of observational
..
assessed.41,93,202 Substantial study data regarding timing of reinstitu- .. studies demonstrates that restarting VKA (but not antiplatelet agents)
tion of oral anticoagulation by using a NOAC after transient ischae- .. is associated with a significantly lower rate of ischaemic stroke without
.. significantly increasing the risk of recurrent ICB.389 However, publica-
mic attack (TIA) or stroke in AF patients are missing,383 as Phase III ..
trials excluded patients within 7–30 days after stroke. .. tion bias as well as selection bias have to be taken into account. In the
..
Therefore, present recommendations are based on consensus .. absence of RCTs, a case-by-case consideration is needed whether or
opinion, and NOACs should be (re-) initiated in analogy to clinical .. not to reintroduce anticoagulation of any type in patients who have
..
practice with VKAs. Recommendations on (re-) starting of oral anti- .. experienced an anticoagulation-related ICB (Figure 15).3 Adequate
coagulation after ischaemic stroke must outweigh (recurrent) stroke .. blood pressure control is of paramount importance in all patients
..
risk vs. secondary haemorrhagic transformation (Figure 14).3,383 As .. post ICB.380 Left atrial appendage occlusion may be considered as
stated in the current ESC guidelines,3 oral anticoagulation using a
.. potential substitute for long-term anticoagulation in AF patients post-
..
NOAC may be continued (according to prescription and label) or .. ICB.3 However, this strategy requires a period of antiplatelet treat-
started one day after a transient ischaemic attack (TIA) and exclusion
.. ment post-deployment, which also carries a risk of ICB. The safety
..
of ICB by imaging. If stroke size is not expected to substantially .. and effectiveness of shorter duration antiplatelet therapy (or fore-
increase the risk of secondary haemorrhagic transformation in
.. going anticoagulation altogether) is not known. Overall, RCT evidence
..
patients with mild stroke, oral anticoagulation may be initiated .. for LAA occlusion after OAC-related ICB under OAC is missing,
>_3 days after an ischaemic stroke. In patients with moderate stroke,
.. which is why, ideally, treatment should occur in the framework of a
..
anticoagulation may be started >_6–8 days and in patients with severe .. randomized trial to contribute to evidence.
..
stroke at >_12–14 days, after excluding secondary haemorrhagic ..
transformation by repeating brain imaging [using computed tomogra- .. Patients post intracerebral bleeding
..
phy (CT) or magnetic resonance imaging (MRI)].383–385 .. In analogy to the management of VKA-related intracerebral bleeding,
Due to the rapid onset of action of NOACs as well as an associ- .. administration of NOACs may be restarted 4–8 weeks after intra-
..
ated risk of bleeding, ‘bridging’ with heparin (LMWH or UFH) is not .. cerebral bleeding if the individual risk of cardioembolic stroke is esti-
recommended. Moreover, a meta-analysis revealed that administra- .. mated to be high and the risk of recurrent ICB is estimated to be
..
tion of parental anticoagulants within 7–14 days after ischaemic .. lower.391 In practice, however, the same risk factors (including old
stroke is associated with a significant increase in symptomatic ICB.386 .. age, hypertension, and previous stroke) are predictive for ischaemic
..
.. stroke as well as recurrent intracerebral bleeding.381
..
Atrial fibrillation patients with ischaemic stroke and .. Arguments for not resuming or initiating anticoagulation in intra-
.. cerebral bleeding patients with AF should be assessed on an individ-
concomitant atherosclerosis ..
Besides a (well-tolerated) statin therapy, temporally limited addition .. ual basis (Figure 15).3,380 Patients with (probable) cerebral amyloid
.. angiopathy have a very high risk of recurrent ICB and should not be
of aspirin to a NOAC may be considered in selected patients if ..
underlying large-vessel disease is suspected and bleeding risk is con- .. anticoagulated.390 Whether long-term anticoagulation should be
.. avoided after a lobar bleed, as currently recommended by the AHA
sidered to be comparably low. However, evidence for both ..
approaches is lacking and further studies are required. Patients with .. guidelines, is a matter of debate, since a recent meta-analysis of three
.. retrospective studies indicate decreased mortality and favourable
AF and known carotid atherosclerosis with an asymptomatic stenosis ..
of the internal carotid artery should be treated with a statin and an .. functional outcome after resumption of oral anticoagulation after
.. intracerebral bleeding, irrespective of haematoma localization.391
oral anticoagulant, without the need for additional antiplatelet ther- ..
apy, similar to the situation in stable coronary heart disease (see ..
..
chapter 14). Acute stroke patients with AF and ‘symptomatic’ high- .. Patients post subarachnoid haemorrhage
grade carotid stenosis should preferably undergo carotid endarterec-
.. There is little evidence to guide the resumption of OAC treatment in
..
tomy,387 as carotid stenting would result in the need for dual . patients with AF following subarachnoid haemorrhage. A thorough

on 23 April 2018
Figure 14 (Re-) initiation of anticoagulation after transient ischaemic attack/stroke. (Re-) start only in the absence of contraindications and if
stroke size is not expected to substantially increase the risk of secondary haemorrhagic transformation. *Consider shorter delays to (re-) start a
non-vitamin K antagonist oral anticoagulant if there is a very high risk of stroke recurrence (e.g. left atrial appendage thrombus) and no haemorrhagic
transformation on follow-up brain imaging (using computed tomography or magnetic resonance imaging). Consider longer delays to (re-)start a non-
vitamin K antagonist oral anticoagulant according to the recommendations made in the European Society of Cardiology Atrial Fibrillation Guidelines
2016. #Without proven evidence; consider inclusion of patient in an ongoing trial.
..
.. subarachnoid haemorrhage occurs in AF patients taking a NOAC in
.. the absence of a remediable aetiology it seems prudent not to re-
..
.. initiate OAC treatment. Despite the absence of data, LAA closure
.. should be considered, ideally in the framework of a randomized trial.
..
..
..
.. Patients post epidural or subdural haematoma
.. Although there are no specific data, it appears to be safe to start or
..
.. reinitiate anticoagulation about 4 weeks after (surgical removal of)
.. traumatic epidural or subdural haematoma, if ongoing (chronic) alco-
..
.. hol abuse or a substantial risk of falling is not present (see chapter
.. 18). Adequately dosed NOAC or no anticoagulation at the time of
..
.. non-traumatic epidural or subdural haematoma does not support
.. (re-) initiation of oral anticoagulation.3 According to clinical presenta-
..
.. tion and haematoma extension, brain imaging (using CT or MRI) is
.. recommended before (re-) starting OAC.
..
..
..
..
.. 18. NOACs in special situations
..
..
.. 18.1. Non-vitamin K antagonist oral
.. anticoagulants in the frail and older
..
.. patients
Figure 15 (Re-) initiation of anticoagulation post intracranial
..
..
bleeding. #Without evidence; ideally include the patient in an .. The 75-year-old patient
ongoing trial. *Brain imaging (CT/MRI) should be considered before ..
.. The incidence of AF rises steadily with each decade.392,393 Stroke
(re-)initiation of (non)-vitamin K antagonist oral anticoagulant. .. prevention in older AF patients is important as stroke risk rises dra-
..
.. matically with age.394 However, OAC remains underutilized in older
.. age groups.395 Older people with AF do better on OAC than not
..
angiographic evaluation and treatment of underlying aneurysm or .. and on NOACs rather than VKA.396–398
arteriovenous malformation is needed. Moreover, neurological/neu- .. All trials of NOAC treatment in AF included significant populations
..
rosurgical evaluation regarding future risk of re-bleeding is key to bal- .. of older people (defined as >_75 years) ranging from 31% to 43% in
ance the risk vs. benefit of OAC resumption in such cases. When
.. the individual trials, comprising over 27 000 older patients in whom

on 23 April 2018
..
NOACs have been studied. Meta-analyses of NOAC trial data sug- .. falling patients on OAC should be referred to a falls service for multi-
gest no interaction of age for safety and efficacy.246 Importantly, the .. disciplinary assessment of diagnosis, risk and to address remediable
..
higher absolute risk resulted in a larger absolute risk reduction by .. pathology and/or prescribe interventions (e.g. exercise programs;
using NOACs instead of VKA in these older patients, resulting in a .. home environmental assessment etc.) that reduce risk of further
..
lower number needed to treat compared to younger patients.399 .. falls.411–413
Older patients had more bleeding but the overall pattern of bleeding ..
..
observed (reduced intracranial and increased GI bleeding) showed .. Dementia and anticoagulation
no difference between NOACs and VKA.246 While ICB remains ..
.. Dementia is common in older age groups. A stroke is a very signifi-
lower with all NOACS compared with VKA, individual trial results .. cant event for patients with dementia with a greater risk of cognitive
showed heterogeneity on the interaction between age and bleeding ..
.. and functional decline, loss of independence and institutionalization
outcomes. There was a significant interaction between age and .. compared to non-dementia patients.414 Indeed, atrial fibrillation is
increased extracranial major bleeding with both doses of dabiga- ..
.. itself a risk factor for dementia and there is encouraging evidence that
tran.155 Conversely, no significant age interaction on rates of extrac- .. use of OAC may reduce the risk of dementia in AF patients.415,416
ranial major bleeding was seen with apixaban, edoxaban, or ..
.. Dementia does pose unique considerations, however, when con-
rivaroxaban compared with overall trial results.399–401 Importantly, .. sidering anticoagulation and in particular around patient capacity in
certain comorbidities (renal insufficiency in particular, see chapter
..
.. decision making, choice of treatment and managing drug adherence
6) are more common in the older patient, and the individual choice .. safely. Importantly dementia should not be a viewed as a general con-
of the NOAC needs to take this into consideration. One interesting
..
.. traindication to anticoagulation, especially if well managed from a
study investigating low-dose edoxaban in the management of elderly .. logistical point of view (see below). All patients with dementia should
Japanese patients with atrial fibrillation who are ineligible for standard
..
.. have a careful assessment of their ability to understand and make a
oral anticoagulant therapies (ELDERCARE-AF study) is currently .. treatment decision regarding OAC in AF, with indicative risks of
..
ongoing.402 .. stroke and bleeding provided. Where capacity is lacking, it may be
..
.. reasonable for the physician to recommend treatment on the basis of
.. the ‘best medical interest’ principle, ideally including next of kin
Frailty and falls ..
.. assent.
Frailty and pre-frail states are common with age and raise specific .. Adherence to OAC intake is a significant consideration in demen-
considerations with regard to the risk-benefit ratio of OAC. Frailty is ..
.. tia. Once daily medications, weekly tablet boxes, reminders or blister
commonly defined as a rules-based distinct phenotype or by clinical .. packing may be helpful. Paradoxically, the fact that others take care of
judgement of deficits in function in a frailty scale (see Table 14).403–405 ..
.. providing medication to dementia patients may guarantee higher
Among others, frailty is a risk for rapid deterioration of renal func- .. adherence. The possible advantages of electronic monitoring, or
tion (see chapter 6) and risk of falling. Community dwelling individu- ..
.. even telemonitoring, in this population should further be explored.51
als over 65 years have a 1–2% risk of falling per year; only 5% of falls, ..
however, result in fracture and hospitalization.406 Falls and risk of
..
.. 18.2. Obesity and low body weight
subdural haemorrhage in particular are often considered by physi- ..
cians as a contraindication to OAC.407 While in states of severe frailty
.. Obesity
..
with poor physical functioning and limited life expectancy there may .. The WHO defines overweight and obesity as a body mass index
be limited benefit to OAC, a Markov decision analytic model has
.. (BMI) of greater than 25 and 30 kg/m2, respectively. The incidence of
..
demonstrated that with VKA a patient would have to fall 295 times in .. obesity has tripled since 1975. In 2016, 650 million adults (13.1%
order for the risk of a subdural haematoma to outweigh the benefit
.. worldwide population) were obese.417 Among many other things,
..
of anticoagulation.408 Given the even lower risk of subdural bleeding .. obesity also increases the risk of atrial fibrillation and recurrences of
..
compared with VKA, this ‘number needed to fall’ would be even .. atrial fibrillation after successful ablation.418–420. As such, weight loss
higher with the use of NOACs. .. is an integral part in the multidisciplinary treatment of patients with
..
The risk of falling can be estimated using simple or more sophisti- .. AF and obesity.421
cated tools (Table 15). The effect of NOACs vs VKA in patients at .. Obesity affects the pharmacokinetics of drugs, including the vol-
..
risk of falling was specifically analysed in two NOAC trials (prospec- .. ume of distribution (of lipophilic drugs in particular) as well as drug
tively defined in ENGAGE-AF TIMI 48, retrospectively in .. clearance. Indeed, renal blood flow and CrCl have been shown to be
..
ARISTOTLE).52,409 The treatment effect of the respective NOAC .. increased in obesity and could increase elimination of OACs.422
was consistent in patients at increased vs. not at increased risk of fall- .. A number of studies of VKA have indicated that obese patients
..
ing. However, the larger absolute risk of events of patients at .. require greater doses and longer lead-in periods for achieving thera-
increased risk of falling resulted in a larger absolute risk reduction vs. .. peutic INR values.423
..
VKA and, consequently, a lower number needed to treat compared .. Studies of dabigatran reported no effect of weight on pharmacoki-
to those not at an increased risk of falling. .. netic variables although analysis in older healthy individuals did not
..
In summary, frailty per se should not be an exclusion criterion to .. include very obese patients.159,166,182 Pharmacokinetic data on both
anticoagulate since frail and older patients are at an increased risk of .. rivaroxaban and apixaban initially reported weight-dependent
..
stroke and have been shown to benefit from OAC. The benefit of .. changes on volume distribution and half-life across a range of weights;
NOACs over VKA has best been demonstrated for edoxaban and
.. however, these were felt unlikely to be clinically significant.185,424,425
..
apixaban in this patient population. To improve things further, all . Data with edoxaban suggests low body weight may be a factor in

on 23 April 2018
Table 14 The ‘Canadian Study of Health and Aging’ (CHSA) Clinical Frailty Scale
From http://www.csha.ca and Ref.404

(1) Very fit – People who are robust, active, energetic, and motivated. These people commonly exercise regularly. They are among the fittest for
their age.
(2) Well – People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g.
seasonally.
(3) Managing well – People whose medical problems are well controlled, but are not regularly active beyond routine walking.
(4) Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being ‘slowed up’, and/or
being tired during the day.
(5) Mildly frail – These people often have more evident slowing, and need help in high order IADLs (finances, transportation, heavy housework,
medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.
(6) Moderately frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need
help with bathing and might need minimal assistance (cuing, standby) with dressing.
(7) Severely frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high
risk of dying (within 6 months).
(8) Very severely frail – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.
(9) Terminally ill – Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently
frail.
IADL, instrumental activities of daily living.
..
reduced clearance of the drug,426 and a converse situation would .. Low body weight
seem plausible. .. There is no unifying definition of low body weight and future criteria
..
Concerns have been expressed about the reliability of the anticoa- .. may need to be race specific as Asian populations tend to be
gulant effect of NOACS in obese patients.427,428 Weight was not an .. smaller and leaner. Low body weight may increase exposure to
..
exclusion criterion in any of the NOAC trials in AF or VTE. .. any NOAC and as such increase the risk of bleeding.433
However, case reports of treatment failure with low serum levels of .. Importantly, patients with low body weight frequently present
..
dabigatran have been reported in cases of severe obesity (BMI .. with other conditions and co-morbidities which may increase the
>_40 kg/m2).429,430 .. risk of stroke as well as bleeding, including old age, frailty, cancer,
..
Apixaban demonstrated no difference in efficacy and safety in .. and renal insufficiency. Of note, renal function may be overesti-
patients <60 kg vs. >60 kg,30 but patients with a BMI >_30 kg/m2 had a .. mated in underweight patients due to their reduced muscle
..
trend towards a better outcome compared to the remainder of the .. mass (especially when calculated with the MDRD formula; see
study (independent of treatment).431 This was in contrast to the .. chapter 6). As such, special care is needed when anticoagulating
..
reduced bleeding seen in the obese patient group in the AMPLIFY .. these patients.
study of apixaban in the treatment of VTE.330 Similarly in ROCKET-
.. Body weight <_60 kg was a dose-reduction criterion for apixaban (if
..
AF, obese patients (BMI >_35 kg/m2) had a reduced stroke risk com- .. also age >_80 years and/or creatinine >_1.5 mg/dL, see chapter 15) as
pared with the remainder of the cohort, and there was no interaction
.. well as for edoxaban. For these drugs, efficacy and safety compared
..
for the efficacy and safety of rivaroxaban vs. warfarin depending on .. to warfarin was consistent in the (few) underweight patients when
BMI.432 ENGAGE-AF did not (yet) report a sub-analysis of efficacy
.. compared with the remainder of the study cohort.30,31 As such, both
..
and safety with edoxaban according to weight criteria.31 Clinical trial .. drugs may be a preferred choice for patients <60 kg.
data from use of edoxaban in acute VTE, included 611 (14.1%)
.. Dabigatran was studied post hoc in patients with low body
..
patients >100 kg and sub analysis by weight showed no difference in .. weight (<50 kg) with consistent efficacy and safety compared with
..
safety or efficacy.332 .. the remainder of the study cohort.28 However, observational
Because of limited data in extreme obesity, the use of VKA in .. studies have suggested that low BMI (<23.9 kg/m2) can be an inde-
..
patients with a BMI >_40 kg/m2or weight >120 kg should be consid- .. pendent predictor of bleeding events with dabigatran.434 In addi-
ered (in line with recommendations from the International .. tion, frequently co-existing renal insufficiency may make
..
Society on Thrombosis and Haemostasis).427 In rare case when a .. dabigatran a less preferably option for the underweight patients.
NOAC is needed in such circumstances, specific measurements of .. Also rivaroxaban showed similar efficacy and safety in an explora-
..
drug trough levels should be considered. This, however, should .. tory analysis of lower body weight, but only patients <70 kg were
only be done under the guidance of a haematologist and in the .. compared with those >70 kg.29 No outcome data are available for
..
knowledge that hard clinical outcome data do not exist for such .. patients with <60 kg or <50 kg in patients on the full AF dose of
an approach. .. rivaroxaban.

on 23 April 2018
..
Table 15 Examples of falls risk tools
.. In a recent case series of NOAC use in the treatment of acute
.. VTE in women of reproductive age, rivaroxaban was associated with
..
.. prolonged (>8 days) menstrual bleeding (27% vs. 8.3%, P = 0.017),
(A) High risk of falls (from ENGAGE-AF TIMI 48)52 .. increased need for menorrhagia-related medical or surgical interven-
..
Presence of one or more of .. tion (25% vs. 7.7%, P = 0.032), and more adaptations of anticoagulant
.. therapy (15% vs. 1.9%, P = 0.031) compared with VKA.438 A similar
• Prior history of falls ..
• Lower extremity weakness .. trend towards increased AUB with rivaroxaban compared to enoxa-
.. parin has also been reported.439 Registry data report a 32% incidence
• Poor balance ..
• Cognitive impairment .. of AUB in women of reproductive age (n = 178) on factor Xa inhibi-
.. tor.440 Most cases were managed successfully with change of hormo-
• Orthostatic hypotension ..
• Use of psychotropic drugs .. nal or anticoagulation therapy, including temporary discontinuation
.. or cessation of factor Xa inhibitor medication. Some authors have
• Severe arthritis ..
• Dizziness .. expressed concern about the lack of robust data for NOAC use in
.. this population with AF.441 In any case, women should be counselled
..
.. about the risk of increased menstrual bleeding while on NOAC and
.. monitored carefully especially during the first cycles after NOAC
(B) Probability falls assessment410 ..
.. initiation.442
1 point for each ‘Yes’ .. All cases of AUB on OAC need to have gynaecological assessment
..
Previous falls Yes/No
.. for underlying structural problems and possibility of local hormonal
.. treatments and/or surgical procedure to reduce risk of recurrence of
..
Medications .. AUB. Importantly, NOACs are contraindicated in pregnancy as well
..
>4 Yes/No .. as during breastfeeding.
..
Psychotropics Yes/No
..
..
.. 18.4. Non-vitamin K antagonist oral
Low visual acuity Yes/No ..
.. anticoagulants in Athletes
Diminished sensation Yes/No .. AF is the most common arrhythmia in athletes and endurance ath-
..
Near tandem stand 10 s Yes/No
.. letes are known to be more prone to AF.443–446 Additional risk fac-
.. tors for stroke may be uncommon in this population; however, older
..
Alternate step test 10 s Yes/No .. individuals are increasingly engaged in competitive and/or vigorous
.. sports activities.447
Sit to stand 12 s Yes/No ..
.. If the CHA2DS2-VASc score is >_1 in men and >_2 in women, the
.. use of anticoagulation may be warranted in such settings according to
..
Score 0–1 2–3 4–5 6þ .. current guidelines.3 Traditional advice to athletes on OAC for VTE
.. has been to avoid contact sports while on treatment and there is little
Probability of fall per year 7% 13% 27% 49% ..
.. published evidence on the use of NOACs in AF in such populations.
..
.. The use of a OD agent may be preferable with intake in the evening
.. to avoid high levels of the drugs during the actual exercise, but no
..
.. outcome data are available to support this. All athletes presenting
Severely underweight patients (<50 kg) were clearly underrepre- .. with AF should have a full cardiological assessment.
sented in the large outcome trials. As such, even for NOACs that
..
..
were dose-reduced based on body weight (apixaban and edoxaban), ..
data are limited for these patients. Of note, bleeding may also be
.. 18.5. Epilepsy
..
increased with VKA therapy in underweight patients.431 If therapy .. A risk of seizures has been reported in >5% of overall post-stroke
..
with a NOAC is warranted in these individuals, measurement of .. patients.448,449 Following an unprovoked seizure after stroke, the risk
trough levels may be considered to check for accumulation of the .. of subsequent unprovoked seizures is about 65% within 10 years.450
drug.435 However, no evidence-based recommendations can be
..
.. OAC poses a special risk for patients with epilepsy due to the risk
given regarding (further) dose reduction in such cases. .. of injury during a seizure (with or without falling). Most seizures in
..
.. older people or post-stroke patients are focal in onset. However,
.. patients who do suffer rare generalized atonic seizures are particu-
..
18.3. Women of reproductive age .. larly vulnerable to head trauma while tongue biting is a risk in the
All OAC use should be considered with caution in women of child- .. tonic component of generalized seizures.
..
bearing age and an appropriate test to rule out pregnancy and contra- .. Anticoagulation is affected by antiepileptic drugs via various
ceptive counselling advice arranged before initiation of any agent. .. potential interactions (Table 5).147 A number of antiepileptic drugs
..
Abnormal uterine bleeding (AUB; formerly called menorrhagia), .. can in addition cause thrombocytopenia or platelet dysfunc-
occurs in 9–14% of the general female population of reproductive
.. tion.147 The significance of these drug–drug interactions is still
..
age,436 which may be exacerbated by oral anticoagulants.437 . largely unknown with only occasional case reports available. In

on 23 April 2018
some situations of severe, relevant interactions NOACs may not

Table 16 Atrial fibrillation and malignancy
be the preferred choice.
Interdisciplinary teamwork
19. Anticoagulation in atrial (1) Estimate individual patient risk profile
fibrillation patients with a • AF-related risk factors (CHA2DS2-VASc, bleeding risk)
malignancy • Cancer-related risk factors (type, liver metastases, coa-

gulopathy, renal/hepatic function etc.
The scope of the problem • Treatment-related risk factors (thrombocytopenia, sur-

gery, radiation, central lines etc.)
Cancers are not infrequent in older patients, similar to AF. One study
(2) Choose anticoagulant
found a prevalence of 2.4% of pre-existing AF and 1.8% new AF
• Current standard of care: VKA/(LMWH)a
among cancer patients.451 Cancer and cancer therapy may in turn
precipitate AF, while both age and malignancy are independent risk
• NOACs: Available data scarce, but encouraging
factors for thrombosis and bleeding.

• Consider patient preference (VKA vs. NOAC)
(3) Protect the patient
The greater incidence and prevalence of AF in patients with malig-
nancy may result from the presence of comorbid conditions (e.g.
• Gastric protection (PPI/H2 blockers)
hypertension, heart failure), a direct tumour effect (including dehy-

• Beware of drug–drug interactions (Table 4)
dration, altered sympathetic tone due to anxiety or pain, systemic

• Dose reduction/treatment interruption (if platelets <50k,
renal dysfunction, bleeding, . . .)
inflammation, etc.) or as a complication of cancer therapy (e.g. after
lung cancer surgery or as a side effect of specific targeted therapies Beware
such as tyrosine kinase inhibitor ibrutinib).452–455 The increasing sur- • Risk of thromboembolism "
vival of cancer patients may additionally increase the incidence of AF • Risk of bleeding "
among patients with active and past malignancies.
The risk of VTE is increased in the presence of cancer through a
host of possible mechanisms.456 Brain, pancreatic, ovarian, lung, or a
If oral therapy is not possible reversion to LMWH is reasonable.
haematological malignancies, as well as many cancer treatments (e.g.
cisplatin, gemcitabine, 5-fluorouracil, erythropoietin, granulocyte col-
ony stimulating factors) are associated with particularly increased ..
.. Moreover, in how far these findings apply to AF patients with can-
thromboembolic risk.457 .. cer requires further data. In cancer patients who develop incident AF,
Conversely, cancers may cause infiltrative liver failure resulting in
..
.. VKAs, or LMWH have been traditionally preferred over NOACs,
thrombocytopenia or coagulopathy and increased risk of bleeding. .. based on greater clinical experience with these drugs, possibility for
Tumours may erode into blood vessels directly, and many GI and
..
.. closer monitoring and availability of ‘reversal’ options. However, evi-
solid tumours such as intracranial tumours, renal cell carcinoma, or .. dence for stroke prevention with LMWH in AF is lacking and LMWH
metastatic melanoma are very vascular and prone to bleeding.
..
.. is contraindicated in secondary prevention in the setting of acute
Haematologic malignancies may cause coagulation defects thus .. stroke.386 Active malignancy was an exclusion criterion in most
increasing the risk of bleeding further. In addition, every form of can-
..
.. NOAC AF trials, and although there were a few patients with cancer
cer therapy, be it surgery, radiation, or chemotherapy, may induce .. in the Phase III AF trials, the absence of information on the type and
..
bleeding through local wounds (surgery), tissue damage (radiation), .. stage of cancer precluded any relevant subgroup analysis. An explor-
or systemic antiproliferative effects reducing platelet count and func- .. atory analysis of AF patients with active cancer (n = 157) or a history
..
tion (e.g. chemotherapy, some forms of irradiation). .. of malignancy (n = 1079) in the ARISTOTLE trial showed consistently
.. superior efficacy and safety of apixaban vs. warfarin in patients with
..
Anticoagulant therapy in atrial .. and without cancer.461 A large registry using prescription based anal-
..
fibrillation patients with malignancy .. ysis for AF patients on VKA or NOAC with and without cancer
So far, the only published RCT specifically targeting cancer patients .. recently reported equivalence for bleeding and thromboembolic risk
..
stems from the HOKUSAI-VTE Cancer trial comparing edoxaban .. and cancer status, although the rates of both were lower in the
with LMWH in patients with VTE (but not AF).458 Edoxaban proved .. NOAC population.462 However, much is still unknown about drug–
..
to be non-inferior regarding the primary endpoint of recurrent VTE .. drug interactions between NOACs and specific chemotherapeutic
and major bleeding; while recurrent VTE trended to be lower with .. agents, urging further caution (Table 4).144
..
edoxaban, major bleeding was higher (driven by an increased risk of .. Overall, antithrombotic therapy in patients with AF suffering from
upper GI bleeding in patients with gastrointestinal cancer). In line .. a malignancy needs a dedicated interdisciplinary team approach
..
with these findings, several meta-analyses of the small subgroup of .. (Table 16).463 Especially, when myelosuppressive chemotherapy or
cancer patients in VTE trials reported similar or better efficacy of .. radiation therapy is planned, temporary dose reduction or cessation
..
NOACs in comparison to VKA or LMWH for VTE prevention, .. of NOAC therapy needs to be evaluated, taking into account full
although major bleeding rates were higher.459,460 Most of these can-
.. blood counts including platelets, renal/liver function, and physical
..
cer patients may have been clinically stable, in contrast to those .. signs of bleeding. Gastric protection with PPI or H2 blockers should
requiring active therapy or in a palliative setting.
.. be considered in all such patients.

on 23 April 2018
20. Optimizing dose adjustments Table 17 Maintenance Warfarin dosing for out-of-
of vitamin-K antagonists therapeutic-range international normalized ratio
In spite of the preferred use of NOACs for stroke prevention in eligi- INR Dose adjustment per week
ble patients with AF,3 some situations still require the use of VKA,
including patients with mechanical heart valves as well as those with <_1.5 " by 15%/week
AF in the setting of rheumatic mitral stenosis. As such, mastering 1.6–1.9 " by 10%/week
VKA therapy and dosing to keep patients in the therapeutic range
remains an important skillset. 2–2.9 Unchanged
Beyond the standard target INR of 2.0–3.0 much of the optimal
3–3.9 # by 10%/week
management of VKA therapy in AF is experience - rather than
evidence-based. As such, various algorithms exist for the manage- 4–4.9 Hold 1 dose, then restart with dose # by 10%/week
ment of different VKA464,465 and experience in the past decades has
>_5 Hold until INR is 2–3, then restart with
led to different clinical routines (e.g. anticoagulation clinics, self-
dose # by 15%/week
measurement via point-of-care devices etc.). One aspect, however, is
key to success in VKA treated patients: Maintenance of a high time in
Suggested dose adjustment in case of out-of-therapeutic-range INR.472
therapeutic range (TTR) has been shown to reduce the risk of ischae-
Importantly, dosing is optimized not using daily dose adjustments but adjustments
mic and bleeding events and should be the primary goal in the treat- based on the weekly intake in warfarin.
ment of these patients independent of the type management
approach. Conversely, a change in the approach to these patients
needs to be considered if a low TTR is consistently observed.
.. usefulness of using dosing algorithms to optimize VKA dosing and,
..
Dosing during initiation of therapy .. ultimately, the time in therapeutic range (TTR).471–473 One such algo-
.. rithm is presented in Table 17, derived from the warfarin arm of the
Automated dosing calculators are available that help in the determi- ..
.. RE-LY trial. Importantly from a conceptual point of view dosing is
nation of the ‘optimal’ starting regimen (e.g. http://www.warfarindos .. optimized not using daily dose adjustments but adjustments based on
ing.org). One randomized trial comparing a 10 mg and 5-mg Warfarin ..
.. the weekly intake in warfarin. Obtaining INR measurements at least
Initiation Nomograms for the outpatient treatment of acute VTE sug- .. every 4 weeks and at least weekly in case of out-of-range values is an
gested the 10 mg scheme to be superior with patients reaching a ..
.. important prerequisite. A similar dosing scheme may be used for
therapeutic INR faster.466 However, a meta-analysis found no evi- ..
dence of superiority of either starting regimen.467 Moreover, the sit- .. phenprocoumon given its even longer half-life, whereas for aceno-
.. coumarol more short-term based adjustment may be feasible given
uation is different in patients with AF as they are generally older and ..
more frail than VTE patients. Furthermore, AF patients are usually .. its shorter half-life.
.. In patients with repeated out-of-range INR values, supplemental
not initiated in the setting of an acute thrombotic event. Indeed, vari- ..
ous factors may play in favour of using a low (or even lower, i.e. 2 mg .. measures may be required including (re-)educating patients on the
.. risk and benefits of VKA intake, the importance of strict adherence as
qd) starting dose, including older age, frailty, and renal insufficiency. ..
As such, no strong recommendation can be made for routinely using
.. well as food- and drug–drug interactions etc. Receiving care at a dedi-
.. cated anticoagulation clinic474,475 as well as self-monitoring and self-
either strategy, and individualizing the approach based on patient ..
characteristics is recommended. In view of the lack of evidence sup-
.. management476 has been shown to improve INR control. However,
.. patient selection is a critical component, particularly for the latter,
porting genotype-based dosing the latter is not recommended on a ..
general basis.465,468
.. and not every patient may be suitable.
.. In summary, every effort needs to be made in VKA treated patients
In many parts of Europe, anticoagulation with phenprocoumon is ..
.. to optimize the individual patient’s TTR. At the same time, however,
frequently started with a loading dose in order to shorten the time to .. it needs to be kept in mind that even being within the therapeutic
therapeutic INR levels owing to the long half-life of the drug,469 ..
.. range does not protect from bleeding events. Recent studies indicate
whereas the situation for warfarin and acenocoumarol is less clear.470 .. that although the risk of ICB increases at an INR >3 (and clearly
In order to prevent a possible transient prothrombotic effect due to a ..
.. >4–5), the vast majority of events in absolute numbers occurs at a
reduction of the equally vitamin K dependent, anticoagulant protein C .. therapeutic INR level.377 Keeping the patient in the therapeutic range
(and S), the first phase of anticoagulation (particularly with phenpro- ..
.. (2.0–3.0) hence primarily confers relative, but not absolute efficacy
coumon) is frequently paralleled by a parenteral anticoagulant, but evi- .. and safety.
dence for the superiority of routinely using this approach is missing. ..
..
..
..
Dosing during maintenance therapy .. Acknowledgements
Interpatient variability of optimal warfarin dose is enormous. Even in .. The authors thank EHRA Scienfitic Documents committee: Gregory
..
(formerly) ‘stable’ patients, intercurrent illness, change in dietary hab- .. Y.H. Lip, Laurent Fauchier, David Arnar, Carina Blomstrom-
its, changes in co-medication etc. may have a substantial impact on
.. Lundqvist, Zbigniew Kalarus, Gulmira Kudaiberdieva, Georges H.
..
INR values. Despite the large variation of warfarin dosing habits .. Mairesse, Tatjana Potpara, Irina Savelieva, Jesper Hastrup Svendsen,
amongst different centres, data have emerged indicating the
.. Vassil B. Traykov.

on 23 April 2018
..
Funding .. Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,
This article and derived educational materials (slide set, website, booklet,
.. Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski
.. P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL,
and NOAC card) were produced by and under the sole responsibility .. Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld
of the European Heart Rhythm Association, and supported by Bayer .. K. 2016 ESC Guidelines for the management of atrial fibrillation developed in
.. collaboration with EACTS. Eur Heart J 2016;37:2893–2962.
Pharma AG, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer .. 4. Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of
Alliance and Daiichi-Sankyo Europe GmbH in the form of an .. Anticoagulation of the International Society on Thrombosis and Haemostasis.
Unrestricted Educational Grant. ..
.. Recommendation on the Nomenclature for Oral Anticoagulants: communica-
The EHRA writing committee collaborated with medical advisors .. tion from the SSC of the ISTH. J Thromb Haemost 2015;13:1154–1156.
from the different companies to assure data accuracy and completeness. .. 5. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B,
.. Lancellotti P, Lansac E, Munoz DR, Rosenhek R, Sjogren J, Tornos Mas P,
Conflict of interest: J. S. has received consultant and/or speaker fees .. Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific
.. Document Group. 2017 ESC/EACTS Guidelines for the management of valvular
from Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, .. heart disease. Eur Heart J 2017;38:2739–2791.
Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, ..
Cook Medical, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Sanofi-Aventis,
.. 6. Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F,
.. Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N,
Sorin, St. Jude Medical/Abbott, and Zoll. He reports ownership of .. Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B; ESC Scientific
CorXL. J.S. has received grant support through his institution from Bayer .. Document Group. Antithrombotic therapy in atrial fibrillation associated with
.. valvular heart disease: a joint consensus document from the European Heart
Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi .. Rhythm Association (EHRA) and European Society of Cardiology Working
Sankyo, Medtronic, and St. Jude Medical/Abbott. P. V. reports grants and .. Group on Thrombosis, endorsed by the ESC Working Group on Valvular
personal fees from Bayer, Boehringer Ingelheim, BMS, Leo Pharma,
..
.. Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart
Daiichi-Sankyo; and personal fees from Pfizer, Medtronic, and Portola. .. Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South
T.S. P. has received speaker fees from Pfizer and Bayer. P. A. reports per- .. African Heart (SA Heart) Association and Sociedad Latinoamericana de
.. Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace
sonal fees from Boehringer Ingelheim, personal fees and non-financial sup- .. 2017;19:1757–1758.
port from Bayer and Portola, and grants, personal fees and non-financial .. 7. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C,
support from Pfizer-BMS and Csl-Behring. M. A. reports personal fees
.. Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J,
..
from Bayer, Boehringer Ingelheim, Daiichi Sankyo, personal fees from .. Granger CB, Alexander JH. Apixaban in comparison with warfarin in patients
Pfizer, Sanofi Aventis, Medtronic, Biosense Webster, Novartis, Abbott, .. with atrial fibrillation and valvular heart disease: findings from the Apixaban for
.. Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
and Biotronik. L.D. has no conflict of interest to disclose. K.G. H. reports .. (ARISTOTLE) Trial. Circulation 2015;132:624–632.
personal fees from Bayer, Boehringer-Ingelheim, Pfizer, Bristol-Myers .. 8. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs
Squibb, Daiichi Sankyo, Medtronic, Edwards Lifesciences, Sanofi, EIP
.. M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of
.. dabigatran and warfarin in patients with atrial fibrillation and valvular heart dis-
Pharma, non-financial support from Getemed AG, and grants from Bayer. .. ease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant
J. O. reports fees to his institution from Bayer, Boehringer Ingelheim, ..
.. Therapy). Circulation 2016;134:589–598.
Bristol-Myers Squibb, Daichii-Sankyo, Pfizer, and Sanofi. H. R. reports per- .. 9. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens
sonal fees from BMS, MedUpdate, NephroUpdate, Pfizer, and Pluristem; .. SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W,
and grants from the German Federal Ministry for Education and Research
.. Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering
.. Committee & Investigators. Clinical characteristics and outcomes with rivaroxa-
(BMBF), Bard, Bayer, and Biotronik. V. R. has received consultant and/or .. ban vs. warfarin in patients with non-valvular atrial fibrillation but underlying na-
speaker fees from Bayer Healthcare, Boehringer-Ingelheim, Bristol-Myers .. tive mitral and aortic valve disease participating in the ROCKET AF trial. Eur
..
Squibb, Leo Pharma, Pfizer, and Rovi. N. R. reports personal fees from .. Heart J 2014;35:3377–3385.
BMS, Pfizer, Daiichi-Sankyo, Bayer and Boehringer Ingelheim. P. S. .. 10. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff
reports grants from Daiichi Sankyo and Astra Zeneca, and institutional
.. CT, Antman EM, Braunwald E, Giugliano RP. Valvular heart disease patients on
.. edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol
fees from BMS, Pfizer, and Boehringer. R. C. reports personal fees from .. 2017;69:1372–1382.
Daichii Sankyo, Pfizer, Bayer and Boehringer Ingelheim. A. J.C. has .. 11. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-
.. vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial
received institutional research grants and personal fees for advice and ..
for speaking from Bayer, Boehringer Ingelheim, Daiichi Sankyo, and .. fibrillation and valvular heart disease: a systematic review and meta-analysis.
Pfizer/BMS. H. H. reports personal fees (before June 2017) from .. J Am Heart Assoc 2017;6:e005835.
.. 12. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral
Abbott, Pfizer/BMS, Daiichi-Sankyo, Boehringer-Ingelheim, Cardiome; he .. anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am
received no personal fees after June 2017; he received research grants .. Coll Cardiol 2017;69:1363–1371.
from Bayer, Bracco Imaging Europe, Medtronic, and St. Jude Medical
.. 13. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and
.. safety of non-vitamin K antagonist oral anticoagulants versus warfarin in pa-
through the University of Hasselt or Antwerp. ..
.. tients with atrial fibrillation and valvular heart disease. Int J Cardiol
.. 2016;209:181–183.
.. 14. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and bleeding risks in
References .. NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and

.. atrial fibrillation. J Am Coll Cardiol 2016;67:3020–3021.
1. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve .. 15. Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguchıa J,
P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart .. Garcıa-Pinilla JM, Urbano-Moral JA, Fernandez-Fernandez X, Lopez-Cuenca D,
Rhythm Association Practical Guide on the use of new oral anticoagulants in .. Ajo-Ferrer R, Sanz-Sanchez J, Gomez-Perez Y, L opez-Garrido MA, Barriales-
patients with non-valvular atrial fibrillation. Europace 2013;15:625–651. ..
2. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren
.. Villa R, Gimeno JR, Garcia-Pavia P. Direct oral anticoagulants in patients with
.. hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol
J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm .. 2017;248:232–238.
Association Practical Guide on the use of non-vitamin K antagonist anticoagu- .. 16. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W,
lants in patients with non-valvular atrial fibrillation. Europace .. Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox
2015;17:1467–1507. .. KA, Mahaffey KW. Efficacy and safety of rivaroxaban in patients with heart fail-
3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, .. ure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail
Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, ..
Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron
.. 2013;6:740–747.
.. 17. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J,
Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, . Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M,

on 23 April 2018
Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB;

.. 33. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
..
ARISTOTLECommittees and Investigators. Left ventricular systolic dysfunc- .. Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
tion, heart failure, and the risk of stroke and systemic embolism in patients with .. Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P,
atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013;6: .. Widimsky P. 2017 ESC Guidelines for the management of acute myocardial in-
451–460. .. farction in patients presenting with ST-segment elevation: the Task Force for
18. Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, .. the management of acute myocardial infarction in patients presenting with ST-
Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E. Efficacy and safety of .. segment elevation of the European Society of Cardiology (ESC). Eur Heart J
edoxaban compared with warfarin in patients with atrial fibrillation and
.. 2018;39:119–177.
..
heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail .. 34. Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump in-
2016;18:1153–1161. .. hibitor therapy in acid-related diseases—a position paper addressing benefits
19. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT, .. and potential harms of acid suppression. BMC Med 2016;14:179.
Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, .. 35. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein
Pisters R, Stewart S, Wood K, Potpara TS, Document R, Gorenek B, Conti JB, .. CM. Association of proton pump inhibitors with reduced risk of warfarin-
Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac .. related serious upper gastrointestinal bleeding. Gastroenterology 2016;151:
tachyarrhythmias and patient values and preferences for their management: the
.. 1105–1112.e10.
..
European Heart Rhythm Association (EHRA) consensus document endorsed .. 36. Di Minno A, Spadarella G, Spadarella E, Tremoli E, Di Minno G.
by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society .. Gastrointestinal bleeding in patients receiving oral anticoagulation: current
(APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y .. treatment and pharmacological perspectives. Thromb Res 2015;136:1074–1081.
Electrofisiologia (SOLEACE). Europace 2015;17:1747–1769. .. 37. Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC. Prevention
20. Heidbuchel H, Berti D, Campos M, Desteghe L, Freixo A, Nunes A, Roldan V, .. of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a
Toschi V, Lassila R. Implementation of non-vitamin K antagonist oral anticoagu- .. population-based study. Gastroenterology 2015;149:586–595.e3.
lants in daily practice: the need for comprehensive education for professionals
.. 38. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting
..
and patients. Thromb J 2015;13:22. .. oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med
21. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of .. 2015;278:1–18.
anticoagulation control among patients with atrial fibrillation on warfarin: the .. 39. Okumura K, Hori M, Tanahashi N, John Camm A. Special considerations for
SAMe-TT(2)R(2) score. Chest 2013;144:1555–1563. .. therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese
22. Ruiz-Ortiz M, Bertomeu V, Cequier A, Marın F, Anguita M. Validation of the .. patients with nonvalvular atrial fibrillation. Clin Cardiol 2017;40:126–131.
SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation .. 40. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz
patients on vitamin K antagonists. Thromb Haemost 2015;114:695–701.
.. MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA,
..
23. Roldan V, Cancio S, Galvez J, Valdes M, Vicente V, Marin F, Lip GY. The SAMe- .. Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant
TTR score predicts poor anticoagulation control in AF patients: a prospective .. and dose for stroke prevention in individual patients with non-valvular atrial fib-
‘Real-World’ inception cohort study. Am J Med 2015;128:1237–1243. .. rillation: part 1. Eur Heart J 2017;38:852–859.
24. Esteve-Pastor MA, Roldan V, Valdés M, Lip GYH, Marın F. The SAMe-TT2R2 .. 41. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz
score and decision-making between a vitamin K antagonist or a non-vitamin K .. MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA,
antagonist oral anticoagulant in patients with atrial fibrillation. Expert Rev .. Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant
Cardiovasc Ther 2016;14:177–187. .. and dose for stroke prevention in individual patients with non-valvular atrial fib-
25. Lobos-Bejarano JM, Barrios V, Polo-Garcıa J, Escobar C, Vargas-Ortega D,
.. rillation: part 2. Eur Heart J 2017;38:860–868.
..
Marın-Monta~nés N, Prieto-Valiente L, Fuentes S, Prieto MA, Garcıa-Ortiz L. .. 42. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient educa-
Evaluation of SAMe-TT2R2 score and other clinical factors influencing the qual- .. tion. Curr Pharm Des 2015;21:533–543.
ity of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide .. 43. Lane DA, Wood K. Cardiology patient page. Patient guide for taking the non-
study in Spain. Curr Med Res Opin 2016;32:1201–1207. .. vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation
26. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, Lopez-Lopez A, Redondo- .. 2015;131:e412–e415.
Dieguez A, Alvarez-Iglesias D, Rodriguez-Manero M, Pena-Gil C, Gonzalez- .. 44. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, Cools F,
Juanatey JR. Evaluation of SAMe-TT2R2 risk score for predicting the quality of
.. Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y,
..
anticoagulation control in a real-world cohort of patients with non-valvular .. Mantovani LG, Misselwitz F, Oh S, Turpie AGG, Verheugt FWA, Kakkar AK.
atrial fibrillation on vitamin-K antagonists. Europace 2015;17:711–717. .. Evolving antithrombotic treatment patterns for patients with newly diagnosed
27. Proietti M, Lip GY. Simple decision-making between a vitamin K antagonist and .. atrial fibrillation. Heart 2017;103:307–314.
a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. .. 45. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H-C, Dubner SJ,
Eur Heart J Cardiovasc Pharmacother 2015;1:150–152. .. Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GYH. The changing
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, .. landscape for stroke prevention in AF: findings from the GLORIA-AF Registry
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
.. Phase 2. J Am Coll Cardiol 2017;69:777–785.
..
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus .. 46. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, Hindricks G,
warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151. .. Moons P, Heidbuchel H. A proposal for interdisciplinary, nurse-coordinated
29. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, .. atrial fibrillation expert programmes as a way to structure daily practice. Eur
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz .. Heart J 2013;34:2725–2730.
SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrilla- .. 47. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA,
tion. N Engl J Med 2011;365:883–891. .. Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial
30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-
.. fibrillation: results of a randomized trial of integrated chronic care vs. routine
..
Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, .. clinical care in ambulatory patients with atrial fibrillation. Eur Heart J
Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, .. 2012;33:2692–2699.
Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, .. 48. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R,
Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. .. Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: a system-
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med .. atic review and meta-analysis. Heart 2017;103:1947–1953.
2011;365:981–992. .. 49. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray
31. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, .. C, Abdelwahab A, Parkash R. An integrated management approach to atrial fib-
Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y,
.. rillation. J Am Heart Assoc 2016;5:e002950.
..
Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. .. 50. Kirchhof P. The future of atrial fibrillation management: integrated care and
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med .. stratified therapy. Lancet 2017;390:1873–1887.
2013;369: 2093–2104. .. 51. Desteghe L, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, Dendale P,
32. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati .. Heidbuchel H. Telemonitoring-based feedback improves adherence to non-
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, .. vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.
Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet ther- .. Eur Heart J 2018;39:1394–1403.
apy in coronary artery disease developed in collaboration with EACTS: the
.. 52. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P,
..
Task Force for dual antiplatelet therapy in coronary artery disease of the .. White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban versus warfarin in atrial
European Society of Cardiology (ESC) and of the European Association for .. fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:123–260. . Cardiol 2016;68:1169–1178.

on 23 April 2018
53. Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for
.. anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of is-
..
primary care: findings from the Survey of Health, Ageing and Retirement in .. chemic stroke. Int J Cardiol 2016;215(Suppl C):11–13.
Europe (SHARE). BMC Geriatr 2010;10:57. .. 74. McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C,
54. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, .. Schein J, Lefebvre P. Comparison of adherence to rivaroxaban versus apixaban
Chung FP, Chen TJ, Chen SA. Relationship of aging and incident comorbidities .. among patients with atrial fibrillation. Clin Ther 2016;38:2477–2488.
to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol .. 75. Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and
2018;71:122–132. .. apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial
55. Lip GYH, Skjoth F, Nielsen PB, Kjaeldgaard JN, Larsen TB. The HAS-BLED,
.. fibrillation. J Manag Care Spec Pharm 2016;22:1319–1329.
..
ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using .. 76. Zhou M, Chang HY, Segal JB, Alexander GC, Singh S. Adherence to a novel
non-vitamin K antagonist oral anticoagulants. Am J Med 2017; [Epub ahead of .. oral anticoagulant among patients with atrial fibrillation. J Manag Care Spec
print]. .. Pharm 2015;21:1054–1062.
56. Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused .. 77. Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA. Real-
on modifiable risk factors only versus validated bleeding risk scores in atrial fib- .. world adherence and persistence with direct oral anticoagulants in adults with
rillation. Am J Med 2018;131:185–192. .. atrial fibrillation. Pharmacotherapy 2017;37:1221–1230.
57. Esteve-Pastor M, Rivera-Caravaca J, Shantsila A, Roldan V, Lip G, Marın F.
.. 78. Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T, White R. A retro-
..
Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding .. spective descriptive analysis of patient adherence to dabigatran at a large aca-
risk score based only on modifiable bleeding risk factors against the .. demic medical center. J Manag Care Spec Pharm 2014;20:1028–1034.
HAS-BLED Score. The AMADEUS Trial. Thromb Haemost 2017;117:2261– .. 79. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson
2266. .. M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C,
58. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung .. Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare pa-
FP, Chen TJ, Chen SA. Major bleeding and intracranial hemorrhage risk predic- .. tients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
tion in patients with atrial fibrillation: attention to modifiable bleeding risk fac-
.. Circulation 2015;131:157–164.
..
tors or use of a bleeding risk stratification score? A nationwide cohort study. Int .. 80. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip
J Cardiol 2018;254:157–161. .. GY. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ pa-
59. Hijazi Z, Oldgren J, Lindb€ack J, Alexander JH, Connolly SJ, Eikelboom JW, .. tients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll
Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, .. Cardiol 2013;61:2264–2273.
Wallentin L. ARISTOTLE and RE-LY Investigators. Lancet 2016;387:2302–2311. .. 81. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M.
60. O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, .. Real-world comparison of major bleeding risk among non-valvular atrial fibrilla-
Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The
.. tion patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A pro-
..
ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial .. pensity score matched analysis. Thromb Haemost 2016;116:975–986.
fibrillation. Eur Heart J 2015;36:3258–3264. .. 82. Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J,
61. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on .. Crawford G, Redberg R. Major bleeding risk during anticoagulation with war-
the use and misuse of bleeding risk scores. J Thromb Haemost .. farin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fib-
2016;14:1711–1714. .. rillation. J Manag Care Spec Pharm 2017;23:968–978.
62. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to .. 83. Bai Y, Deng H, Shantsila A, Lip GYH. Rivaroxaban versus dabigatran or warfarin
oral anticoagulant therapy in patients with atrial fibrillation. Focus on non- .. in real-world studies of stroke prevention in atrial fibrillation: systematic review
vitamin K antagonist oral anticoagulants. Thromb Haemost 2016;117:209–218.
.. and meta-analysis. Stroke 2017;48:970–976.
..
63. Montalescot G. Abstract 18842: adherence and persistence to apixaban treat- .. 84. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of
ment in patients with non valvular atrial fibrillation is high and similar with .. apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrilla-
standard of care patient education or with an additional educational program: .. tion. Am J Cardiol 2017;120:1813–1819.
the randomized AEGEAN Study. Circulation 2016;134(Suppl 1): A18842– .. 85. Bai Y, Shi X-B, Ma C-S, Lip GYH. Meta-analysis of effectiveness and safety of
A18842. .. oral anticoagulants in atrial fibrillation with focus on apixaban. Am J Cardiol
64. Desteghe L, Engelhard L, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, .. 2017;120:1689–1695.
Dendale P, Heidbuchel H. Effect of individualised education sessions on the
.. 86. Staerk L, Fosbøl EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C,
..
knowledge level of patients with atrial fibrillation. EP Europace 2017;19:iii147. .. Ozenne B, Gerds TA, Gislason GH, Olesen JB. Ischaemic and haemorrhagic
P817. .. stroke associated with non-vitamin K antagonist oral anticoagulants and war-
65. Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelli- .. farin use in patients with atrial fibrillation: a nationwide cohort study. Europ
gence to reduce the risk of nonadherence in patients on anticoagulation ther- .. Heart J 2017;38:907–915.
apy. Stroke 2017;48:1416–1419. .. 87. Beyer-Westendorf J, Camm AJ, Coleman CI, Tamayo S. Rivaroxaban real-world
66. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham .. evidence: validating safety and effectiveness in clinical practice. Thromb Haemost
LR, Gersh BJ, Shah ND, Noseworthy PA. Effect of adherence to oral anticoagu-
.. 2016;116:S13–S23.
..
lants on risk of stroke and major bleeding among patients with atrial fibrillation. .. 88. Potpara TS, Lip GH. Postapproval observational studies of non–vitamin k antag-
J Am Heart Assoc 2016;5:e003074. .. onist oral anticoagulants in atrial fibrillation. JAMA 2017;317:1115–1116.
67. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence .. 89. Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anti-
to oral anticoagulation for stroke risk reduction in patients with atrial fibrilla- .. coagulants compared with warfarin in patients with atrial fibrillation. Open Heart
tion. Europace 2016;18:1150–1157. .. 2017;4:e000682.
68. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, .. 90. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-
Bradley SM, Maddox TM, Grunwald GK, Baron AE, Rumsfeld JS, Varosy PD,
.. world setting comparison of nonvitamin-K antagonist oral anticoagulants versus
..
Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longi- .. vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic re-
tudinal patient outcomes: insights from the veterans health administration. Am .. view and meta-analysis. Stroke 2017;48:2494–2503.
Heart J 2014;167:810–817. .. 91. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effective-
69. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. .. ness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in
Dabigatran adherence in atrial fibrillation patients during the first year after .. patients with atrial fibrillation: propensity weighted nationwide cohort study.
diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495–504. .. BMJ 2016;353:i3189.
70. McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B, .. 92. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson
Martin S, Schein J, Lefebvre P, Deitelzweig S. Adherence to non-vitamin-K-
.. C. A nationwide registry study to compare bleeding rates in patients with atrial
..
antagonist oral anticoagulant medications based on the Pharmacy Quality .. fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc
Alliance measure. Curr Med Res Opin 2015;31:2167–2173. .. Pharmacother 2017;3:28–36.
71. Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberte F, Schein J, .. 93. Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB.
Lefebvre P. Pharmacy quality alliance measure: adherence to non-warfarin oral .. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anti-
anticoagulant medications. Curr Med Res Opin 2015;31:1889–1895. .. coagulants and warfarin in patients with atrial fibrillation: propensity weighted
72. Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and .. nationwide cohort study. BMJ 2017;356, https://www.ncbi.nlm.nih.gov/pubmed/
dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
.. 28188243.
..
in the United States. Int J Cardiol 2016;212:171–173. .. 94. Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new
73. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D, Schein JR, .. oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrilla-
Coleman CI. Association between once- and twice-daily direct oral . tion: a post-marketing surveillance study. Clin Res Cardiol 2017;106:618–628.

on 23 April 2018
95. Lamberts M, Staerk L, Olesen JB, Fosbol EL, Hansen ML, Harboe L, Lefevre C,
.. 115. Santo K, Richtering SS, Chalmers J, Thiagalingam A, Chow CK, Redfern J.
..
Evans D, Gislason GH. Major bleeding complications and persistence with oral .. Mobile phone apps to improve medication adherence: a systematic stepwise
anticoagulation in non-valvular atrial fibrillation: contemporary findings in real- .. process to identify high-quality apps. JMIR Mhealth Uhealth 2016;4:e132.
life Danish patients. J Am Heart Assoc 2017;6:e004517. .. 116. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin
96. Coleman CI, Antz M. Real-world evidence with apixaban for stroke prevention .. ME. Adherence and dosing frequency of common medications for cardiovascu-
in patients with nonvalvular atrial fibrillation in Germany: a retrospective study .. lar patients. Am J Manag Care 2012;18:139–146.
(REASSESS). Intern Emerg Med 2017;12:419–422. .. 117. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM.
97. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X,
.. Impact of once- or twice-daily dosing frequency on adherence to chronic car-
..
Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of .. diovascular disease medications: a meta-regression analysis. Int J Cardiol
apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’ .. 2016;216:104–109.
clinical practice. A propensity-matched analysis of 76,940 patients. Thromb .. 118. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.
Haemost 2017;117:1072–1082. .. Impact of daily dosing frequency on adherence to chronic medications among
98. Deitelzweig S, Farmer C, Luo X, Li X, Vo L, Mardekian J, Fahrbach K, Ashaye A. .. nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675–690.
Comparison of major bleeding risk in patients with non-valvular atrial fibrillation .. 119. Sorensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji-Young Lee C, Torp-
receiving direct oral anticoagulants in the real-world setting: a network meta-
.. Pedersen C. Adherence with oral anticoagulation in non-valvular atrial fibrilla-
..
analysis. Curr Med Res Opin 2018;34:487–498. .. tion: a comparison of vitamin K antagonists and non-vitamin K antagonists. Eur
99. Obamiro KO, Chalmers L, Bereznicki LR. A summary of the literature evaluat- .. Heart J Cardiovasc Pharmacother 2017;3:151–156.
ing adherence and persistence with oral anticoagulants in atrial fibrillation. Am J .. 120. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence
Cardiovasc Drugs 2016;16:349–363. .. with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin
100. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in .. Pharmacol 2016;72:329–338.
newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. .. 121. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah
A cohort study. Thromb Haemost 2016;115:31–39.
.. ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effective-
..
101. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, .. ness and safety in nonvalvular atrial fibrillation. Chest 2016;150:1302–1312.
Schein JR. Medication persistence and discontinuation of rivaroxaban versus .. 122. Al-Khalili F, Lindström C, Benson L. The safety and persistence of non-vitamin-
warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin .. K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well
2014;30:2461–2469. .. structured atrial fibrillation clinic. Curr Med Res Opin 2016;32:779–785.
102. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, .. 123. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: consid-
Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and .. erations on once- vs. twice-daily regimens and their potential impact on medi-
safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr
.. cation adherence. Europace 2015;17:514–523.
..
Med Res Opin 2014;30:1317–1325. .. 124. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, Becka M,
103. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, .. Hemmrich M. Dissociation between the pharmacokinetics and pharmaco-
Miyasato G, Matchar D, Sanchez H. Higher persistence in newly diagnosed non- .. dynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized
valvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ .. crossover study. J Thromb Haemost 2017;15:2017–2028.
Cardiovasc Qual Outcomes 2013;6:567–574. .. 125. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, Grip L,
104. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M, .. Cange AL, Crompton AE, Murphy SA, Deenadayalu N, Antman EM. Transition
Michalski F, Endig H, Sahin K, Tittl L, Weiss N. Drug persistence with rivaroxa- .. of patients from blinded study drug to open-label anticoagulation: the
ban therapy in atrial fibrillation patients-results from the Dresden non-
.. ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014;64:576–584.
..
interventional oral anticoagulation registry. Europace 2015;17:530–538. .. 126. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer
105. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persist- .. DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC,
ence, and switching patterns of dabigatran etexilate. Am J Manag Care .. Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Outcomes of discontinuing
2013;19:e325–e332. .. rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrilla-
106. Jackevicius CA, Tsadok MA, Essebag V, Atzema C, Eisenberg MJ, Tu JV, Lu L, .. tion: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct
Rahme E, Ho PM, Turakhia M, Humphries KH, Behlouli H, Zhou L, Pilote L. .. Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of
Early non-persistence with dabigatran and rivaroxaban in patients with atrial fib-
.. Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol
..
rillation. Heart 2017;103:1331–1338. .. 2013;61:651–658.
107. Paquette M, Riou Franca L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, .. 127. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L,
Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaat R. .. Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical
Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. .. events after transitioning from apixaban versus warfarin to warfarin at the end
J Am Coll Cardiol 2017;70:1573–1583. .. of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
108. Lane DA, Wood KA. A patient’s guide to taking the non-vitamin K antagonist .. Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015;169:25–30.
oral anticoagulants (NOACs) for atrial fibrillation: lane; patient’s guide to taking
.. 128. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and
..
NOACs. Circulation 2015;131:e412–e415. .. in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp
109. Desteghe L, Engelhard L, Raymaekers Z, Kluts K, Vijgen J, Dilling-Boer D, .. Ther 2011;338:372–380.
Koopman P, Schurmans J, Dendale P, Heidbuchel H. Knowledge gaps in patients .. 129. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs
with atrial fibrillation revealed by a new validated knowledge questionnaire. Int J .. that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Cardiol 2016;223:906–914. .. Br J Clin Pharmacol 2013;76:455–466.
110. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian .. 130. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, Maxwell BD, Chen S-y,
Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O,
.. He K, Goosen TC, Griffith WH, Grossman SJ. In vitro assessment of metabolic
..
Tajer C, de Barros e Silva PGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF .. drug-drug interaction potential of apixaban through cytochrome P450 pheno-
investigators. A multifaceted intervention to improve treatment with oral anti- .. typing, inhibition, and induction studies. Drug Metab Dispos 2010;38:448–458.
coagulants in atrial fibrillation (IMPACT-AF): an international, cluster- .. 131. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and phar-
randomised trial. Lancet 2017;390:1737–1746. .. macodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1–16.
111. Camm AJ, Luscher TF, Serruys P. The ESC Textbook of Cardiovascular Medicine, .. 132. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I,
2nd ed. Oxford, NY: Oxford University Press; 2009. .. Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M,
112. Germeys J, Desteghe L, Vijgen J, Dilling-Boer D, Koopman P, Schurmans J, .. Tachibana M, Zhou S, Rohatagi S. Modelling and simulation of edoxaban expos-
Dendale P, Heidbuchel H. The effect of online targeted education on
.. ure and response relationships in patients with atrial fibrillation. Thromb
..
procedure-specific knowledge of atrial fibrillation patients undergoing cardio- .. Haemost 2012;107:925–936.
version or ablation. Acta Cardiol 2017;72:573. .. 133. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm
113. Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F, .. AJ, Antman EM, Ruff CT. Edoxaban vs. warfarin in patients with atrial fibrillation
Longo L, Jackevicius C, Rose A, Turakhia MP. Site-level variation in and prac- .. on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart
tices associated with dabigatran adherence. JAMA 2015;313:1443–1450. .. J 2015;36:2239–2245.
114. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile health .. 134. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M.
technology for atrial fibrillation management integrating decision sup-
.. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein,
..
port, education, and patient involvement: MAF App Trial. Am J Med .. an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa
2017;130:1388–1396.e6. .. inhibitor. Am J Cardiovasc Drugs 2013;13:331–342.
.

on 23 April 2018
135. Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, Pollack A, LaCreta F. The
.. AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial
..
effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy .. fibrillation—the J-ROCKET AF study. Circ J 2012;76:2104–2111.
subjects. Clin Pharmacol 2017;9:19–28. .. 157. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA,
136. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, Zhang D, Yu Z, .. Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM,
Dias C, Shenker A, LaCreta F. Effect of ketoconazole and diltiazem on the .. Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other
pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin .. Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE)
Pharmacol 2015;79:838–846. .. Investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with
137. Mendell J, Noveck R, Zahir H, Lee F, Petrushin V, Rubets I, Zhang G, Shi M,
.. atrial fibrillation and advanced age, low body weight, or high creatinine: a sec-
..
Chen S. The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibi- .. ondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:673–681.
tors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin .. 158. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism
Pharmacol Toxicol 2010;107:2848. (Abstract). .. and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
138. Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, Yu Z, Dias C, .. Drug Metab Dispos 2008;36:386–399.
Shenker A, LaCreta F. Effect of rifampin on the pharmacokinetics of apixaban, .. 159. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynam-
an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016;16:119–127. .. ics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
139. Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, Zhang D, Byon
.. Clinical Pharmacokinetics 2008;47:47–59.
..
W, Boyd RA, LaCreta F. Evaluation of the effect of naproxen on the pharmaco- .. 160. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokin-
kinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol .. etics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin
2014;78:877–885. .. Pharmacol 2011;51:687–694.
140. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and .. 161. Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, Lacreta F, Frost CE.
the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), .. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor
an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol .. Xa inhibitor. Clin Pharmacol 2013;5:59–66.
2006;46:549–558.
.. 162. Song Y, Chang M, Suzuki A, Frost RJ, Kelly A, LaCreta F, Frost C. Evaluation of
..
141. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely .. crushed tablet for oral administration and the effect of food on apixaban
B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, .. pharmacokinetics in healthy adults. Clin Ther 2016;38:1674–1685.e1.
Ten Berg JM, Steg PG, Hohnloser SH. Dual antithrombotic therapy with dabiga- .. 163. Duchin K, Duggal A, Atiee GJ, Kidokoro M, Takatani T, Shipitofsky NL, He L,
tran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–1524. .. Zhang G, Kakkar T. An open-label crossover study of the pharmacokinetics of
142. U.S. Food and Drug Administration. Drug Development and Drug Interactions: .. the 60-mg edoxaban tablet crushed and administered either by a nasogastric
Table of Substrates, Inhibitors and Inducers. https://www.fda.gov/Drugs/ .. tube or in apple puree in healthy adults. Clin Pharmacokinet 2018;57:221–228.
DevelopmentApprovalProcess/DevelopmentResources/
.. 164. Moore KT, Krook MA, Vaidyanathan S, Sarich TC, Damaraju CV, Fields LE.
..
DrugInteractionsLabeling/ucm093664.htm (8 Febuary 2018). .. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability
143. Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. .. in healthy adults when administered orally or via nasogastric tube. Clin
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclo- .. Pharmacol Drug Dev 2014;3:321–327.
sporine. Br J Clin Pharmacol 2016;82:1591–1600. .. 165. Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Relative
144. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. .. bioavailability of apixaban solution or crushed tablet formulations administered
Oncologist 2014;19:82–93. .. by mouth or nasogastric tube in healthy subjects. Clin Ther 2015;37:1703–1712.
145. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P- .. 166. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD,
glycoprotein. Adv Drug Deliv Rev 2012;64:930–942.
.. Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis
..
146. Schelleman H, Pollard JR, Newcomb C, Markowitz CE, Bilker WB, Leonard MB, .. of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular
Hennessy S. Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepi- .. atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168–2175.
leptic agents and the risk of fractures. Pharmacoepidemiol Drug Saf .. 167. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M,
2011;20:619–625. .. Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the
147. Stollberger C, Finsterer J. Interactions between non-vitamin K oral anticoagu- .. novel factor Xa inhibitor edoxaban compared with warfarin in patients with
lants and antiepileptic drugs. Epilepsy Res 2016;126:98–101. .. atrial fibrillation: design and rationale for the Effective aNticoaGulation with fac-
148. Wiggins BS, Northup A, Johnson D, Senfield J. Reduced anticoagulant effect of
.. tor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial
..
dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy .. Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635–641.
2016;36:e5–e7. .. 168. Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M,
149. Stollberger C, Finsterer J. Prolonged anticoagulant activity of rivaroxaban in a .. Golmard JL, Mullier F, Gouin-Thibault I. Predictors of pre-procedural concen-
polymorbid elderly female with non-convulsive epileptic state. Heart Lung .. trations of direct oral anticoagulants: a prospective multicentre study. Eur Heart
2014;43:262–263. .. J 2017;38:2431–2439.
150. Stollberger C. Drug interactions with new oral anticoagulants in elderly pa- .. 169. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant re-
tients. Expert Rev Clin Pharmacol 2017;10:1191–1202.
.. jection due to Saint John’s wort. Lancet 2000;355:548–549.
..
151. LaHaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC. A clinical de- .. 170. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M,
cision aid for the selection of antithrombotic therapy for the prevention of .. Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of
stroke due to atrial fibrillation. Eur Heart J 2012;33:2163–2171. .. antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation
152. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz .. of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation
MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabiga- .. 2013;127:634–640.
tran plasma concentrations and patient characteristics on the frequency of is- .. 171. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,
chemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial
.. Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
..
(Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll .. Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51
Cardiol 2014;63:321–328. .. Investigators. Rivaroxaban in patients with a recent acute coronary syndrome.
153. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, .. N Engl J Med 2012;366:9–19.
Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, .. 172. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA,
Antman EM. Association between edoxaban dose, concentration, anti-Factor .. Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J,
Xa activity, and outcomes: an analysis of data from the randomised, double- .. Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.
blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288–2295. .. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with anti-
154. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes
.. platelet therapy after acute coronary syndrome: results of the Apixaban for
..
using the European label for dabigatran. A post-hoc analysis from the RE-LY .. Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation
database. Thromb Haemost 2014;111:933–942. .. 2009;119:2877–2885.
155. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, .. 173. Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse
Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, .. events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol
Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran com- .. 2016;105:412–420.
pared with warfarin in older and younger patients with atrial fibrillation: an ana- .. 174. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD,
lysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY)
.. Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox
..
trial. Circulation 2011;123:2363–2372. .. KA, Patel MR. Polypharmacy and the efficacy and safety of rivaroxaban versus
156. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi .. warfarin in the prevention of stroke in patients with nonvalvular atrial fibrilla-
T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET . tion. Circulation 2016;133:352–360.

on 23 April 2018
175. Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F,
.. patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term
..
Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. .. Anticoagulation Therapy) trial analysis. Circulation 2014;129:961–970.
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fib- .. 196. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF,
rillation: post hoc analysis of the ARISTOTLE trial. Bmj 2016;353:i2868. .. Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke
176. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R, .. and systemic embolism with rivaroxaban compared with warfarin in patients
Kestenbaum B, Mathew J, Robinson-Cohen C, Sarnak MJ, Shlipak MG, .. with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J
Sotoodehnia N, Young B, Heckbert SR. eGFR and albuminuria in relation to .. 2011;32:2387–2394.
risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the
.. 197. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai
..
Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin .. M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of
J Am Soc Nephrol 2017;12:1386–1398. .. apixaban when compared with warfarin in relation to renal function in patients
177. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer .. with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J
DE. Impact of proteinuria and glomerular filtration rate on risk of thrombo- .. 2012;33:2821–2830.
embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrilla- .. 198. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M,
tion (ATRIA) study. Circulation 2009;119:1363–1369. .. Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB,
178. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL,
.. Wallentin L. Efficacy and safety of apixaban compared with warfarin in patients
..
Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, .. with atrial fibrillation in relation to renal function over time: insights from the
Feldman HI. Chronic kidney disease and prevalent atrial fibrillation: the Chronic .. ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016;1:451–460.
Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102–1107. .. 199. Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC,
179. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidir- .. Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE,
ectional relationship between chronic kidney disease and atrial fibrillation: the .. Patel MR. On-treatment outcomes in patients with worsening renal function
Niigata preventive medicine study. Am Heart J 2009;158:629–636. .. with rivaroxaban compared with warfarin: insights from ROCKET AF.
180. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H,
.. Circulation 2016;134:37–47.
..
Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kid- .. 200. Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA,
ney disease. J Am Soc Nephrol 2009;20:705–711. .. Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC,
181. Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation be- .. Hijazi Z, Wallentin L. Changes in renal function in patients with atrial fibrillation:
tween the Scylla and Charybdis. Eur Heart J 2012;33:2766–2768. .. an analysis from the RE-LY Trial. J Am Coll Cardiol 2015;65:2481–2493.
182. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, .. 201. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt
pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct .. UY, Hebert LA. Warfarin-related nephropathy occurs in patients with and with-
thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292–303.
.. out chronic kidney disease and is associated with an increased mortality rate.
..
183. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen .. Kidney Int 2011;80:181–189.
S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinet- .. 202. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K
ics after oral administration to humans. Drug Metab Dispos 2009;37:74–81. .. antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal
184. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, .. dysfunction. J Am Coll Cardiol 2017;69:2779–2790.
Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynam- .. 203. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E,
ics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin .. Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk
Pharmacol 2010;50:743–753. .. for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
185. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F.
.. Circulation 2014;129:1196–1203.
..
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute .. 204. Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK,
deep-vein thrombosis and exposure simulations in patients with atrial fibrilla- .. Hiemstra TF. Vitamin K antagonists predispose to calciphylaxis in patients with
tion treated for stroke prevention. Clin Pharmacokinet 2011;50:675–686. .. end-stage renal disease. Nephron 2015;129:197–201.
186. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmaco- .. 205. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y; Japanese
dynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct .. Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese
factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412–421. .. end-stage renal disease patients. Nephrol Dial Transplant 2012;27:1580–1584.
187. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI 3rd,
.. 206. Han KH, O’Neill WC. Increased peripheral arterial calcification in patients
..
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic .. receiving warfarin. J Am Heart Assoc 2016;5:e002665.
Kidney Disease Epidemiology Collaboration). A new equation to estimate glom- .. 207. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diag-
erular filtration rate. Ann Intern Med 2009;150:604–612. .. nosis, and treatment. Semin Dial 2002;15:172–186.
188. Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, .. 208. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt
Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, .. KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E.
Nessel CC, Becker RC, Fox KA, Patel MR; ROCKET AF Steering Committee .. Cardiovascular disease in chronic kidney disease. A clinical update from
and Investigators. Treatment consistency across levels of baseline renal function
.. Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011;80:
..
with rivaroxaban or warfarin: a ROCKET AF (Rivaroxaban Once-Daily, Oral, .. 572–586.
Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for .. 209. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and
Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. .. rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation
Circulation 2017;135:1001–1003. .. 2015;131:972–979.
189. Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for .. 210. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharma-
stroke prevention in atrial fibrillation. Am J Med 2017;130:1015–1023. .. cokinetics at steady state in hemodialysis patients. J Am Soc Nephrol
190. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM,
.. 2017;28:2241–2248.
..
Braunwald E. Impact of renal function on outcomes with edoxaban in the .. 211. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-
ENGAGE AF-TIMI 48 Trial. Circulation 2016;134:24–36. .. term safety and plasma concentrations of edoxaban in Japanese patients with
191. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation pa- .. non-valvular atrial fibrillation and severe renal impairment. Circ J
tients with moderate chronic kidney disease. Clin J Am Soc Nephrol .. 2015;79:1486–1495.
2011;6:2599–2604. .. 212. De Vriese AS, Caluwe R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B,
192. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, .. Vandecasteele SJ, Emmerechts J. Dose-finding study of rivaroxaban in hemodi-
Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with .. alysis patients. Am J Kidney Dis 2015;66:91–98.
chronic kidney disease. N Engl J Med 2012;367:625–635.
.. 213. Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with
..
193. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen .. chronic kidney disease and atrial fibrillation: benefit and risks of old and new
ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antith- .. oral anticoagulants. Stroke 2013;44:2935–2941.
rombotic therapy in patients with atrial fibrillation and chronic kidney disease: a .. 214. Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The complex
nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471–2482. .. role of anticoagulation in cirrhosis: an updated review of where we are and
194. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with .. where we are going. Digestion 2016;93:149–159.
atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. .. 215. Lauschke VM, Ingelman-Sundberg M. The importance of patient-specific factors
Eur Heart J 2015;36:297–306.
.. for hepatic drug response and toxicity. Int J Mol Sci 2016;17:1714.
..
195. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, .. 216. Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JI,
Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety .. Zhao S, Jasuja GK, Rose AJ. Stratifying the risks of oral anticoagulation in pa-
of dabigatran compared with warfarin in relation to baseline renal function in . tients with liver disease. Circ Cardiovasc Qual Outcomes 2014;7:461–467.

on 23 April 2018
217. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W.

.. the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other
..
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics .. Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and
of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin .. Clinical Outcomes. J Am Coll Cardiol 2014;63:2141–2147.
Pharmacol 2013;76:89–98. .. 241. Peetermans M, Pollack C Jr, Reilly P, Liesenborghs L, Jacquemin M, Levy JH,
218. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, .. Weitz JI, Verhamme P. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila)
Caldwell SH. Direct oral anticoagulants in cirrhosis patients pose similar risks of .. 2016;54:644–646.
bleeding when compared to traditional anticoagulation. Dig Dis Sci .. 242. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz
2016;61:1721–1727.
.. SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW,
..
219. Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral .. Singer DE, Califf RM, Fox KA; ROCKET AF Investigators. Management of major
anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol .. bleeding events in patients treated with rivaroxaban vs. warfarin: results from
2017;98:393–397. .. the ROCKET AF trial. Eur Heart J 2014;35:1873–1880.
220. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of xime- .. 243. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L,
lagatran. Handb Exp Pharmacol 2010;196:407–418. .. Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes
221. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J. Risk .. of major bleeding during treatment with dabigatran or warfarin. Circulation
of drug-induced liver injury with the new oral anticoagulants: systematic review
.. 2013;128:2325–2332.
..
and meta-analysis. Heart 2014;100:550–556. .. 244. Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M,
222. Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL, .. Mercuri MF, Antman EM, Braunwald E. Mortality in patients with atrial fibrilla-
Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in pa- .. tion randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI
tients with atrial fibrillation. Heart 2017;103:834–839. .. 48 Trial. Am J Med 2016;129:850–857.e2.
223. Potpara TS, Lip GY. Drug-induced liver injury with oral anticoagulants: a threat .. 245. Kawabori M, Niiya Y, Iwasaki M, Mabuchi S, Ozaki H, Matsubara K, Houkin K.
or not? Heart 2017;103:809–811. .. Characteristics of symptomatic intracerebral hemorrhage in patient receiving
224. Licata A, Puccia F, Lombardo V, Serruto A, Minissale MG, Morreale I,
.. direct oral anticoagulants: comparison with warfarin. J Stroke Cerebrovasc Dis
..
Giannitrapani L, Soresi M, Montalto G, Almasio PL. Rivaroxaban-induced hep- .. 2018; [Epub ahead of print].
atotoxicity: review of the literature and report of new cases. Eur J Gastroenterol .. 246. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz
Hepatol 2018;30:226–232. .. MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
225. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogne .. Comparison of the efficacy and safety of new oral anticoagulants with warfarin
JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagu- .. in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
lants: a practical guide for clinicians. J Thromb Haemost 2018;16:209–219. .. 2014;383:955–962.
226. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM.
.. 247. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW,
..
Assessment of the impact of rivaroxaban on coagulation assays: laboratory rec- .. Florido R, Hucker W, Mehran R, Messe SR, Pollack CV Jr, Rodriguez F, Sarode
ommendations for the monitoring of rivaroxaban and review of the literature. .. R, Siegal D, Wiggins BS. 2017 ACC expert consensus decision pathway on man-
Thromb Res 2012;130:956–966. .. agement of bleeding in patients on oral anticoagulants: a report of the
227. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of .. American College of Cardiology Task Force on Expert Consensus Decision
dabigatran on a large panel of routine or specific coagulation assays. Laboratory .. Pathways. J Am Coll Cardiol 2017;70:3042–3067.
recommendations for monitoring of dabigatran etexilate. Thromb Haemost .. 248. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA,
2012;107:985–997. .. Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy
228. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in
.. JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L,
..
patients treated with dabigatran. Am J Med 2012;125:417–420. .. Weitz JI. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J
229. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, .. Med 2017;377:431–441.
Clemens A. Dabigatran etexilate–a novel, reversible, oral direct thrombin in- .. 249. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A,
hibitor: interpretation of coagulation assays and reversal of anticoagulant activ- .. Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen
ity. Thromb Haemost 2010;103:1116–1127. .. AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J,
230. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham- .. Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M;
Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or
.. ANNEXA-4 Investigators. Andexanet Alfa for acute major bleeding associated
..
without concomitant aspirin compared with warfarin alone in patients with .. with factor Xa inhibitors. N Engl J Med 2016;375:1131–1141.
nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419–1426. .. 250. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V,
231. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on .. Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of
routine and specific coagulation assays: a practical laboratory guide. Thromb .. edoxaban. N Engl J Med 2014;371:2141–2142.
Haemost 2013;110:283–294. .. 251. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C,
232. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activ- .. Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, man-
ity of edoxaban: a systematic review. J Thromb Thrombolysis 2015;39:288–294.
.. agement, and outcome of rivaroxaban bleeding in daily care: results from the
..
233. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring .. Dresden NOAC registry. Blood 2014;124:955–962.
rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673–679. .. 252. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for
234. Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, .. old and new anticoagulants and antiplatelet agents. J Thromb Haemost
Linnemann B, Herrmann E, Lindhoff-Last E. Point-of-care coagulation testing for .. 2011;9:1705–1712.
assessment of the pharmacodynamic anticoagulant effect of direct oral anti- .. 253. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the
coagulant. Ther Drug Monit 2014;36:624–631. .. pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-
235. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, Grebmer C,
.. label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259–268.
..
Bourier F, Buiatti A, Kolb C, Deisenhofer I, Hessling G. Comparison of safety of .. 254. Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D. Intermittent
left atrial catheter ablation procedures for atrial arrhythmias under continuous .. haemodialysis and continuous veno-venous dialysis are effective in mitigating
anticoagulation with apixaban versus phenprocoumon. Am J Cardiol .. major bleeding due to dabigatran. Br J Haematol 2015;169:603–604.
2015;115:47–51. .. 255. Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He
236. Auer J, Huber K, Granger CB. Interruption of non-vitamin K antagonist anti- .. L, Dishy V, Brown KS. Pharmacokinetics, safety, and tolerability of edoxaban in
coagulants in patients undergoing planned invasive procedures: how long is long .. end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost
enough? Eur Heart J 2017;38:2440–2443. .. 2015;113:719–727.
237. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharma-
.. 256. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y,
..
cokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. .. Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety
Curr Med Res Opin 2008;24:2757–2765. .. of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin
238. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. .. Pharmacol 2016;56:628–636.
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: .. 257. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H,
resolving uncertainties in routine practice. Thromb Haemost 2012;107:838–847. .. Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H,
239. Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is .. Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O,
activated charcoal still effective? J Toxicol Clin Toxicol 2001;39:601–605.
.. Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of
..
240. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, .. tranexamic acid on death, vascular occlusive events, and blood transfusion in
Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. .. trauma patients with significant haemorrhage (CRASH-2): a randomised,
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: . placebo-controlled trial. Lancet 2010;376:23–32.

on 23 April 2018
258. Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F,

.. direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol
..
Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients .. 2016;122:e146–e155.
undergoing total hip or knee arthroplasty in the United States: retrospective .. 277. Patel JP, Woolcombe SA, Patel RK, Obisesan O, Roberts LN, Bryant C, Arya R.
analysis of effectiveness and safety. BMJ 2014;349:g4829. .. Managing direct oral anticoagulants in patients undergoing dentoalveolar sur-
259. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the .. gery. Br Dent J 2017;222:245–249.
non-vitamin K oral anticoagulants. Europace 2016;18:955–964. .. 278. Yagyuu T, Kawakami M, Ueyama Y, Imada M, Kurihara M, Matsusue Y, Imai Y,
260. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, .. Yamamoto K, Kirita T. Risks of postextraction bleeding after receiving direct
Heidbuchel H, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S,
.. oral anticoagulants or warfarin: a retrospective cohort study. BMJ Open
..
Ezekowitz M. Periprocedural bleeding and thromboembolic events with dabiga- .. 2017;7:e015952.
tran compared with warfarin: results from the Randomized Evaluation of Long- .. 279. Miclotte I, Vanhaverbeke M, Agbaje JO, Legrand P, Vanassche T, Verhamme P,
Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation .. Politis C. Pragmatic approach to manage new oral anticoagulants in patients
2012;126:343–348. .. undergoing dental extractions: a prospective case-control study. Clin Oral
261. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, .. Investig 2017;21:2183–2188.
Heiland S, van Ryn J, Veltkamp R. Hemostatic therapy in experimental intra- .. 280. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS,
cerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
.. Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL
..
Stroke 2011;42:3594–3599. .. Investigators. Pacemaker or defibrillator surgery without interruption of antico-
262. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J. .. agulation. N Engl J Med 2013;368:2084–2093.
Reversal of dabigatran anticoagulation by prothrombin complex concentrate .. 281. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M,
(Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841–1848. .. Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip
263. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, .. GY. Antithrombotic management in patients undergoing electrophysiological
Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of prothrombin .. procedures: a European Heart Rhythm Association (EHRA) position document
complex concentrate and recombinant activated factor VII to reverse rivaroxa-
.. endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society
..
ban in a rabbit model. Anesthesiology 2012;116:94–102. .. (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace
264. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner .. 2015;17:1197–1214.
A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleed- .. 282. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer
ing following punch biopsy and reversal by a 4-factor prothrombin complex .. TR, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients
concentrate. Circulation 2015;131:82–90. .. on antiplatelet and anticoagulant medications: guidelines from the American
265. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. .. Society of Regional Anesthesia and Pain Medicine, the European Society of
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a
.. Regional Anaesthesia and Pain Therapy, the American Academy of Pain
..
randomized, placebo-controlled, crossover study in healthy subjects. Circulation .. Medicine, the International Neuromodulation Society, the North American
2011;124:1573–1579. .. Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med
266. Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, Frost C. Reversal of .. 2015;40:182–212.
apixaban anticoagulation by four-factor prothrombin complex concentrates in .. 283. Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A,
healthy subjects: a randomized three-period crossover study. J Thromb Haemost .. Llau J, Longrois D, Marret E, Mismetti P, Rosencher N, Roullet S, Samama CM,
2017;15:2125–2137. .. Schved JF, Sie P, Steib A, Susen S; French Working Group on Perioperative
267. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, .. Hemostasis (GIHP). Management of direct oral anticoagulants in patients
Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and
.. undergoing elective surgeries and invasive procedures: updated guidelines from
..
four-factor prothrombin complex concentrates regarding reversal of the anti- .. the French Working Group on Perioperative Hemostasis (GIHP)—September
coagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost .. 2015. Anaesth Crit Care Pain Med 2017;36:73–76.
2014;12:1428–1436. .. 284. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T,
268. Albaladejo P, Samama C-M, Sié P, Kauffmann S, Mémier V, Suchon P, Viallon A, .. Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on
David JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G, .. antiplatelet and anticoagulant medications (Second Edition): guidelines from the
Bosson J-L; GIHP-NACO Study Group. Management of severe bleeding in pa- .. American Society of Regional Anesthesia and Pain Medicine, the European
tients treated with direct oral anticoagulants: an observational registry analysis.
.. Society of Regional Anaesthesia and Pain Therapy, the American Academy of
..
Anesthesiology 2017;127:111–120. .. Pain Medicine, the International Neuromodulation Society, the North American
269. Majeed A, Agren A, Holmstrom M, Bruzelius M, Chaireti R, Odeberg J, Hempel .. Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med
EL, Magnusson M, Frisk T, Schulman S. Management of rivaroxaban- or .. 2017; [Epub ahead of print].
apixaban-associated major bleeding with prothrombin complex concentrates: a .. 285. Tripodi A. To measure or not to measure direct oral anticoagulants before sur-
cohort study. Blood 2017;130:1706–1712. .. gery or invasive procedures: reply. J Thromb Haemost 2016;14:2559–2561.
270. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. .. 286. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG,
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive
.. Badhwar V, Brugada J, Camm J, Chen P-S, Chen S-A, Chung MK, Nielsen JC,
..
dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172–2174. .. Curtis AB, Wyn Davies D, Day JD, D’Avila A, de Groot NMS, Di Biase L,
271. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, .. Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G,
Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, .. Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM,
Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, .. Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R,
Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, .. Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF,
Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery .. Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E,
Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need
.. Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao H-M, Verma
..
an elective surgery or procedure: design and rationale. Thromb Haemost .. A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert
2017;117:2415–2424. .. consensus statement on catheter and surgical ablation of atrial fibrillation: ex-
272. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, .. ecutive summary. J Interv Card Electrophysiol 2017;50:1–55.
Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional .. 287. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic
management of novel oral anticoagulants in daily care: results from the pro- .. stroke. Stroke 2012;43:265–270.
spective Dresden NOAC registry. Eur Heart J 2014;35:1888–1896. .. 288. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R,
273. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, .. Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S,
Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad
.. Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G,
..
V, Ortel TL. Perioperative bridging anticoagulation in patients with atrial fibrilla- .. Pelargonio G, Narducci ML, Russo AD, Casella M, Fassini G, Tondo C,
tion. N Engl J Med 2015;373:823–833. .. Schweikert RA, Natale A. Periprocedural stroke and bleeding complications in
274. Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveo- .. patients undergoing catheter ablation of atrial fibrillation with different anticoa-
lar surgical procedures in patients taking new oral anticoagulants. Odontology .. gulation management: results from the role of coumadin in preventing
2015;103:258–263. .. thromboembolism in atrial fibrillation (AF) patients undergoing catheter abla-
275. Johnston S. An evidence summary of the management of patients taking direct .. tion (COMPARE) randomized trial. Circulation 2014;129:2638–2644.
oral anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac
.. 289. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH,
..
Surg 2016;45:618–630. .. Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M.
276. Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. .. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl
Management of dental extraction in patients undergoing anticoagulant oral . J Med 2017;376:1627–1636.

on 23 April 2018
290. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ,
.. intervention who require oral anticoagulation: insights from the Canadian ob-
..
Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De .. servational AntiPlatelet sTudy. Am Heart J 2016;180:82–89.
Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. .. 306. Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter .. AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey
ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–1811. .. KW. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and
291. Di Biase L, Callans D, Hæusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis .. coronary artery disease. Am J Med 2016;129:592–599.e1.
Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA- .. 307. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M,
AFNET 5: an investigator-initiated, randomized, open, blinded outcome assess-
.. Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for
..
ment, multi-centre trial to comparing continuous apixaban to vitamin K antag- .. atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for
onists in patients undergoing atrial fibrillation catheter ablation. Europace .. prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
2017;19:132–138. .. Lancet 2006;367:1903–1912.
292. Ukaigwe A, Shrestha P, Karmacharya P, Hussain SK, Samii S, Gonzalez MD, .. 308. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Wolbrette D, Naccarrelli GV. Meta-analysis of efficacy and safety of apixaban .. Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip
and uninterrupted apixaban therapy compared to vitamin K antagonists in pa- .. GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in
tients undergoing catheter ablation for atrial fibrillation. J Interv Card
.. patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:
..
Electrophysiol 2017;48:223–233. .. 2423–2434.
293. Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, .. 309. Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med
Mercuri MF, Antman EM, Giugliano RP. First experience with edoxaban and .. 2017;377:1580–1582.
atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. Int J .. 310. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz P-E, Eckardt L, Lanz H-J,
Cardiol 2017;244:192–195. .. Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an
294. Kottmaier M, Bourier F, Pausch H, Reents T, Semmler V, Telishevska M, Koch- .. edoxaban-based antithrombotic regimen in patients with atrial fibrillation fol-
Buttner K, Lennerz C, Lengauer S, Kornmayer M, Rousseva E, Brooks S, Brkic
.. lowing successful percutaneous coronary intervention (PCI) with stent place-
..
A, Ammar-Busch S, Kaess B, Dillier R, Grebmer C, Kolb C, Hessling G, .. ment: rationale and design of the ENTRUST-AF PCI trial. Am Heart J
Deisenhofer I. Safety of uninterrupted periprocedural edoxaban versus phen- .. 196:105–112.
procoumon for patients who underwent left atrial catheter ablation proced- .. 311. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van
ures. Am J Cardiol 2018;121:445–449. .. Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label,
295. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and .. randomized, controlled, multicenter study exploring two treatment strategies
recommendations. Br J Haematol 2003;123:676–682. .. of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy
296. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein
.. in subjects with atrial fibrillation who undergo percutaneous coronary interven-
..
A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, .. tion (PIONEER AF-PCI). Am Heart J 2015;169:472–478.e5.
Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, .. 312. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J.
Lindsay BD, Wazni O. Use of dabigatran for periprocedural anticoagulation in .. New oral anticoagulants in addition to single or dual antiplatelet therapy after
patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm .. an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J
Electrophysiol 2013;6:460–466. .. 2013;34:1670–1680.
297. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, .. 313. Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M,
Mohanty P, Prakash S, Bai R, Reddy M, Gianni C, Horton R, Bailey S, Sigmund E, .. Antman EM, Braunwald E. Concomitant use of single antiplatelet therapy with
Derndorfer M, Schade A, Mueller P, Szoelloes A, Sanchez J, Al-Ahmad A,
.. edoxaban or warfarin in patients with atrial fibrillation: analysis from the
..
Hranitzky P, Gallinghouse GJ, Hongo RH, Beheiry S, Pürerfellner H, Burkhardt .. ENGAGE AF-TIMI48 Trial. J Am Heart Assoc 2016;5:e002587.
JD, Natale A. Feasibility and safety of uninterrupted periprocedural apixaban .. 314. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J,
administration in patients undergoing radiofrequency catheter ablation for .. Richardt G, Iniguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland
atrial fibrillation: results from a multicenter study. Heart Rhythm 2015;12: .. J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll
1162–1168. .. HP, Morice MC. Polymer-free drug-coated coronary stents in patients at high
298. Death NCEiPOa. The NCEPOD Classification of Intervention. http://www.ncepod. .. bleeding risk. N Engl J Med 2015;373:2038–2047.
org.uk/classification.html (8 March 2018).
.. 315. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D, Hovasse T, Garot
..
299. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; .. P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-
Subcommittee on Control of Anticoagulation. When and how to use antidotes .. Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M,
for the reversal of direct oral anticoagulants: guidance from the SSC of the .. Morice MC, Sinnaeve PR. Drug-eluting stents in elderly patients with coronary
ISTH. J Thromb Haemost 2016;14:623–627. .. artery disease (SENIOR): a randomised single-blind trial. Lancet
300. Gwyn JCV, Thomas MR, Kirchhof P. Triple antithrombotic therapy in patients .. 2018;391:41–50.
with atrial fibrillation undergoing percutaneous coronary intervention: a view- .. 316. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G,
point. Eur Heart J Cardiovasc Pharmacother 2017;3:157–162.
.. Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U,
..
301. Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, .. Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG,
Alexander KP. Atrial fibrillation and acute myocardial infarction: antithrombotic .. Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/
therapy and outcomes. Am J Med 2012;125:897–905. .. EACTS Guidelines on myocardial revascularization: the Task Force on
302. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, .. Myocardial Revascularization of the European Society of Cardiology (ESC) and
Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg .. the European Association for Cardio-Thoracic Surgery (EACTS). Developed
PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. Apixaban vs. war- .. with the special contribution of the European Association of Percutaneous
farin with concomitant aspirin in patients with atrial fibrillation: insights from
.. Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
..
the ARISTOTLE trial. Eur Heart J 2014;35:224–232. .. 317. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,
303. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, .. Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW, .. KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA,
ten Berg JM; WOEST study investigators. Use of clopidogrel with or without .. Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarc-
aspirin in patients taking oral anticoagulant therapy and undergoing percutan- .. tion, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
eous coronary intervention: an open-label, randomised, controlled trial. Lancet .. J Am Coll Cardiol 2007;49:1982–1988.
2013;381:1107–1115. .. 318. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
304. Rubboli A, Saia F, Sciahbasi A, Leone AM, Palmieri C, Bacchi-Reggiani ML,
.. Normand S-LT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW,
..
Calabro P, Bordoni B, Piccalo G, Franco N, Nicolino A, Magnavacchi P, Vignali .. Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow
L, Mameli S, Dallago M, Maggiolini S, Steffanon L, Piovaccari G, Di Pasquale G. .. TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet
Twelve-month outcome of patients with an established indication for oral anti- .. therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166.
coagulation undergoing coronary artery stenting and stratified by the baseline .. 319. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,
risk of bleeding: insights from the Warfarin and Coronary Stenting (War-Stent) .. Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P,
Registry. Cardiovasc Revasc Med 2017;18:425–430. .. Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott
305. Sra S, Tan MK, Mehta SR, Fisher HN, Dery JP, Welsh RC, Eisenberg MJ,
.. SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients
..
Overgaard CB, Rose BF, Siega AJ, Cheema AN, Wong BY, Henderson MA, .. with prior myocardial infarction. N Engl J Med 2015;372:1791–1800.
Lutchmedial S, Lavi S, Goodman SG, Yan AT. Ischemic and bleeding events in .. 320. Karjalainen PP, Vikman S, Niemela M, Porela P, Ylitalo A, Vaittinen MA,
patients with myocardial infarction undergoing percutaneous coronary . Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE. Safety of

on 23 April 2018
percutaneous coronary intervention during uninterrupted oral anticoagulant

.. P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous
..
treatment. Eur Heart J 2008;29:1001–1010. .. thromboembolism. N Engl J Med 2013;369:1406–1415.
321. Vranckx P, Verheugt FW, de Maat MP, Ulmans VA, Regar E, Smits P, ten Berg .. 333. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS,
JM, Lindeboom W, Jones RL, Friedman J, Reilly P, Leebeek FW. A randomised .. Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells
study of dabigatran in elective percutaneous coronary intervention in stable .. P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.
coronary artery disease patients. EuroIntervention 2013;8:1052–1060. .. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med
322. Vranckx P, Leebeek FWG, Tijssen JGP, Koolen J, Stammen F, Herman J-PR, de .. 2010;363:2499–2510.
Winter RJ, van T Hof AWJ, Backx B, Lindeboom W, Kim S-Y, Kirsch B, van
.. 334. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky
..
Eickels M, Misselwitz F, Verheugt FWA. Peri-procedural use of rivaroxaban in .. J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H,
elective percutaneous coronary intervention to treat stable coronary artery dis- .. Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral
ease. The X-PLORER trial. Thromb Haemost 2015;114:258–267. .. rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J
323. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, .. Med 2012;366:1287–1297.
Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, .. 335. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A,
Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, .. Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treat-
Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB,
.. ment of venous thromboembolism. N Engl J Med 2013;368:699–708.
..
Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro- .. 336. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D,
Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractio- .. Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial
nated heparin in high-risk patients with non-ST-segment elevation acute coron- .. Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, war-
ary syndromes managed with an intended early invasive strategy: primary .. farin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709–718.
results of the SYNERGY randomized trial. JAMA 2004;292:45–54. .. 337. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J,
324. Valgimigli M, Gagnor A, Calabr o P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, .. Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas
Briguori C, And o G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A,
.. MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD,
..
Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, .. Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.
Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, .. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N
Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, .. Engl J Med 2017;376:1211–1222.
Vranckx P, Jüni P. Radial versus femoral access in patients with acute coronary .. 338. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients
syndromes undergoing invasive management: a randomised multicentre trial. .. with total knee arthroplasty. A meta-analysis of randomised trials. Thromb
Lancet 2015;385:2465–2476. .. Haemost 2010;105:245.
325. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG,
.. 339. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM,
..
Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey .. Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after
RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, .. primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind,
Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. .. non-inferiority trial. Thromb Haemost 2011;105:721–729.
Management of antithrombotic therapy in atrial fibrillation patients presenting .. 340. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, VAN Dijk CN, Frostick SP,
with acute coronary syndrome and/or undergoing percutaneous coronary or .. K€alebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral
valve interventions: a joint consensus document of the European Society of .. dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous
Cardiology Working Group on Thrombosis, European Heart Rhythm .. thromboembolism after total knee replacement: the RE-MODEL randomized
Association (EHRA), European Association of Percutaneous Cardiovascular
.. trial. J Thromb Haemost 2007;5:2178–2185.
..
Interventions (EAPCI) and European Association of Acute Cardiac Care .. 341. Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, Ibusuki K, Ushida H,
(ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart .. Abe K, Tachibana S. Safety and efficacy of edoxaban, an oral factor Xa inhibitor,
Rhythm Society (APHRS). Eur Heart J 2014;35:3155–3179. .. versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the
326. Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh .. STARS E-3 trial. Thromb Res 2014;134:1198–1204.
R, Bode C, Gibson CM. A randomized trial to compare the safety of rivaroxa- .. 342. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, Abe K,
ban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary .. Tachibana S. Efficacy and safety of edoxaban versus enoxaparin for the preven-
syndrome: the design of the GEMINI-ACS-1 phase II study. Am Heart J
.. tion of venous thromboembolism following total hip arthroplasty: STARS J-V.
..
2016;174:120–128. .. Thromb J 2015;13:27.
327. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, .. 343. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, .. TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus
Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, .. enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med
Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, .. 2008;358:2765–2775.
Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, .. 344. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG,
Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS,
.. Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term
..
Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis .. enoxaparin for the prevention of venous thromboembolism after total hip
Zamorano J. 2015 ESC Guidelines for the management of acute coronary syn- .. arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:
dromes in patients presenting without persistent ST-segment elevation: task .. 31–39.
Force for the Management of Acute Coronary Syndromes in Patients .. 345. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ,
Presenting without Persistent ST-Segment Elevation of the European Society of .. Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophy-
Cardiology (ESC). Eur Heart J 2016;37:267–315. .. laxis after total knee arthroplasty. N Engl J Med 2008;358:2776–2786.
328. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL,
.. 346. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner
..
Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation .. FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD.
of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation pa- .. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthro-
tients following myocardial infarction and coronary intervention: a nationwide .. plasty (RECORD4): a randomised trial. Lancet 2009;373:1673–1680.
cohort study. Circulation 2012;126:1185–1193. .. 347. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O,
329. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, .. Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas
Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events .. LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-
in patients with atrial fibrillation treated with dabigatran or warfarin in the RE- .. Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G,
LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
.. Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ,
..
Circulation 2012;125:669–676. .. Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM,
330. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz .. Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz
U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixa- .. F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or
ban for the treatment of acute venous thromboembolism. N Engl J Med .. without aspirin in stable cardiovascular disease. N Engl J Med
2013;369:799–808. .. 2017;377:1319–1330.
331. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, .. 348. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti
Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treat-
.. JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG,
..
ment of acute venous thromboembolism. N Engl J Med 2009;361:2342–2352. .. Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American
332. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, .. Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS
Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme . guideline for the management of patients with atrial fibrillation: a report of the

on 23 April 2018
American College of Cardiology/American Heart Association Task Force on

.. healthcare professionals from the American Heart Association/American
..
practice guidelines and the Heart Rhythm Society. Circulation .. Stroke Association. Stroke 2018; [Epub ahead of print].
2014;130:e199–e267. .. 364. Tse DM, Young L, Ranta A, Barber PA. Intravenous alteplase and endovascular
349. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic .. clot retrieval following reversal of dabigatran with idarucizumab. J Neurol
M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, .. Neurosurg Psychiatry 2017; [Epub ahead of print].
Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Rivaroxaban .. 365. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K,
vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J .. Berrouschot J, Cangur H, Daffertshofer M, Edelbusch S, Groschel K, Haase CG,
2014;35:3346–3355.
.. Harloff A, Held V, Kauert A, Kraft P, Lenz A, Mullges W, Obermann M, Partowi
..
350. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri .. S, Purrucker J, Ringleb PA, Rother J, Rossi R, Schafer N, Schneider A,
MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, .. Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizu-
Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY. Edoxaban versus .. mab in cases of ischemic stroke or intracranial hemorrhage in Germany—a na-
enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation .. tional case collection. Int J Stroke 2017;12:383–391.
(ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet .. 366. Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, Muller
2016;388:1995–2003. .. MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U,
351. McCready JW, Nunn L, Lambiase PD, Ahsan SY, Segal OR, Rowland E, Lowe
.. Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris DA, Engelter ST.
..
MD, Chow AW. Incidence of left atrial thrombus prior to atrial fibrillation abla- .. Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug
tion: is pre-procedural transoesophageal echocardiography mandatory? .. specific plasma levels: experience with a standard operation procedure in clin-
Europace 2010;12:927–932. .. ical practice. J Stroke 2017;19:347–355.
352. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WH, Gabriel RS, Wazni .. 367. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL,
OM, Bhargava M, Saliba WI, Thomas JD, Lindsay BD, Klein AL. Role of the .. Smith EE, Fonarow GC, Peterson ED. Use of intravenous recombinant tissue
CHADS2 score in the evaluation of thromboembolic risk in patients with atrial .. plasminogen activator in patients with acute ischemic stroke who take non-
fibrillation undergoing transesophageal echocardiography before pulmonary
.. vitamin K antagonist oral anticoagulants before stroke. Circulation
..
vein isolation. J Am Coll Cardiol 2009;54:2032–2039. .. 2017;135:1024–1035.
353. Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson CA, Nazarian S, .. 368. Ebner M, Birschmann I, Peter A, Hartig F, Spencer C, Kuhn J, Blumenstock G,
Cheng A, Berger RD, Abraham TP, Calkins H, Marine JE. Incidence and pre- .. Zuern CS, Ziemann U, Poli S. Emergency coagulation assessment during treat-
dictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J .. ment with direct oral anticoagulants: limitations and solutions. Stroke
Cardiovasc Electrophysiol 2009;20:379–384. .. 2017;48:2457–2463.
354. Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, .. 369. Ebner M, Birschmann I, Peter A, Spencer C, Hartig F, Kuhn J, Blumenstock G,
Breazna A, Kirchhof P, Oldgren J. Apixaban compared with parenteral heparin
.. Zuern CS, Ziemann U, Poli S. Point-of-care testing for emergency assessment
..
and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation .. of coagulation in patients treated with direct oral anticoagulants. Crit Care
undergoing cardioversion: rationale and design of the EMANATE trial. Am .. 2017;21:32.
Heart J 2016;179:59–68. .. 370. Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K an-
355. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, .. tagonist oral anticoagulant levels: when is it appropriate and which methods
Hansen J, Kober L, Husted S, Torp-Pedersen C. Thromboembolic risk in 16 .. should be used? Int J Stroke 2016;11:748–758.
274 atrial fibrillation patients undergoing direct current cardioversion with and .. 371. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW,
without oral anticoagulant therapy. Europace 2015;17:18–23. .. Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, Cardona P, Devlin
356. Gronberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE.
.. TG, Frei DF, Du Mesnil de Rochemont R, Berkhemer OA, Jovin TG, Siddiqui
..
Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardiover- .. AH, van Zwam WH, Davis SM, Castano C, Sapkota BL, Fransen PS, Molina C,
sion of acute atrial fibrillation (from the FinCV Study). Am J Cardiol .. van Oostenbrugge RJ, Chamorro A, Lingsma H, Silver FL, Donnan GA, Shuaib
2016;117:1294–1298. .. A, Brown S, Stouch B, Mitchell PJ, Davalos A, Roos YB, Hill MD; HERMES
357. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardio- .. Collaborators. Time to treatment with endovascular thrombectomy and out-
version for acute atrial fibrillation and thromboembolic complications. JAMA .. comes from ischemic stroke: a meta-analysis. JAMA 2016;316:1279–1288.
2014;312:647–649. .. 372. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal
358. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH,
.. DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI,
..
Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. .. Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP,
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of pa- .. Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L,
tients undergoing cardioversion. Circulation 2011;123:131–136. .. Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ,
359. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, .. Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields
Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, .. R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG.
Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and .. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and
Investigators. Efficacy and safety of apixaban in patients after cardioversion for
.. infarct. N Engl J Med 2018;378:11–21.
..
atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in .. 373. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S,
Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll .. McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE,
Cardiol 2014;63:1082–1087. .. Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S,
360. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey .. Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP,
GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, .. Lansberg MG, Investigators D. Thrombectomy for stroke at 6 to 16 hours with
Breithardt G; ROCKET AF Steering Committee & Investigators. Outcomes .. selection by perfusion imaging. N Engl J Med 2018; [Epub ahead of print].
after cardioversion and atrial fibrillation ablation in patients treated with rivar-
.. 374. Wahlgren N, Moreira T, Michel P, Steiner T, Jansen O, Cognard C, Mattle HP,
..
oxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol .. van Zwam W, Holmin S, Tatlisumak T, Petersson J, Caso V, Hacke W, Mazighi
2013;61:1998–2006. .. M, Arnold M, Fischer U, Szikora I, Pierot L, Fiehler J, Gralla J, Fazekas F, Lees
361. Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels .. KR; ESO-KSU, ESO, ESMINT, ESNR and EAN. Mechanical thrombectomy in
M, Cohen A, Study XT; X-TRA study and CLOT-AF registry investigators. .. acute ischemic stroke: consensus statement by ESO-Karolinska Stroke Update
Left atrial thrombus resolution in atrial fibrillation or flutter: results of a .. 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int J Stroke
prospective study with rivaroxaban (X-TRA) and a retrospective observa- .. 2016;11:134–147.
tional registry providing baseline data (CLOT-AF). Am Heart J .. 375. Purrucker JC, Wolf M, Haas K, Rizos T, Khan S, Dziewas R, Kleinschnitz C,
2016;178:126–134.
.. Binder A, Groschel K, Hennerici MG, Lobotesis K, Poli S, Seidel G, Neumann-
..
362. Purrucker JC, Haas K, Rizos T, Khan S, Poli S, Kraft P, Kleinschnitz C, Dziewas .. Haefelin T, Ringleb PA, Heuschmann PU, Veltkamp R. Safety of endovascular
R, Binder A, Palm F, Jander S, Soda H, Heuschmann PU, Veltkamp R; .. thrombectomy in patients receiving non-vitamin K antagonist oral anticoagu-
RASUNOA Investigators (Registry of Acute Stroke Under New Oral .. lants. Stroke 2016;47:1127–1130.
Anticoagulants). Coagulation Testing in acute ischemic stroke patients taking .. 376. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrilla-
non-vitamin K antagonist oral anticoagulants. Stroke 2017;48:152–158. .. tion: what have we learned? Curr Cardiol Rep 2014;16:480.
363. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker .. 377. Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M,
K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-
.. Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de
..
Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, .. Barros ESP, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in
Tirschwell DL; American Heart Association Stroke Council. 2018 guidelines for .. patients with atrial fibrillation receiving anticoagulation therapy. Blood
the early management of patients with acute ischemic stroke: a guideline for . 2017;129:2980–2987.

on 23 April 2018
378. Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, Sobowale OA,
.. antithrombotic treatment in intracranial hemorrhage survivors with atrial fibril-
..
Sallinen H, Yeh SJ, Wu TY, Ferrigno M, Houben R, Schreuder F, Perry LA, .. lation. Neurology 2017;89:687–696.
Tanaka J, Boulanger M, Al-Shahi Salman R, Jager HR, Ambler G, Shakeshaft C, .. 390. Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE,
Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, .. Buchem MV, Grond JV, Verbeek MM, Werring DJ. The increasing impact of
Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A. Werring DJ. .. cerebral amyloid angiopathy: essential new insights for clinical practice. J Neurol
Outcome of intracerebral hemorrhage associated with different oral anticoagu- .. Neurosurg Psychiatry 2017;88:982–994.
lants. Neurology 2017;88:1693–1700. .. 391. Biffi A, Kuramatsu JB, Leasure A, Kamel H, Kourkoulis C, Schwab K, Ayres AM,
379. Inohara T, Xian Y, Liang L, Matsouaka RA, Saver JL, Smith EE, Schwamm LH,
.. Elm J, Gurol ME, Greenberg SM, Viswanathan A, Anderson CD, Schwab S,
..
Reeves MJ, Hernandez AF, Bhatt DL, Peterson ED, Fonarow GC. Association of .. Rosand J, Testai FD, Woo D, Huttner HB, Sheth KN. Oral anticoagulation and
intracerebral hemorrhage among patients taking non-vitamin K antagonist vs .. functional outcome after intracerebral hemorrhage. Ann Neurol 2017;82:755–765.
vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA .. 392. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence,
2018;319:463–473. .. prevalence, and prediction of stroke using the Congestive heart failure,
380. Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, .. Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ische-
Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo .. mic attack (CHADS2) risk stratification scheme. Am Heart J 2008;156:57–64.
D. Guidelines for the management of spontaneous intracerebral hemorrhage: a
.. 393. Wolff A, Shantsila E, Lip GY, Lane DA. Impact of advanced age on management
..
guideline for healthcare professionals from the American Heart Association/ .. and prognosis in atrial fibrillation: insights from a population-based study in gen-
American Stroke Association. Stroke 2015;46:2032–2060. .. eral practice. Age Ageing 2015;44:874–878.
381. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, .. 394. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk fac-
Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, .. tor for stroke: the Framingham Study. Stroke 1991;22:983–988.
Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner .. 395. Fohtung RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescrib-
H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, .. ing practices for atrial fibrillation in older adults. J Am Geriatr Soc
Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H,
.. 2017;65:2405–2412.
..
Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann- .. 396. Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS, Lip GYH. Effectiveness
Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, .. and safety of oral anticoagulants in older patients with atrial fibrillation: a sys-
Schwab S, Huttner HB. Anticoagulant reversal, blood pressure levels, and anti- .. tematic review and meta-regression analysis. Age Ageing 2018;47:9–17.
coagulant resumption in patients with anticoagulation-related intracerebral .. 397. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreanu D,
hemorrhage. JAMA 2015;313:824–836. .. Proclemer A, Dagres N. Frailty syndrome: an emerging clinical problem in the
382. Gerner ST, Kuramatsu JB, Sembill JA, Sprugel MI, Endres M, Haeusler KG, .. everyday management of clinical arrhythmias. The results of the European
Vajkoczy P, Ringleb PA, Purrucker J, Rizos T, Erbguth F, Schellinger PD, Fink
.. Heart Rhythm Association survey. Europace 2017;19:1896–1902.
..
GR, Stetefeld H, Schneider H, Neugebauer H, Rother J, Classen J, Michalski D, .. 398. Wehling M, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P,
Dorfler A, Schwab S, Huttner HB, Investigators RI. Association of prothrombin .. Quinn TJ, Ropers D, Sergi G, Verheugt FWA. Appropriateness of oral anti-
complex concentrate administration and hematoma enlargement in non-vitamin .. coagulants for the long-term treatment of atrial fibrillation in older people: re-
K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol .. sults of an evidence-based review and international consensus validation
2018;83:186–196. .. process (OAC-FORTA 2016). Drugs Aging 2017;34:499–507.
383. Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, .. 399. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F,
Chondrogianni M, Bovi P, Carletti M, Cappellari M, Zedde M, Ntaios G, .. Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM.
Karagkiozi E, Athanasakis G, Makaritsis K, Silvestrelli G, Lanari A, Ciccone A,
.. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the
..
Putaala J, Tomppo L, Tatlisumak T, Abdul-Rahim AH, Lees KR, Alberti A, Venti .. ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016;5:e003432.
M, Acciarresi M, D’Amore C, Becattini C, Mosconi MG, Cimini LA, Soloperto .. 400. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR,
R, Masotti L, Vannucchi V, Lorenzini G, Tassi R, Guideri F, Acampa M, Martini .. Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey
G, Sohn SI, Marcheselli S, Mumoli N, De Lodovici ML, Bono G, Furie KL, Tadi .. KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigator.
P, Yaghi S, Toni D, Letteri F, Tassinari T, Kargiotis O, Lotti EM, Flomin Y, .. Efficacy and safety of rivaroxaban compared with warfarin among elderly pa-
Mancuso M, Maccarrone M, Giannini N, Bandini F, Pezzini A, Poli L, Padovani A, .. tients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral,
Scoditti U, Denti L, Consoli D, Galati F, Sacco S, Carolei A, Tiseo C, Gourbali
.. Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for
..
V, Orlandi G, Giuntini M, Chiti A, Giorli E, Gialdini G, Corea F, Ageno W, .. Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Bellesini M, Colombo G, Monaco S, Maimone Baronello M, Karapanayiotides T, .. Circulation 2014;130:138–146.
Caso V. Early recurrence and major bleeding in patients with acute ischemic .. 401. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB,
stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants .. Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W,
(RAF-NOACs) study. J Am Heart Assoc 2017;6:e007034. .. Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin
384. Ahmed N, Steiner T, Caso V, Wahlgren N. Recommendations from the ESO- .. according to age for stroke prevention in atrial fibrillation: observations from
Karolinska Stroke Update Conference, Stockholm 13–15 November 2016. Eur
.. the ARISTOTLE trial. Eur Heart J 2014;35:1864–1872.
..
Stroke J 2017;2:95–102. .. 402. Okumura K, Lip GYH, Akao M, Tanizawa K, Fukuzawa M, Abe K, Akishita M,
385. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert .. Yamashita T. Edoxaban for the management of elderly Japanese patients with
C, Pezzini A, Poli L, Padovani A, Csiba L, Szab o L, Sohn S-I, Tassinari T, Abdul- .. atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale
Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, .. and design of the ELDERCARE-AF study. Am Heart J 2017;194:99–106.
Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli .. 403. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman
A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, .. T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study
Tsivgoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De
.. Collaborative Research Group. Frailty in older adults: evidence for a phenotype.
..
Lodovici ML, Bono G, Baldi A, D’Anna S, Sacco S, Carolei A, Tiseo C, .. J Gerontol A Biol Sci Med Sci 2001;56:M146–M156.
Acciarresi M, D’Amore C, Imberti D, Zabzuni D, Doronin B, Volodina V, .. 404. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB. A
Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, .. brief clinical instrument to classify frailty in elderly people. Lancet
Pallesen L-P, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim .. 1999;353:205–206.
F, Akhtar N, Mosconi MG, Bubba V, Silvestri I, Lees KR. Early recurrence and .. 405. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I,
cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: ef- .. Mitnitski A. A global clinical measure of fitness and frailty in elderly people.
fect of anticoagulation and its timing: the RAF study. Stroke 2015;46:2175–2182. .. CMAJ 2005;173:489–495.
386. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant
.. 406. Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies
..
treatment in acute cardioembolic stroke: a meta-analysis of randomized con- .. for prevention. Age Ageing 2006;35(Suppl 2):ii37–ii41.
trolled trials. Stroke 2007;38:423–430. .. 407. Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S.
387. Orrapin S, Rerkasem K. Carotid endarterectomy for symptomatic carotid sten- .. Translating the results of randomized trials into clinical practice: the challenge
osis. Cochrane Database Syst Rev 2017;6:CD001081. .. of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.
388. Brønnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjøth F, Rasmussen LH, .. Stroke 2006;37:1075–1080.
Lip GYH. Intracranial hemorrhage and subsequent ischemic stroke in patients .. 408. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic ther-
with atrial fibrillation: a nationwide cohort study. Chest 2015;147:1651–1658.
.. apy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern
..
389. Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, .. Med 1999;159:677–685.
Huttner HB, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, .. 409. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna
Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R. Long-term . M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in

on 23 April 2018
Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

.. Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart
..
Investigators. Clinical outcomes and history of fall in patients with atrial fibrilla- .. J 2016;37:2869–2878.
tion treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J .. 432. Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox
Med 2018;131:269–275. .. KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP,
410. Tiedemann A, Lord SR, Sherrington C. The development and validation of a .. Singer DE, Patel MR. Relation of risk of stroke in patients with atrial fibrillation
brief performance-based fall risk assessment tool for use in primary care. .. to body mass index (from Patients Treated With Rivaroxaban and Warfarin in
J Gerontol A Biol Sci Med Sci 2010;65:896–903. .. the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with
411. Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F,
.. Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
..
Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY; French Society .. Fibrillation Trial). Am J Cardiol 2017;119:1989–1996.
of Geriatrics, Gerantology, French Society of Cardiology. Expert consensus of .. 433. Braekkan SK, van der Graaf Y, Visseren FL, Algra A. Obesity and risk of bleed-
the French Society of Geriatrics and Gerontology and the French Society of .. ing: the SMART study. J Thromb Haemost 2016;14:65–72.
Cardiology on the management of atrial fibrillation in elderly people. Arch .. 434. Lee CH, Lin TY, Chang SH, Chen CH, Hsu YJ, Hung KC, Wen MS. Body mass
Cardiovasc Dis 2013;106:303–323. .. index is an independent predictor of major bleeding in non-valvular atrial fibril-
412. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. .. lation patients taking dabigatran. Int J Cardiol 2017;228:771–778.
Effective exercise for the prevention of falls: a systematic review and meta-ana-
.. 435. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants
..
lysis. J Am Geriatr Soc 2008;56:2234–2243. .. (NOACs) and extremes of body weight-a systematic literature review. Clin Res
413. Tricco AC, Thomas SM, Veroniki AA, Hamid JS, Cogo E, Strifler L, Khan PA, .. Cardiol 2017;106:565–572.
Robson R, Sibley KM, MacDonald H, Riva JJ, Thavorn K, Wilson C, Holroyd- .. 436. Van Eijkeren MA, Christiaens GC, Sixma JJ, Haspels AA. Menorrhagia: a review.
Leduc J, Kerr GD, Feldman F, Majumdar SR, Jaglal SB, Hui W, Straus SE. .. Obstet Gynecol Surv 1989;44:421–429.
Comparisons of interventions for preventing falls in older adults: a systematic .. 437. Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception
review and meta-analysis. JAMA 2017;318:1687–1699. .. in women of reproductive age receiving oral anticoagulation. Contraception
414. Garcia-Ptacek S, Contreras Escamez B, Zupanic E, Religa D, von Koch L, Johnell
.. 2011;84:128–132.
..
K, von Euler M, Kåreholt I, Eriksdotter M. Prestroke mobility and dementia as .. 438. De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S,
predictors of stroke outcomes in patients over 65 years of age: a cohort study .. Verhamme P, Peetermans M. Abnormal uterine bleeding in VTE patients
from the Swedish Dementia and Stroke Registries. J Am Med Dir Assoc .. treated with rivaroxaban compared to vitamin K antagonists. Thromb Res
2018;19:154–161. .. 2015;136:749–753.
415. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrilla- .. 439. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen
tion. Eur Heart J 2018;39:453–460. .. B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P,
416. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline
.. Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine
..
and dementia? Europace 2018;20:408. .. bleeding with anticoagulant and hormone therapy use. Blood
417. World Health Organization. Obesity and Overweight Fact Sheet. http://www.who. .. 2016;127:1417–1425.
int/mediacentre/factsheets/fs311/en/ (8 March 2018). .. 440. Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dörschel S, Marten S.
418. Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. .. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in
Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471–2477. .. women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a
419. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation .. case series. Lancet Haematol 2016;3:e480–e488.
prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. .. 441. Rolden HJA, Maas A, van der Wilt GJ, Grutters JPC. Uncertainty on the effect-
J Am Coll Cardiol 2017;70:2022–2035.
.. iveness and safety of rivaroxaban in premenopausal women with atrial fibrilla-
..
420. Sivasambu B, Balouch MA, Zghaib T, Bajwa RJ, Chrispin J, Berger RD, Ashikaga .. tion: empirical evidence needed. BMC Cardiovasc Disord 2017;17:260.
H, Nazarian S, Marine JE, Calkins H, Spragg DD. Increased rates of atrial fibrilla- .. 442. Tobenkin A, Mohamoud M, Munoz M, Waldron P. Direct oral anticoagulants
tion recurrence following pulmonary vein isolation in overweight and obese pa- .. and menorrhagia in premenopausal women: data from the food and drug ad-
tients. J Cardiovasc Electrophysiol 2018;29:239–245. .. ministration adverse event reporting system and US drug utilization.
421. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, .. Haemophilia 2017;23(Suppl 3):43.
Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, .. 443. Nielsen JR, Wachtell K, Abdulla J. The relationship between physical activity
Sanders P. Effect of weight reduction and cardiometabolic risk factor manage-
.. and risk of atrial fibrillation-a systematic review and meta-analysis. J Atr
..
ment on symptom burden and severity in patients with atrial fibrillation: a .. Fibrillation 2013;5:789.
randomized clinical trial. JAMA 2013;310:2050–2060. .. 444. Zhu WG, Wan R, Din Y, Xu Z, Yang X, Hong K. Sex differences in the associ-
422. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular .. ation between regular physical activity and incident atrial fibrillation: a meta-
hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278:F817–F822. .. analysis of 13 prospective studies. Clin Cardiol 2016;39:360–367.
423. Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, .. 445. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical activity and
Sands CW, Self TH. Comparison of initial warfarin response in obese patients .. incidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol
versus non-obese patients. J Thromb Thrombolysis 2013;36:96–101.
.. 2014;177:467–476.
..
424. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence .. 446. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de Werf F, Ector H.
on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxa- .. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flut-
ban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47:218–226. .. ter. Int J Cardiol 2006;107:67–72.
425. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost .. 447. Caselli S, Vaquer Sequi A, Lemme E, Quattrini F, Milan A, D’Ascenzi F, Spataro
CE. Effect of extremes of body weight on the pharmacokinetics, pharmaco- .. A, Pelliccia A. Prevalence and Management of Systemic Hypertension in
dynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin .. Athletes. Am J Cardiol 2017;119:1616–1622.
Pharmacol 2013;76:908–916.
.. 448. Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hayes M, Kase CS, Devinsky
..
426. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and .. O, Seshadri S, Friedman D. Incidence of seizures following initial ischemic
exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J .. stroke in a community-based cohort: the Framingham Heart Study. Seizure
Clin Pharmacol 2014;70:1339–1351. .. 2017;47:105–110.
427. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. .. 449. Beghi E, D’Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, Gandolfo C,
Use of the direct oral anticoagulants in obese patients: guidance from the SSC .. Greco G, La Neve A, Manfredi M, Mattana F, Musolino R, Provinciali L,
of the ISTH. J Thromb Haemost 2016;14:1308–1313. .. Santangelo M, Specchio LM, Zaccara G, Epistroke G. Incidence and predictors
428. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance .. of acute symptomatic seizures after stroke. Neurology 2011;77:1785–1793.
for the practical management of the direct oral anticoagulants (DOACs) in VTE
.. 450. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic
..
treatment. J Thromb Thrombolysis 2016;41:206–232. .. seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia
429. Breuer L, Ringwald J, Schwab S, Kohrmann M. Ischemic stroke in an obese pa- .. 2009;50:1102–1108.
tient receiving dabigatran. N Engl J Med 2013;368:2440–2442. .. 451. Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH,
430. Safouris A, Demulder A, Triantafyllou N, Tsivgoulis G. Rivaroxaban presents a .. Chao TF, Chung FP, Liao JN, Chen TJ, Chen SA. Incident thromboembolism
better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke .. and heart failure associated with new-onset atrial fibrillation in cancer patients.
patient. J Neurol Sci 2014;346:366–367. .. Int J Cardiol 2013;165:355–357.
431. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S,
.. 452. Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fib-
..
Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The ‘obesity paradox’ in .. rillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons
atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in .. general thoracic surgery database. Ann Thorac Surg 2010;90:368–374.
.

on 23 April 2018
453. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: .. 466. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E,
chemotherapy-induced arrhythmia. Europace 2009;11:1579–1586. .. Wells PS. Comparison of 10-mg and 5-mg warfarin initiation nomograms to-
454. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrilla-
.. gether with low-molecular-weight heparin for outpatient treatment of acute
..
tion in cancer. J Am Coll Cardiol 2014;63:945–953. .. venous thromboembolism. A randomized, double-blind, controlled trial. Ann
455. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients .. Intern Med 2003;138:714–719.
with cancer: a systematic review and meta-analysis. PLoS Med 2012;9:e1001275. .. 467. Garcia P, Ruiz W, Loza Munarriz C. Warfarin initiation nomograms for venous
456. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malig- .. thromboembolism. Cochrane Database Syst Rev 2016;1:CD007699.
nancy: pathogenesis and current debate. Neoplasia 2002;4:465–473. .. 468. Belley-Cote EP, Hanif H, D’Aragon F, Eikelboom JW, Anderson JL, Borgman M,
457. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of .. Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee
cancer-related treatment. Circ Res 2016;118:1008–1020.
.. AH, Pirmohamed M, Whitlock RP. Genotype-guided versus standard vitamin K
..
458. Raskob GE, van Es N, Verhamme P, Carrier M,D, Nisio M, Garcia D, Grosso .. antagonist dosing algorithms in patients initiating anticoagulation. A systematic
MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, .. review and meta-analysis. Thromb Haemost 2015;114:768–777.
Yeo E, Zhang G, Zwicker JI, Weitz JI, Buller HR; Hokusai VTE Cancer .. 469. van Schie RM, Wessels JA, Le Cessie S, de Boer A, Schalekamp T, van der Meer
Investigators. Edoxaban for the treatment of cancer-associated venous .. FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-
thromboembolism. N Engl J Med 2018;378:615–624. .. PACT Study Group. Loading and maintenance dose algorithms for phenprocou-
459. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous .. mon and acenocoumarol using patient characteristics and pharmacogenetic
thromboembolism in patients with cancer: a network meta-analysis comparing
.. data. Eur Heart J 2011;32:1909–1917.
..
efficacy and safety of anticoagulants. Thromb Res 2015;136:582–589. .. 470. Mahtani KR, Heneghan CJ, Nunan D, Bankhead C, Keeling D, Ward AM, Harrison
460. Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, .. SE, Roberts NW, Hobbs FD, Perera R. Optimal loading dose of warfarin for the
Di Biase M. Direct oral anti-coagulants compared with vitamin-K inhibitors and .. initiation of oral anticoagulation. Cochrane Database Syst Rev 2012;12:CD008685.
low-molecular-weight-heparin for the prevention of venous thromboembolism .. 471. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation
in patients with cancer: a meta-analysis study. Int J Cardiol 2017;230:214–221. .. of the pattern of treatment, level of anticoagulation control, and outcome of
461. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, .. treatment with warfarin in patients with non-valvar atrial fibrillation: a record
Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD. Efficacy and
.. linkage study in a large British population. Heart 2005;91:472–477.
safety of apixaban versus warfarin in patients with atrial fibrillation and a history of
.. 472. Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali
..
cancer: insights from the ARISTOTLE Trial. Am J Med 2017;130:1440–1448. .. C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment
462. Ording AG, Horvath-Puh o E, Adelborg K, Pedersen L, Prandoni P, Sørensen .. practice is responsible for differences in the quality of anticoagulation control
HT. Thromboembolic and bleeding complications during oral anticoagulation .. between centers and countries: an analysis of patients receiving warfarin in the
therapy in cancer patients with atrial fibrillation: a Danish nationwide .. randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
population-based cohort study. Cancer Med 2017;6:1165–1172. .. Circulation 2012;126:2309–2316.
463. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, .. 473. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P,
Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty
.. Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ,
..
D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; Authors/Task Force Members; .. Investigators R. L. Efficacy and safety of dabigatran compared with warfarin at dif-
ESC Committee for Practice Guidelines(CPG); Document Reviewers. 2016 .. ferent levels of international normalised ratio control for stroke prevention in
ESC Position Paper on cancer treatments and cardiovascular toxicity developed .. atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–983.
under the auspices of the ESC Committee for Practice Guidelines: the Task .. 474. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral
Force for cancer treatments and cardiovascular toxicity of the European .. anticoagulation management in primary care with the use of computerized deci-
Society of Cardiology (ESC). Eur Heart J 2016;37:2768–2801. .. sion support and near-patient testing: a randomized, controlled trial. Arch Intern
464. Zhang Y, de Boer A, Verhoef TI, van der Meer FJM, Le Cessie S, Maitland-van
.. Med 2000;160:2343–2348.
..
der Zee AH, Barallon R, de Boer A, Daly A, Maitland-van der Zee A-H, .. 475. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR.
Redekop K, Stingl J, Manolopoulos VG, Rosendaal FR, Wadelius M. Comparison .. Comparing the quality of oral anticoagulant management by anticoagulation clinics
of dosing algorithms for acenocoumarol and phenprocoumon using clinical fac- .. and by family physicians: a randomized controlled trial. CMAJ 2003;169:293–298.
tors with the standard care in the Netherlands. Thromb Res 2015;136:94–100. .. 476. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead
465. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and .. C, Alonso-Coello P, Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring
its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med .. and self-management of oral anticoagulation. Cochrane Database Syst Rev
2014;174:1330–1338.
.. 2016;7:CD003839.
..

on 23 April 2018

Ghid ERHA Privitor NOAK 2018 PDF

Uploaded by

Copyright:

Available Formats

Ghid ERHA Privitor NOAK 2018 PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ghid ERHA Privitor NOAK 2018 PDF

Uploaded by

Copyright:

Available Formats

European Heart Journal (2018) 39, 1330–1393 SPECIAL ARTICLE

The 2018 European Heart Rhythm Association

Document reviewers (ESC scientific document group): Gregory YH Lip (EHRA

Online publish-ahead-of-print 19 March 2018

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Condion Eligibility for NOAC therapy

Mitral valve repair (aer > 3 months

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Table 2 Checklist during follow-up contacts of atrial fibrillation patients on anticoagulation

2. Thromboembolism Each visit • Systemic circulation (TIA, stroke, peripheral)

6. Blood sampling Yearly Patients other than those specified below

If needed If intercurrent condition that may impact renal or hepatic function

7. Assessing and Each visit • As recommended by current guidelines3

For frequency of visits: see Figure 1.

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

patient support websites, including EHRA (http://www.afibmatters.

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Purine analogs: Mercaptopurine, Thioguanine, Pentostatin, Cladribine, Clofarabine, Fludarabine.

• Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Anticipated effects of common antiepileptic drugs on NOACs plasma levels.147,150

• Strong CYP3A4 and/or P-gp inducer—should not be used (dark brown).

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

.. OD in the upper range of CrCl in an exploratory (not pre-defined)

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Table 6 Absorption and metabolism of the different NOACs

Dabigatran158,182 Apixaban183 Edoxaban184 Rivaroxaban185,186

Bioavailability 3–7% 50% 62% 15 mg/20 mg: 66% without food,

Clearance non-renal/renal 20%/80% 73%/27% 50%/50% 65%/35%

Plasma protein binding 35% 87% 55% 95%

Dialysability 50–60% 14% n.a. n.a.

Absorption with H2B/PPI -12% to 30% (not No effect No effect No effect

Asian ethnicity þ25%166 No effect No effect No effect

Elimination half-life 12–17 h 12 h 10–14 h 5–9 h (young)

Other Dyspepsia (5–10%) Intake of 15 mg/20 mg with

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

Decreased GFRa GFR <60 mL/min/1.73 m2

GFR category CKD stage GFRa Descriptions

G1 1 >_90 Normal or high

G2 2 60–89 Mildly decreased

G3a 45–59 Mildly to moderately decreased

G4 4 15–29 Severely decreased

Estimation of renal function in NOAC patients best by Creatinine Clearance (Cockroft–Gault):

ð140 – ageÞweight ðin kgÞ½0:85 if female

Online calculators available at (e.g.): www.kidney.org/professionals/kdoqi/gfr_calculator; www.nephron.com/cgi-bin/CGSI.cgi; www.mdcalc.com/creatinine-clearance-cockcroft-

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/16/1330/4942493

CrCl Dabigatran Rivaroxaban Edoxaban Apixaban

ð140 – ageÞweight ðin kgÞ½0:85 if female

Dabigatran28 2 150 mg / 2 110 mg No pre-specified dose-reduction criteriaa

Rivaroxaban29 1 20 mg 1 15 mg if CrCl <_50 mL/min

Dabigatran336 2 150 mg No pre-specified dose-reduction criteriad